nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,id,nct_id,mesh_term,downcase_mesh_term,intervention_type,intervention_name,description,intervention_count,status,facility_name,city,state,zip,country,site_count
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"May 1, 2020",Anticipated,2020-05-01,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,ProCov,,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov),Recruiting,NA,N/A,25,Anticipated,Centre Hospitalier Intercommunal Aix-Pertuis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-24T09:06:39Z,2020-04-24T09:06:39Z,5099125,NCT04344106,Coronavirus Infections,coronavirus infections,Procedure,Prone positioning,"The prone positioning consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day.",1,Recruiting,CHI Aix-Pertuis,Aix-en-Provence,,13100,France,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-07,NA,NA,2020-04-12,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,"April 10, 2020",Actual,2020-04-10,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,COVID-19 Convalescent Plasma,Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center,Recruiting,NA,Early Phase 1,10,Anticipated,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database,NA,NA,Yes,We will share individual participant data that is de-identified available to all qualified investigators,2020-04-24T09:07:29Z,2020-04-24T09:07:29Z,5099275,NCT04340050,Coronavirus Infections,coronavirus infections,Biological,anti-SARS-CoV-2 convalescent plasma,Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours,1,Recruiting,University of Chicago Medicine,Chicago,Illinois,60637,United States,1
"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-07,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-10,Actual,"April 30, 2020",Anticipated,2020-04-30,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Effects of DPP4 Inhibition on COVID-19,Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes,Not yet recruiting,NA,Phase 4,20,Anticipated,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:49:45Z,2020-04-20T08:49:45Z,5057333,NCT04341935,Coronavirus Infections,coronavirus infections,Drug|Drug,Linagliptin|Insulin regimen,5 mg Linagliptin administered by mouth once daily|Standard of care insulin regimen as per hospital protocol,2,,University of Miami,Miami,Florida,33136,United States,1
"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-07,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-10,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Observational,BIOCOVU,,Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient,Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Admitted to Emergency Departments During an Epidemic,Not yet recruiting,NA,NA,1000,Anticipated,"University Hospital, Lille",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:49:51Z,2020-04-20T08:49:51Z,5057349,NCT04341792,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-04,NA,NA,2020-04-08,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,"August 1, 2021",Anticipated,2021-08-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,WU352,,"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection","WU 352: Open-label, Randomized Controlled Trial of Hydroxychloroquine Alone or Hydroxychloroquine Plus Azithromycin or Chloroquine Alone or Chloroquine Plus Azithromycin in the Treatment of SARS CoV-2 Infection",Recruiting,NA,Phase 3,500,Anticipated,Washington University School of Medicine,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-20T08:49:53Z,2020-04-20T08:49:53Z,5057360,NCT04341727,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug,Hydroxychloroquine Sulfate|Azithromycin|Chloroquine Sulfate,anti-rheumatic drug (DMARD)|Antibiotic|Antimalarial,3,Recruiting|Recruiting,Washington University School of Medicine Infectious Disease Clinical Research Unit|Washington University School of Medicine,Saint Louis|Saint Louis,Missouri|Missouri,63110|63110,United States|United States,2
"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-07,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-10,Actual,"April 9, 2020",Anticipated,2020-04-09,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Observational,BURDENCOV,,"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","""Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers"" ""Impact Psychologique de l'Ã©pidÃ©mie COVID-19 Chez Les Patients, Familles et Soignants de Reanimation"" ""BURDENCOV""",Not yet recruiting,NA,NA,1464,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:50:00Z,2020-04-20T08:50:00Z,5057385,NCT04341519,Coronavirus Infections,coronavirus infections,Behavioral|Behavioral,PTSD|Burnout,"family members: post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days
Patients:
post-traumatic stress disorder (PTSD) related symptoms assessed by Impact of Event Scale Revised (IES-R) at 90 days|Symptoms of burnout as assessed by the Maslash Burnout Inventory",2,,Saint-Louis Hospital,Paris,Ile De France,75010,France,1
"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-27,NA,NA,2020-04-08,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Recruiting,NA,Phase 3,3500,Anticipated,University of Minnesota,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-20T08:51:27Z,2020-04-20T08:51:27Z,5057652,NCT04328467,Coronavirus Infections,coronavirus infections,Drug|Other,Hydroxychloroquine|Placebo,Hydroxychloroquine; 200mg tablet; oral|Placebo; tablet; oral,2,Recruiting|Recruiting,"Nationwide Enrollment via Internet, please email: covid19@umn.edu|University of Minnesota",Minneapolis|Minneapolis,Minnesota|Minnesota,55455|55455,United States|United States,2
"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-26,NA,NA,2020-04-09,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Anticipated,2020-07-01,NA,Observational,NA,,Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia,"Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study",Recruiting,NA,NA,80,Anticipated,Istinye University,,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-20T08:51:32Z,2020-04-20T08:51:32Z,5057678,NCT04326725,Coronavirus Infections,coronavirus infections,Drug,Plaquenil 200Mg Tablet,health workers under risk who took this medications,1,Recruiting,Istinye University Medical School,Istanbul,,34010,Turkey,1
"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-26,NA,NA,2020-04-09,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"October 7, 2021",Anticipated,2021-10-07,"April 7, 2021",Anticipated,2021-04-07,NA,Observational,COVIDx,,Evaluation of Novel Diagnostic Tests for COVID-19,Evaluation of Novel Diagnostic Tests for 2019-nCOV,Recruiting,NA,NA,200,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Throat/Nasal Swab, Nasopharyngeal Swab, Endotracheal tube aspirate and whole blood-serum for
      viral-RNA analysis
    ",NA,NA,NA,Undecided,NA,2020-04-20T08:51:32Z,2020-04-20T08:51:32Z,5057681,NCT04326387,Coronavirus Infections,coronavirus infections,Diagnostic Test|Diagnostic Test|Diagnostic Test|Diagnostic Test,SAMBA II (Diagnostic for the Real World)|Public Health England Gold Standard|Cambridge Validated Viral Detection Method|Radiological Detection,Point of care Isothermal-PCR Viral RNA Amplication for virus detection|Reverse Transcription PCR|Reverse Transcription PCR|Chest X-ray & CT Scan detection of viral infection in the lungs,4,Recruiting,Cambridge University Hospitals NHS Foundation Trust,Cambridge,Cambridgeshire,CB2 0QQ,United Kingdom,1
"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-02,NA,NA,2020-04-08,2020-03-06,2020-03-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,NA,NA,NA,April 2020,2020-04-30,NA,NA,NA,NA,NA,NA,NA,Expanded Access,NA,,Expanded Access Remdesivir (RDV; GS-5734â„¢),Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734â„¢),Available,NA,NA,NA,NA,U.S. Army Medical Research and Development Command,,NA,NA,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:52:19Z,2020-04-20T08:52:19Z,5057908,NCT04302766,Coronavirus Infections,coronavirus infections,Drug,Remdesivir,"Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 17, 2020",2020-01-26,NA,NA,2020-04-09,2020-01-26,2020-01-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"January 1, 2020",Actual,2020-01-01,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,,"Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV","Development of a Simple, Fast and Portable Recombinase Aided Amplification (RAA) Assay for 2019-nCoV",Recruiting,NA,NA,50,Anticipated,Beijing Ditan Hospital,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:53:29Z,2020-04-20T08:53:29Z,5058192,NCT04245631,Coronavirus Infections,coronavirus infections,Diagnostic Test,Recombinase aided amplification (RAA) assay,"We established a real time reverse-transcription RAA (RT-RAA) assay for detection of 2019-nCoV. This assay was performed at 42Â°C within 30min using a portable real-time fluorescence detector, Recombinant plasmids containing conserved ORF1ab genes was used to analyze the specificity and sensitivity. Clinical specimens from patients who were suspected of being infected with 2019-nCoV were used to evaluate the performance of the assay. In parallel, we also used the commercial RT-qPCR assay kit for 2019-nCoV as a reference. Sample types include either of nasal swab, oral swab, bronchoalveolar-lavage fluid, urea, blood, fecal.",1,Recruiting,"Department of Hepatology Division 2, Beijing Ditan Hospital",Beijing,Beijing,100015,China,1
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-26,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"September 20, 2020",Anticipated,2020-09-20,"July 20, 2020",Anticipated,2020-07-20,NA,Observational,NA,,Active Monitoring And Determinants of Incidence Infection of COVDI-19,Active Monitoring And Determinants of Incidence Infection of COVDI-19 in a Hospital Population (AMADIICH) Study Protocol,Recruiting,NA,NA,1000,Anticipated,"FundaciÃ³n TeÃ³filo Hernando, Spain",,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-11T09:13:56Z,2020-04-11T09:13:56Z,4953508,NCT04326400,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,Hospital Universitario de la Princesa,Madrid,,28006,Spain,1
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-24,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 28, 2020",Anticipated,2020-03-28,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,NA,N/A,30,Anticipated,Mazandaran University of Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-10T09:15:52Z,2020-04-10T09:15:52Z,4940011,NCT04327349,Coronavirus Infections,coronavirus infections,Biological,Convalescent Plasma,Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU,1,,"Imam Khomeini Hospital, Mazandaran University of Medical Sciences",Sari,Mazandaran,4816633131,"Iran, Islamic Republic of",1
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-26,NA,NA,2020-03-30,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,GARM-COVID19,,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection,Enrolling by invitation,NA,Early Phase 1,10,Anticipated,Healeon Medical Inc,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,In discussion phase,2020-04-10T09:16:11Z,2020-04-10T09:16:11Z,4940077,NCT04326036,Coronavirus Infections,coronavirus infections,Device|Procedure|Procedure|Drug|Drug,Centricyte 1000|Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Liberase Enzyme (Roche)|Sterile Normal Saline for Intravenous Use,"Centricyte 1000 (Healeon Medical) Digestive (sterile Roche Liberase TM) Isolation/Concentration Protocol, Rinsing/Neutralization, and Pelletize the cSVF For Deployment Via Sterile Saline IV fluid Standard Protocol|Use of Disposable Microcannula Closed System (Tulip Med, 2.2 mm) Harvest of Autologous Adipose Stroma and Stem/Stromal Cell Content|Sterile Normal Saline Suspension cSVF in 250cc for Intravenous Delivery Including Use of 150 micron in-line filtration|Sterile Collagenase Blend to separate cSVF from the AD-SVF|Sterile Normal Saline IV solution to provide suspension of cSVF in 250 cc via standard IV line, including sterile 150 micron in-line standard filter",5,,"Robert W. Alexander, MD, FICS, LLC",Stevensville,Montana,59870,United States,1
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-21,NA,NA,2020-03-30,2020-03-21,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"January 21, 2020",Actual,2020-01-21,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area,Recruiting,NA,Phase 3,2944,Anticipated,Shanghai Jiao Tong University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-10T09:16:56Z,2020-04-10T09:16:56Z,4940274,NCT04320238,Coronavirus Infections,coronavirus infections,Drug|Drug,recombinant human interferon Alpha-1b|thymosin alpha 1,"recombinant human interferon Alpha-1b nasal drops, 2-3 drops for each nostril per time, 4 times per day.|thymosin alpha 1 subcutaneous injection 1 time per week.",2,Recruiting,Taihe Hospital,Shiyan,Hubei,,China,1
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-19,NA,NA,2020-03-30,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 19, 2020",Actual,2020-03-19,March 2020,2020-03-31,"March 19, 2022",Anticipated,2022-03-19,"March 19, 2022",Anticipated,2022-03-19,NA,Observational,COVID-BioB,,"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response",Recruiting,NA,NA,1000,Anticipated,UniversitÃ  Vita-Salute San Raffaele,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-10T09:17:06Z,2020-04-10T09:17:06Z,4940288,NCT04318366,Coronavirus Infections,coronavirus infections,Other,Observational Study,Not required,1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute|Nephrology Unit - IRCCS San Raffaele Scientific Institute|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute|UniversitÃ  Vita-Salute San Raffaele",Milan|Milan|Milan|Milan|Milan|Milan|Milan|Milan|Milan|Milan|Milan|Milan|Milano,Lombardy|Lombardy|Lombardy|Lombardy|Lombardy|Lombardy|Lombardy|Lombardy|Lombardy|Lombardy|Lombardy|Lombardy|Mi,2012|20132|20132|20132|20132|20132|20132|20132|20132|20132|20132|2132|20132,Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy|Italy,13
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-08,NA,NA,2020-04-13,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,STOP COVID,,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Recruiting,NA,Phase 2,152,Anticipated,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-25T09:17:38Z,2020-04-25T09:17:38Z,5111029,NCT04342663,Coronavirus Infections,coronavirus infections,Drug|Drug,Fluvoxamine|Placebo,Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.|Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.,2,Recruiting|Recruiting,BJC|Washington University School of Medicine,Belleville|Saint Louis,Illinois|Missouri,62220|63110,United States|United States,2
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-18,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,"January 1, 2020",Actual,2020-01-01,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 20, 2020",Anticipated,2020-04-20,3 Months,Observational [Patient Registry],I-COVID,,Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.,Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy,Recruiting,NA,NA,20,Anticipated,Federico II University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,not decided yet,2020-04-01T09:19:07Z,2020-04-01T09:19:07Z,4273926,NCT04315870,Coronavirus Infections,coronavirus infections,Other,pregnant women with laboratory-confirmed 2019-n-CoV,Clinical records and compiled data of all consecutive hospitalized and outpatient pregnant women with laboratory-confirmed 2019-n-CoV were included in a merged database,1,Recruiting,University of Naples Federico II,Napoli,,80100,Italy,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-03,NA,NA,2020-03-03,2020-03-03,2020-03-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-05,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"January 1, 2021",Anticipated,2021-01-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Medical Masks vs N95 Respirators for COVID-19,Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial,Not yet recruiting,NA,N/A,576,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-01T09:21:31Z,2020-04-01T09:21:31Z,4276330,NCT04296643,Coronavirus Infections,coronavirus infections,Device|Device,Medical Mask|N95 respirator,Medical Mask (known also as Surgical Mask)|N95 respirator,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-03,NA,NA,2020-03-03,2020-03-03,2020-03-04,Actual,NA,NA,NA,NA,NA,NA,2020-03-03,2020-03-04,Actual,"March 14, 2020",Anticipated,2020-03-14,March 2020,2020-03-31,"April 14, 2021",Anticipated,2021-04-14,"July 14, 2020",Anticipated,2020-07-14,NA,Interventional,NA,,Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe),Not yet recruiting,NA,N/A,80,Anticipated,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:21:39Z,2020-04-01T09:21:39Z,4276474,NCT04295551,Coronavirus Infections,coronavirus infections,Drug|Drug,Lopinavir / ritonavir tablets combined with Xiyanping injection|Lopinavir/ritonavir treatment,"Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-07,NA,NA,2020-04-13,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 7, 2020",Actual,2020-04-07,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,WHIP COVID-19,,Will Hydroxychloroquine Impede or Prevent COVID-19,Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study,Recruiting,NA,Phase 3,3000,Anticipated,Henry Ford Health System,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-25T09:17:50Z,2020-04-25T09:17:50Z,5111063,NCT04341441,Coronavirus Infections,coronavirus infections,Drug|Drug|Other|Diagnostic Test|Diagnostic Test|Diagnostic Test|Other,Hydroxychloroquine - Daily Dosing|Hydroxychloroquine - Weekly Dosing|Placebo oral tablet|Monitoring Visit - Baseline|Monitoring Visit - Week 4|Monitoring Visit - Week 8|Weekly Assessment,"The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.
All treatment groups will receive placebo pills to have the patients take 2 pills a day.|The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria
All treatment groups will receive placebo pills to have the patients take 2 pills a day.|Participants randomized to this arm will be provided with daily dosing of oral placebo to have the patients take 2 pills a day..
Participants will receive a monitoring phone call at 4 weeks post study entry to monitor for COVID-19 symptoms and medication side effects. At week 8, participants will provide additional samples of whole blood.
Additional studies will include serology, inflammatory and other disease associated markers. Clinical data and location of main work area will be collected.|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.|Face-to-face monitoring visit to obtain monitoring questionnaires to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects, and collect study blood samples. Three (3) blood specimens will be collected from each Participant using the sterile procedure as routine standard of care. A total of five (5) 10 mL tubes of whole blood will be collected at each timepoint.|Participants will be asked to contact the study team if COVID-19 infection is established at any time during the study. For study weeks 1,2,3,5,6 &7, Participants will receive a monitoring questionnaire to assess for COVID-19 symptoms/diagnosis, adherence and medication side effects. These monitoring visits will be done by telephone and/or electronic encounters (virtual visits, email), whichever method the patient prefers to encourage adherence to the monitoring.",7,Recruiting|Recruiting|Recruiting|Recruiting,Henry Ford Hospital|Detroit Department of Transportation (DDOT)|Detroit Fire Department & Detroit EMS|Detroit Police Department,Detroit|Detroit|Detroit|Detroit,Michigan|Michigan|Michigan|Michigan,48202|48226|48226|48226,United States|United States|United States|United States,4
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-20,NA,NA,2020-02-21,2020-02-21,2020-02-24,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-24,Actual,February 2020,Anticipated,2020-02-29,February 2020,2020-02-29,March 2020,Anticipated,2020-03-31,March 2020,Anticipated,2020-03-31,NA,Interventional,NA,,A New Screening Strategy for 2019 Novel Coronavirus Infection,Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection,Not yet recruiting,NA,N/A,230,Anticipated,Affiliated Hospital to Academy of Military Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:23:25Z,2020-04-01T09:23:25Z,4278288,NCT04281693,Coronavirus Infections,coronavirus infections,Diagnostic Test|Diagnostic Test,Standard screening strategy|New screening strategy,The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by individual testing.|The pharyngeal swab specimen was obtained and sent for NCIP RNA detection by minipool testing.,2,,the Fifth Medical Center of Chinese PLA General Hospital,Beijing,Beijing,100071,China,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-17,NA,NA,2020-02-18,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-18,2020-02-19,Actual,"February 14, 2020",Anticipated,2020-02-14,February 2020,2020-02-29,"December 14, 2021",Anticipated,2021-12-14,"May 14, 2020",Anticipated,2020-05-14,NA,Interventional,NA,,Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia,"A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia",Not yet recruiting,NA,N/A,348,Anticipated,Jiangxi Qingfeng Pharmaceutical Co. Ltd.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:24:13Z,2020-04-01T09:24:13Z,4279053,NCT04275388,Coronavirus Infections,coronavirus infections,Drug|Drug,"Xiyanping injection|Lopinavir / ritonavir, alpha-interferon nebulization","Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days,|Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-06,NA,NA,2020-02-06,2020-02-06,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-02-06,2020-02-10,Actual,"February 7, 2020",Anticipated,2020-02-07,February 2020,2020-02-29,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection,"A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection",Not yet recruiting,NA,N/A,160,Anticipated,First Affiliated Hospital of Zhejiang University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:26:07Z,2020-04-01T09:26:07Z,4280708,NCT04261907,Coronavirus Infections,coronavirus infections,Drug|Drug,ASC09/ritonavir group|lopinavir/ritonavir group,"ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment|Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-17,NA,NA,2020-03-17,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COVID MECH,,Mechanisms to Morbidity and Mortality for Covid-19,"Changes in Organ Specific Biomarkers, Virus Expression and Prognosis for Covid-19",Not yet recruiting,NA,NA,200,Anticipated,"University Hospital, Akershus",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:19:19Z,2020-04-01T09:19:19Z,4274145,NCT04314232,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-02,NA,NA,2020-04-14,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 7, 2020",Actual,2020-04-07,April 2020,2020-04-30,"October 21, 2021",Anticipated,2021-10-21,"September 1, 2020",Anticipated,2020-09-01,NA,Observational,NA,,Rutgers COVID-19 Cohort Study,"Cohort Study of SARS-CoV-2 Incidence, Transmission, and Disease Severity in Healthcare Workers",Recruiting,NA,NA,750,Anticipated,"Rutgers, The State University of New Jersey",,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      nasopharyngeal or throat swabs, saliva, and blood (for detecting SARS-CoV-2 positivity and
      immunity)
    ",NA,NA,NA,No,NA,2020-04-25T09:18:12Z,2020-04-25T09:18:12Z,5111137,NCT04336215,Coronavirus Infections,coronavirus infections,Other,Non-Interventional,This non-interventional study poses no additional risks to people with pre-existing conditions.,1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -|Robert Wood Johnson University Hospital|Clinical Research Unit Rutgers New Jersey Medical School|Rutgers School of Dental Medicine|University Hospital|Environmental and Occupational Health Sciences Institute|RUCDR Infinite Biologics,New Brunswick|New Brunswick|Newark|Newark|Newark|Piscataway|Piscataway,New Jersey|New Jersey|New Jersey|New Jersey|New Jersey|New Jersey|New Jersey,08901|08901|07103|07103|07103|08854|08854,United States|United States|United States|United States|United States|United States|United States,7
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-06,NA,NA,2020-02-07,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-02-07,2020-02-11,Actual,"February 7, 2020",Actual,2020-02-07,February 2020,2020-02-29,"August 7, 2023",Anticipated,2023-08-07,"August 7, 2020",Anticipated,2020-08-07,NA,Observational,CCP-nCoV,,Clinical Characterisation Protocol for Severe Emerging Infections,Clinical Characterisation Protocol for Severe Emerging Infections,Recruiting,NA,NA,500,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood, urine, stool /rectal swab, respiratory samples (nose and throat swab, endotracheal
      aspirate, nasopharyngeal aspirate), samples from infected sites/sores, CSF
    ",NA,NA,NA,Undecided,NA,2020-04-01T09:25:58Z,2020-04-01T09:25:58Z,4280580,NCT04262921,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting|Recruiting|Recruiting|Recruiting,"CHU Pellegrin, service des Maladies Infectieuses et Tropicales|APHP La PitiÃ© SalpÃªtriÃ¨re, service des Maladies Infectieuses et Tropicales|APHP Bichat, Service de rÃ©animation mÃ©dicale et infectieuse|APHP Bichat, Service des Maladies Infectieuses et Tropicales",Bordeaux|Paris|Paris|Paris,|||,33075|75013|75018|75018,France|France|France|France,4
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,CCAP,,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,"Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multi-stage, 6-armed Placebo-controlled Trial in the Framework of an Adaptive Trial Platform",Not yet recruiting,NA,Phase 3,1500,Anticipated,Hvidovre University Hospital,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-24T09:05:54Z,2020-04-24T09:05:54Z,5098996,NCT04345289,Coronavirus Infections,coronavirus infections,Biological|Drug|Drug|Drug|Other|Other,Convalescent anti-SARS-CoV-2 plasma|Sarilumab|Baricitinib|Hydroxychloroquine|Injective placebo|Oral placebo,Single infusion of convalescent anti-SARS-CoV-2 plasma (2 x 300 mL)|Pre-filled syringe 200 mg (1.14 mL) as a single dose|Tablets 4 mg/day for 7 days|Tablets 600 mg/day for 7 days|Saline 0.9% (600 ml) as an iv single dose infusion + placebo treatment with saline 0.9% (1.14 mL) as a single sc injection|Three glucose monohydrate placebo capsules daily for 7 days,6,|||||||||||,Aalborg University Hospital|Aarhus University Hospital|Bispebjerg Hospital|Rigshospitalet|Herlev Gentofte Hospital|Herning Hospital|NordsjÃ¦llands Hospital|Hvidovre Hospital|Kolding Hospital|Odense University Hospital|Roskilde Hospital|Vejle Hospital,Aalborg|Arhus|Copenhagen|Copenhagen|Herlev|Herning|HillerÃ¸d|Hvidovre|Kolding|Odense|Roskilde|Vejle,|||||||||||,|||||||||||,Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark,12
"ClinicalTrials.gov processed this data on April 22, 2020",2020-03-31,NA,NA,2020-04-13,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"April 4, 2021",Anticipated,2021-04-04,"December 4, 2020",Anticipated,2020-12-04,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,75,Anticipated,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-24T09:06:52Z,2020-04-24T09:06:52Z,5099150,NCT04343651,Coronavirus Infections,coronavirus infections,Drug|Drug,Placebos|Leronlimab (700mg),"Placebo|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)",2,Recruiting,Montefiore Medical Center,Bronx,New York,10467,United States,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-08,NA,NA,2020-04-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-14,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Not yet recruiting,NA,Phase 2,15,Anticipated,Saint Francis Care,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-24T09:06:57Z,2020-04-24T09:06:57Z,5099164,NCT04343261,Coronavirus Infections,coronavirus infections,Biological,Convalescent Plasma,treatment with 2 Units of convalescent plasma,1,,Trinity Health Of New England,Hartford,Connecticut,06105,United States,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-04,NA,NA,2020-04-10,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,CloroCOVID19II,,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",Recruiting,NA,Phase 2,210,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication,Upon formal request to researchers.,NA,Yes,all patient data will be shared after study publication,2020-04-24T09:07:05Z,2020-04-24T09:07:05Z,5099189,NCT04342650,Coronavirus Infections,coronavirus infections,Drug|Drug,Chloroquine Diphosphate|Placebo oral tablet,150mg tablets|150mg placebo tablets,2,Recruiting,Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz,Manaus,Amazonas,69093-415,Brazil,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-07,NA,NA,2020-04-10,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,May 2020,Anticipated,2020-05-31,NA,Interventional,CORIMUNO-ANA,,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19",Not yet recruiting,NA,Phase 2,240,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-24T09:07:20Z,2020-04-24T09:07:20Z,5099241,NCT04341584,Coronavirus Infections,coronavirus infections,Drug,Anakinra,"Treatment includes the administration of Two IV infusions / day of ANAKINRA KINERETÂ® 200mg (Total 400 mg) at day 1 (D1), D2 and D3, two IV infusions / day of ANAKINRA KINERETÂ® 100mg (Total 200 mg) at day 4 (D4), and one IV infusion of ANAKINRA KINERETÂ® 100mg (Total 100 mg) at day 5 (D5).
In case of absence of improvement at D4 (absence of clinical improvement AND absence of decrease of CRP level > 50%), 3 supplementary days of treatment at 400 mg/day will be done at D4, D5, D6 followed by a decrease at 200 mg/day at D7 and 100 mg/day at D8 and stop thereafter",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-07,NA,NA,2020-04-10,2020-04-07,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"June 30, 2020",Anticipated,2020-06-30,28 Days,Observational [Patient Registry],FRENCH CORONA,,French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study,French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study,Recruiting,NA,NA,220,Anticipated,Centre Hospitalier Universitaire de NÄ«mes,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-24T09:07:27Z,2020-04-24T09:07:27Z,5099263,NCT04340466,Coronavirus Infections,coronavirus infections,Other,No intervention,No intervention,1,Recruiting,CHU Nimes,NÃ®mes,,30029,France,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-03-26,NA,NA,2020-04-10,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"March 25, 2020",Actual,2020-03-25,April 2020,2020-04-30,"April 10, 2020",Anticipated,2020-04-10,"April 3, 2020",Anticipated,2020-04-03,NA,Observational,NA,,A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research,A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research,Recruiting,NA,NA,120,Anticipated,UnitedHealth Group,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Patients will return at the following times to complete the same battery of sample
      collection:

        -  7-9 days after initially testing positive;

        -  14-18 days after initially testing positive;

        -  28-42 days after initially testing positive. Additional visits, during which additional
           samples could be collected may occur after 42 days if agreeable to the participants and
           desired by the study investigators.
    ",2 months,"The data collected due to this study will be extracted from the medical record and stored for additional research analysis to demonstrate equivalence between location in the two nasal swabs. Blood samples will be delivered to PATH and the Mayo Clinic for storage and analysis. Patients may not have access to these samples or the blood features derived from them after sample collection. Data will be shared between the participating clinics, UHG and collaborating partners performing the analysis of the samples and returning results.",NA,Yes,"Four data sources will be recorded for each patient who consents to participate in the study:
Electronic medical record (EMR);
Results of testing from the foam and polyester nasal swab samples;
Results of any blood testing performed on the blood samples;
Responses to a set of standard questions posed to each participant.",2020-04-24T09:08:15Z,2020-04-24T09:08:15Z,5099425,NCT04327804,Coronavirus Infections,coronavirus infections,Diagnostic Test,Odd/Even birth year intervention groups,The nostril used and order of testing will be different in each arm.,1,Recruiting,Everett Clinic,Seattle,Washington,98133,United States,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-03-25,NA,NA,2020-04-10,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,September 2021,Anticipated,2021-09-30,June 2021,Anticipated,2021-06-30,2 Months,Observational [Patient Registry],NA,,Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients,Single-Arm Observational Study Designed to Clinically Evaluate Cordio Application in Adult Patients Positive to COVID-19,Not yet recruiting,NA,NA,5000,Anticipated,Cordio Medical,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-24T09:08:23Z,2020-04-24T09:08:23Z,5099456,NCT04325048,Coronavirus Infections,coronavirus infections,Device,Cordio App,Adult patients positive to COVID-19 virus will record several predefined sentences via a smartphone / tablet and will answer questions via the app,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 22, 2020",2020-03-25,NA,NA,2020-04-10,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"March 10, 2020",Actual,2020-03-10,April 2020,2020-04-30,"May 8, 2020",Anticipated,2020-05-08,"April 10, 2020",Anticipated,2020-04-10,NA,Observational,CORONADO,,"""COVID-19 and Diabetes Outcomes""","""Coronavirus SARS-CoV2 and Diabetes Outcomes"" : CORONADO",Recruiting,NA,NA,1000,Anticipated,Nantes University Hospital,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-24T09:08:24Z,2020-04-24T09:08:24Z,5099458,NCT04324736,Coronavirus Infections,coronavirus infections,Other,no interventional study,no interventional study,1,Recruiting,CHU Nantes,Nantes,,44000,France,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-03-23,NA,NA,2020-04-10,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"March 28, 2020",Actual,2020-03-28,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients,Recruiting,NA,Phase 2/Phase 3,700,Anticipated,Oslo University Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The study will end according the requirements to WHO,WHO COVID 19 investigators,NA,Yes,All patients included in this study will automatically be included in the WHO COVID 19 protocol,2020-04-24T09:08:36Z,2020-04-24T09:08:36Z,5099508,NCT04321616,Coronavirus Infections,coronavirus infections,Drug|Drug|Other,Hydroxychloroquine|Remdesivir|(Standard of Care) SoC,Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.|Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.|The standard of care will be supplied to all patients not receiving a drug intervention.,3,Recruiting,Andreas Barratt-Due,Oslo,,0756,Norway,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-02-28,NA,NA,2020-04-13,2020-03-05,2020-03-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-14,Actual,"May 10, 2020",Anticipated,2020-05-10,April 2020,2020-04-30,"November 10, 2020",Anticipated,2020-11-10,"October 9, 2020",Anticipated,2020-10-09,NA,Interventional,NA,,Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19,Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Not yet recruiting,NA,Phase 2,20,Anticipated,Tianhe Stem Cell Biotechnologies Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-24T09:09:24Z,2020-04-24T09:09:24Z,5099699,NCT04299152,Coronavirus Infections,coronavirus infections,Combination Product,Stem Cell Educator-Treated Mononuclear Cells Apheresis,"SCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the ""educated"" autologous immune cells to the patient's circulation.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 22, 2020",2020-02-13,NA,NA,2020-04-11,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,NK Cells Treatment for COVID-19,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,30,Anticipated,Xinxiang medical university,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-24T09:09:48Z,2020-04-24T09:09:48Z,5099792,NCT04280224,Coronavirus Infections,coronavirus infections,Biological,NK Cells,twice a week of NK cells (0.1-2*10E7 cells/kg body weight),1,Recruiting,The First Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan,453000,China,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-02-14,NA,NA,2020-04-10,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"February 15, 2022",Anticipated,2022-02-15,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19,Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19,Not yet recruiting,NA,N/A,48,Anticipated,"Wuhan Union Hospital, China",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-24T09:10:01Z,2020-04-24T09:10:01Z,5099841,NCT04273646,Coronavirus Infections,coronavirus infections,Biological|Drug,UC-MSCs|Placebo,"4 times of UC-MSCs(0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7).|4 times of cell-free stem cell suspension (saline containing 1% human albumin) intravenously at Day 1, Day 3, Day 5, Day 7).",2,,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Wuhan,Hubei,430000,China,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-14,NA,NA,2020-04-15,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"June 1, 2021",Anticipated,2021-06-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Early Extubation for Patients With Acute Hypoxemic Respiratory Failure,Early Extubation for Patients With Acute Hypoxemic Respiratory Failure,Not yet recruiting,NA,N/A,108,Anticipated,University of Chicago,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-26T09:04:42Z,2020-04-26T09:04:42Z,5123451,NCT04349332,Coronavirus Infections,coronavirus infections,Device,Helmet non-invasive ventilation (NIV),"After application of the helmet, arterial blood gas sampling will be utilized to follow gas-exchange; Noninvasive support will be reduced progressively in accordance to clinical improvement and will be discontinued if patient maintains respiratory rate <30breaths/min and PaO2 >75mm Hg with FiO2 0.5 without ventilatory support. If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay.",1,,University of Chicago Medical Center,Chicago,Illinois,60637,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-16,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Observational,BLAST COVID-19,,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Recruiting,NA,NA,50000,Anticipated,William Beaumont Hospitals,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,Samples With DNA,"
      Whole blood and serum
    ",NA,NA,NA,No,NA,2020-04-26T09:04:46Z,2020-04-26T09:04:46Z,5123462,NCT04349202,Coronavirus Infections,coronavirus infections,Diagnostic Test,EUROIMMUN assay,Serology testing to detect SARS-CoV-2 antibodies,1,Recruiting|Not yet recruiting,Beaumont Health System|Beaumont Health,Royal Oak|Royal Oak,Michigan|Michigan,48073|48073,United States|United States,2
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-09,NA,NA,2020-04-15,2020-04-10,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"June 1, 2022",Anticipated,2022-06-01,"April 15, 2020",Anticipated,2020-04-15,NA,Observational,STOP-COVID,,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,Recruiting,NA,NA,2000,Anticipated,Brigham and Women's Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-26T09:06:09Z,2020-04-26T09:06:09Z,5123689,NCT04343898,Coronavirus Infections,coronavirus infections,Other,No intervention,Observational,1,Recruiting,Brigham and Women's Hospital,Boston,Massachusetts,02115,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-07,NA,NA,2020-04-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,April 2023,Anticipated,2023-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,University of Utah COVID-19 Hydrochloroquine Trial,Hydroxychloroquine for Outpatients With Confirmed COVID-19,Recruiting,NA,Phase 2,400,Anticipated,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-26T09:06:22Z,2020-04-26T09:06:22Z,5123732,NCT04342169,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,"HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days|Placebo to be taken on the same schedule as HCQ.",2,Recruiting,University of Utah,Salt Lake City,Utah,84108,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-02,NA,NA,2020-04-14,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic,Not yet recruiting,NA,N/A,30,Anticipated,Istanbul University-Cerrahpasa,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-26T09:06:53Z,2020-04-26T09:06:53Z,5123850,NCT04334434,Coronavirus Infections,coronavirus infections,Other,Telerehabilitation,15 volunteers over 65 years old who are at home during the social isolation process due to the coronavirus outbreak will be included in this group. An online exercise protocol was created for individuals who will participate in the study. Each exercise session was planned as 30 minutes for 3 days a week for 4 weeks. It was planned to start the protocol with warm-up exercises and finish with cooling exercises. The exercise protocol was additionally determined as a combination of aerobic and strengthening exercises. Individuals were asked to participate in the study via Skype and aimed to do their exercises with a physiotherapist,1,,Istanbul university Cerrahpasa,Istanbul,,,Turkey,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-23,NA,NA,2020-04-15,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-16,Actual,"March 23, 2020",Actual,2020-03-23,April 2020,2020-04-30,"March 23, 2022",Anticipated,2022-03-23,"March 23, 2022",Anticipated,2022-03-23,NA,Interventional,EPI-COVID-19,,Household Transmission Investigation Study for COVID-19 in French Guiana,Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in French Guiana,Recruiting,NA,N/A,450,Anticipated,Institut Pasteur,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-26T09:07:12Z,2020-04-26T09:07:12Z,5123911,NCT04328129,Coronavirus Infections,coronavirus infections,Procedure,Human biological samples,"Blood sample
Nasopharyngeal swab.",1,Enrolling by invitation|Recruiting,Centre Hospitalier AndrÃ©e Rosemon|Institut Pasteur de la Guyane,Cayenne|Cayenne,|,|,French Guiana|French Guiana,2
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 14, 2020",Anticipated,2020-04-14,April 2020,2020-04-30,"May 28, 2021",Anticipated,2021-05-28,"April 28, 2020",Anticipated,2020-04-28,NA,Interventional,PEACE,,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate,Not yet recruiting,NA,Phase 4,400,Anticipated,"Government of Punjab, Specialized Healthcare and Medical Education Department",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-25T09:16:28Z,2020-04-25T09:16:28Z,5110849,NCT04346667,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug|Drug,Hydroxychloroquine Sulfate Regular dose|Hydroxychloroquine Sulfate Loading Dose|Chloroquine|Placebo,Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2|Hydroxychloroquine administered as a loading dose only|Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2|Standard of Care plus placebo,4,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-23,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19),Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial,Not yet recruiting,NA,Phase 1/Phase 2,20,Anticipated,Guangzhou Institute of Respiratory Disease,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-25T09:16:39Z,2020-04-25T09:16:39Z,5110877,NCT04346368,Coronavirus Infections,coronavirus infections,Biological|Biological,BM-MSCs|Placebo,Participants will receive conventional treatment plus BM-MSCs(1*10E6 /kg body weight intravenously at Day 1).|Placebo,2,,"Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University",Guangzhou,Guangdong,510120,China,1
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-30,NA,NA,2020-04-01,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,CP-COVID-19,,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Not yet recruiting,NA,Phase 2,10,Anticipated,Universidad del Rosario,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-12T09:05:59Z,2020-04-12T09:05:59Z,4966025,NCT04332380,Coronavirus Infections,coronavirus infections,Drug,Plasma,"Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.",1,,Universidad del Rosario,Bogota,Cundinamarca,11100,Colombia,1
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-26,NA,NA,2020-03-31,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,GRECCO-19,,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Not yet recruiting,NA,Phase 2,180,Anticipated,National and Kapodistrian University of Athens,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-12T09:07:41Z,2020-04-12T09:07:41Z,4966351,NCT04326790,Coronavirus Infections,coronavirus infections,Drug|Drug,Colchicine|Standard treatment,"Low-dose colchicine treatment, 0.5 mg bid|Standard treatment",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-04,2020-04-04,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-04,2020-04-08,Actual,"April 6, 2020",Anticipated,2020-04-06,March 2020,2020-03-31,"January 29, 2021",Anticipated,2021-01-29,"December 29, 2020",Anticipated,2020-12-29,NA,Observational,POCUSCO,,Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients,Point Of Care UltraSonography to Perform Risk-stratification of Patients With Suspected or Confirmed COVID-19 - POCUSCO Study,Not yet recruiting,NA,NA,300,Anticipated,"University Hospital, Angers",,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-18T09:10:37Z,2020-04-18T09:10:37Z,5035657,NCT04338100,Coronavirus Infections,coronavirus infections,Procedure,Follow-up at 14 days,Point of care chest ultrasonography and 14-day follow-up to assess the evolution of the infection and care requirement (invasive ventilation or death),1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-03,NA,NA,2020-04-07,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,COVIDeHPAD,,Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease,Gerontological Telemonitoring of Older Adults Living in Nursing Homes With Symptoms of Confirmed or Probable COVID-19 Disease,Not yet recruiting,NA,N/A,200,Anticipated,"University Hospital, Limoges",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:10:48Z,2020-04-18T09:10:48Z,5035693,NCT04337788,Coronavirus Infections,coronavirus infections,Other,telehealth applications,telehealth applications during 30 days/patient,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-31,NA,NA,2020-04-06,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIMUNO-TOC,,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI),Not yet recruiting,NA,Phase 2,240,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-18T09:11:35Z,2020-04-18T09:11:35Z,5035849,NCT04331808,Coronavirus Infections,coronavirus infections,Drug,Tocilizumab,Tocilizumab 8mg/kg D1 and if no response (no decrease of oxygen requirement) a second injection at D3.,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-25,NA,NA,2020-04-07,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,HYCOVID,,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,"Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study",Recruiting,NA,Phase 3,1300,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-18T09:12:01Z,2020-04-18T09:12:01Z,5035938,NCT04325893,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine|Placebo,"First dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and the treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.|The first dose of 400 mg will be taken immediately after inclusion at day 0, the second dose of 400 mg will be taken on the same evening and the treatment will then be continued for the following eight days at a rate of 200 mg in the morning and evening.",2,Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting,CH Agen|CHU Amiens|CHU Angers|APHP Avicenne|CHU Brest|CHU Caen|CH Cherbroug|CH Cholet|CH Colmar|APHP Henri Mondor|CHU Dijon|CHD VendÃ©e|CH Laval|CH Le Mans|CHU Limoges|CH Lorient|CH Melun|CHU Nantes|HÃ´pital PrivÃ© du Confluent|CH Niort|CHR OrlÃ©ans|APHP Saint-Antoine|La PitiÃ©-SalpÃ©triÃ¨re|CHU Poitiers|CH Pointoise|CH Quimper|CH Saint-Brieuc|CH Saint-Nazaire|CHU Saint-Etienne|CHU Toulouse|CH Tourcoing|CHU Tours|CH Valenciennes|Clinique Tessier Valenciennes|CH Vannes|CH Versailles|CH Princesse Grace,Agen|Amiens|Angers|Bobigny|Brest|Caen|Cherbourg|Cholet|Colmar|CrÃ©teil|Dijon|La Roche-sur-Yon|Laval|Le Mans|Limoges|Lorient|Melun|Nantes|Nantes|Niort|OrlÃ©ans|Paris|Paris|Poitiers|Pontoise|Quimper|Saint-Brieuc|Saint-Nazaire|Saint-Ã‰tienne|Toulouse|Tourcoing|Tours|Valenciennes|Valenciennes|Vannes|Versailles|Monaco,||||||||||||||||||||||||||||||||||||,||||||||||||||||||||||||||||||||||||,France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|Monaco,37
"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-24,NA,NA,2020-04-06,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,January 2023,Anticipated,2023-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,CSSC-001,,Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19,"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19",Not yet recruiting,NA,Phase 2,150,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Sharing is governed by Johns Hopkins University Institutional Guidelines,2020-04-18T09:12:11Z,2020-04-18T09:12:11Z,5035980,NCT04323800,Coronavirus Infections,coronavirus infections,Biological|Biological,Anti- SARS-CoV-2 Plasma|SARS-CoV-2 non-immune Plasma,SARS-CoV-2 convalescent plasma (1 unit; ~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and was found to have a titer of neutralizing antibody >1:64)|Standard plasma collected prior to December 2019,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-11,NA,NA,2020-04-06,2020-03-11,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"March 17, 2020",Actual,2020-03-17,April 2020,2020-04-30,"May 12, 2020",Anticipated,2020-05-12,"April 21, 2020",Anticipated,2020-04-21,NA,Interventional,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Recruiting,NA,Phase 3,3000,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:12:54Z,2020-04-18T09:12:54Z,5036188,NCT04308668,Coronavirus Infections,coronavirus infections,Drug|Other,Hydroxychloroquine|Placebo,"200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days|4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days",2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Nationwide Enrollment via Internet, please email: covid19@umn.edu|University of Minnesota|Internet|University of Alberta|University of Manitoba|Research Institute of the McGill University Heath Centre",Minneapolis|Minneapolis|New York|Edmonton|Winnipeg|MontrÃ©al,Minnesota|Minnesota|New York|Alberta|Manitoba|Quebec,55455|55455|10001|||,United States|United States|United States|Canada|Canada|Canada,6
"ClinicalTrials.gov processed this data on April 08, 2020",2020-03-26,NA,NA,2020-03-26,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"September 25, 2022",Anticipated,2022-09-25,"September 25, 2022",Anticipated,2022-09-25,NA,Observational,NA,,Audio Data Collection for Identification and Classification of Coughing,Audio Data Collection for Identification and Classification of Coughing,Recruiting,NA,NA,1000,Anticipated,HealthMode Inc.,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-09T09:14:27Z,2020-04-09T09:14:27Z,4926554,NCT04326309,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,Virtual Facility,Bronx,New York,10461,United States,1
"ClinicalTrials.gov processed this data on April 01, 2020",2020-03-31,NA,NA,2020-03-31,2020-03-31,2020-04-01,Estimate,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Estimate,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,EPICOS,,EPICOS Clinical Trial for the Prevention of Infection in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarato/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,"Active, not recruiting",NA,Phase 3,4000,Anticipated,Effice Servicios Para la Investigacion S.L.,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-02T09:13:28Z,2020-04-02T09:13:28Z,4840831,NCT04329520,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug|Drug,Emtricitabine/tenofovir disoproxil|Hydroxychloroquine|Placebo: Emtricitabine/tenofovir disoproxil|Placebo: Hydroxychloroquine,"Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.|Placebo. Tablets similar in appearance to Emtricitabine/tenofovir disoproxil|Placebo. Tablets similar in appearance to Hydroxychloroquine",4,,Hospital Universitario RamÃ³n y Cajal,Madrid,,28034,Spain,1
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-23,NA,NA,2020-03-30,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-02,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"March 20, 2022",Anticipated,2022-03-20,"March 20, 2021",Anticipated,2021-03-20,1 Year,Observational [Patient Registry],BEAT19,,"Behavior, Environment And Treatments for Covid-19",A PATIENT-CENTRIC OUTCOMES REGISTRY OF PATIENTS WITH KNOWN OR SUSPECTED NOVEL CORONAVIRUS INFECTION SARS-COV-2 (COVID-19),Recruiting,NA,NA,100000,Anticipated,xCures,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,De-identified datasets will be made available to qualified researchers in accordance with the study protocol.,2020-04-12T09:08:04Z,2020-04-12T09:08:04Z,4966451,NCT04321811,Coronavirus Infections,coronavirus infections,Other,"Observation of patients with known, suspected, or at risk for COVID-19 infection",Participants will receive daily diary surveys to track the symptomatic course of known or suspected COVID-19 patients as well as use of any interventions or treatments.,1,Recruiting,BEAT19.org,San Francisco,California,94022,United States,1
"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-01,NA,NA,2020-04-06,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-08,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Observational,TOVID-49,,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Recruiting,NA,NA,100,Anticipated,"University Hospital, Angers",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-18T09:11:23Z,2020-04-18T09:11:23Z,5035816,NCT04333849,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,Angers University Hospital,Angers,,49933,France,1
"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-06,NA,NA,2020-03-25,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,COPCOV,,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)",Not yet recruiting,NA,N/A,40000,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2020-04-06T08:56:55Z,2020-04-06T08:56:55Z,4894691,NCT04303507,Coronavirus Infections,coronavirus infections,Drug|Drug,Chloroquine or Hydroxychloroquine|Placebo,A loading dose of 10 mg base/ kg followed by 155 mg daily (250mg chloroquine phosphate salt or 200mg of or hydroxychloroquine sulphate) will be taken for 3 months|Placebo,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-04,NA,NA,2020-03-13,2020-03-13,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-16,Actual,"March 5, 2020",Anticipated,2020-03-05,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,TT-NPC,,Tetrandrine Tablets Used in the Treatment of COVID-19,Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19,Enrolling by invitation,NA,Phase 4,60,Anticipated,Henan Provincial People's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:05Z,2020-04-01T09:20:05Z,4274939,NCT04308317,Coronavirus Infections,coronavirus infections,Drug,Tetrandrine,Tetrandrine 60mg QD for 1week,1,,Tetrandrine Tablets,Jinhua,Zhejiang,321000,China,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),"A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,390,Anticipated,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-25T09:16:06Z,2020-04-25T09:16:06Z,5110787,NCT04347239,Coronavirus Infections,coronavirus infections,Drug|Drug,Placebos|Leronlimab (700mg),"Placebos|Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)",2,Recruiting,Montefiore Medical Center,Bronx,New York,10467,United States,1
"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-24,NA,NA,2020-03-26,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-27,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Observational,NA,,Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy,Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy,Not yet recruiting,NA,NA,300,Anticipated,Universita di Verona,,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Nasopharyngeal swabs
    ",NA,NA,NA,NA,NA,2020-04-06T08:55:08Z,2020-04-06T08:55:08Z,4894228,NCT04324866,Coronavirus Infections,coronavirus infections,Diagnostic Test,Nasopharyngeal swab,Nasopharyngeal swab for the molecular diagnosis of COVID-19 infection,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-20,NA,NA,2020-03-24,2020-03-20,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-25,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial,Not yet recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-04-04T09:18:34Z,2020-04-04T09:18:34Z,4870202,NCT04318444,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,"Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.|Two tablets (400mg) twice daily on day 1; for days 2-5, they will be instructed to take one tablet (200mg) twice daily.",2,,Columbia University Irving Medical Center,New York,New York,10032,United States,1
"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-19,NA,NA,2020-03-25,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 23, 2020",Anticipated,2020-03-23,March 2020,2020-03-31,"May 30, 2020",Anticipated,2020-05-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,MP-C19,,Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Recruiting,NA,Phase 2/Phase 3,104,Anticipated,University of Trieste,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Anonymised data will be available only to data manager who can visualise clinical chart anytime when is needed,2020-04-06T08:55:46Z,2020-04-06T08:55:46Z,4894358,NCT04323592,Coronavirus Infections,coronavirus infections,Drug|Other,Methylprednisolone|standard care,"Methylprednisolone given at low prolonged dose infusion after initial 80mg iv bolus at admission followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description|usual standard of care:
oxygen therapy (regular or high-flow) and monitoring
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
ECMO when needed and available
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins",2,Recruiting,Marco Confalonieri,Trieste,TS,34149,Italy,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19),Investigation Of The Effectiveness Of Video-Based Exercise Program Applied To Adult Individuals Who Experience Social Isolation At Houses Due To The Coronavirus (COVID-19) Pandemic,Not yet recruiting,NA,N/A,128,Anticipated,Istinye University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-25T09:16:16Z,2020-04-25T09:16:16Z,5110815,NCT04346953,Coronavirus Infections,coronavirus infections,Behavioral,Video based exercise,"Individuals (n = 64) to be included in the study group will be grouped according to the levels of physical activity (low, medium, high level) determined by the International Physical Activity Questionnaire. An exercise program will be created for each group based on physical activity levels and videos of these exercise programs will be prepared. The videos will be scheduled for 20 minutes. Individuals will be asked to apply for these programs with video for 20 minutes every day for 6 weeks. Exercise programs will start with pulmonary exercises and warm-up exercises to prepare for exercise. The exercise program will end with cool down exercises. The exercise protocol will be determined as a combination of aerobic and strengthening exercises.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 10, 2020",Anticipated,2020-06-10,NA,Interventional,COVID-19,,Telerehabilitation for Patients Diagnosed With Coronavirus,Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home,Not yet recruiting,NA,N/A,30,Anticipated,Istinye University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-25T09:16:17Z,2020-04-25T09:16:17Z,5110816,NCT04346927,Coronavirus Infections,coronavirus infections,Other|Other,Telerehabilitation|exercise brochure,"15 volunteers diagnosed with coronavirus will be included in experimental group. An online exercise program has been created for individuals who will participate in the study. This program is planned to continue 3-4 days a week, in a 30-minute session and for 6 weeks. Treatment sessions will include breathing exercises, posture exercises, peripheral muscle exercises and light aerobic exercises. Individuals were asked to participate in the research via telerehabilitation connection system and were told that they would do their exercises with a physiotherapist.|15 volunteers diagnosed with coronavirus will be included in control group.The same exercises will be given to the control group as a brochure and they will be asked to do it for 6 weeks.",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-03,NA,NA,2020-04-08,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-13,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,ATTAC-Co,,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Patterns and Changes in Platelet Reactivity, Thrombotic Status and Endothelial Function in Hospitalized Patients With SARS-Cov-2 Infection",Recruiting,NA,N/A,60,Anticipated,University Hospital of Ferrara,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,After specific request to study PIs,2020-04-23T09:13:15Z,2020-04-23T09:13:15Z,5086687,NCT04343053,Coronavirus Infections,coronavirus infections,Other,SARS-Cov-2 infection,blood sample withdrawal,1,Recruiting,Azienda Ospedaliera Universitaria di Ferrara,Ferrara,,,Italy,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-08,NA,NA,2020-04-08,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-13,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,,COVID-19 Community Research Partnership,"A Multicenter, Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records",Not yet recruiting,NA,NA,150000,Anticipated,Wake Forest University Health Sciences,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-23T09:13:21Z,2020-04-23T09:13:21Z,5086700,NCT04342884,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,,Wake Forest Baptist Medical Center,Winston-Salem,North Carolina,27157,United States,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-05,NA,NA,2020-04-09,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,HOME-CoV,,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study,Recruiting,NA,N/A,4000,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-23T09:14:19Z,2020-04-23T09:14:19Z,5086903,NCT04338841,Coronavirus Infections,coronavirus infections,Other,HOME-CoV rule implementation,"HOME-CoV rule is an easy-to-use clinical rule aiming to help emergency physicians in hospitalisation or outpatient management decision making. The definition of the rule is performed using the Delphi method to reach a consensus of a large panel of experts.
Between before and after period, educational lectures, posters, and pocket cards showing and explaining HOME-CoV rule are communicated to participating Emergency Departments.",1,"Not yet recruiting|Not yet recruiting|Active, not recruiting|Not yet recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting|Recruiting|Active, not recruiting|Active, not recruiting|Active, not recruiting",Clinique Universitaire Saint-Luc|CHU de LiÃ¨ge|Ch Argenteuil|CHU Brest|CH Cholet|CHU Clermont Ferrand|Ch Colmar|CH Alpes Lemant|CHU Dijon|CH Le Mans|CH Libourne|CH Limoges|Ch Longjumeau|Hospices Civils de Lyon (University Hospital of Lyon)|Chu Montpellier|Centre Hospitalier Universitaire de Nantes|CH Niort|Hopital Paris Saint Joseph|Hopital Saint Antoine|HÃ´pital Bichat|HÃ´pital LariboisiÃ¨re|CHU de Poitiers|CH Reims|Ch Remiremont|Chu Rennes|CHU de Rouen|CHU de St Etienne|CH de Saint-Brieuc|Ch Troyes|CH VICHY|CH Princesse Grace,Bruxelles|Liege|Argenteuil|Brest|Cholet|Clermont Ferrand|Colmar|Contamine-sur-Arve|Dijon|Le Mans|Libourne|Limoges|Longjumeau|Lyon|Montpellier|Nantes|Niort|Paris|Paris|Paris|Paris|Poitiers|Reims|Remiremont|Rennes|Rouen|Saint Etienne|Saint-Brieuc|Troyes|Vichy|Monaco,||||||||||||||||||||||||||||||,|||||||||||||||||||||86000|||||42000||||,Belgium|Belgium|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|France|Monaco,31
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-03,NA,NA,2020-04-09,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 12, 2020",Anticipated,2020-04-12,April 2020,2020-04-30,"June 10, 2020",Anticipated,2020-06-10,"May 10, 2020",Anticipated,2020-05-10,NA,Observational,NA,,"Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine","Determination Of Physical Activity, Sleep And Stress Level Of Pregnant Women In The CovÄ±d-19 Quarantine Period",Not yet recruiting,NA,NA,100,Anticipated,Istanbul KÃ¼ltÃ¼r University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-23T09:14:28Z,2020-04-23T09:14:28Z,5086912,NCT04336787,Coronavirus Infections,coronavirus infections,Other,Survey,"A Google Survey which included that consent form, demographic information form, International Physical Activity Questionnaire, Pittsburgh Sleep Quality Index, Perceived Stress Scale and The Numeric Rating Scale will be created. Then the survey link will be shared via social media such as Whatsapp, Facebook, etc.",1,,Istanbul University - CerrahpaÅŸa,Istanbul,,,Turkey,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-02-21,NA,NA,2020-04-09,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 3, 2020",Actual,2020-03-03,"February 20, 2020",2020-02-20,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults",Recruiting,NA,Phase 1,45,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-23T09:16:50Z,2020-04-23T09:16:50Z,5087463,NCT04283461,Coronavirus Infections,coronavirus infections,Biological,mRNA-1273,"Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.",1,Recruiting|Not yet recruiting|Recruiting,Emory Vaccine Center - The Hope Clinic|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases,Decatur|Bethesda|Seattle,Georgia|Maryland|Washington,30030-1705|20892|98101-1466,United States|United States|United States,3
"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-26,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Observational,CovidSurg,,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Not yet recruiting,NA,NA,1000,Anticipated,University of Birmingham,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No individual participant data will be available to other researchers,2020-04-05T09:04:25Z,2020-04-05T09:04:25Z,4883038,NCT04323644,Coronavirus Infections,coronavirus infections,Procedure,Surgery,Emergency or elective surgery,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-24,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 9, 2020",Actual,2020-03-09,March 2020,2020-03-31,"May 1, 2020",Anticipated,2020-05-01,"May 1, 2020",Anticipated,2020-05-01,NA,Observational,NA,,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection (CoV-CONTACT-SERO),Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection,Recruiting,NA,NA,300,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood samples
    ",NA,NA,NA,Undecided,NA,2020-04-05T09:05:16Z,2020-04-05T09:05:16Z,4883242,NCT04322279,Coronavirus Infections,coronavirus infections,Diagnostic Test|Genetic,Serology|Sequencing,SARS-CoV-2 serology|Whole exome sequencing,2,Recruiting,CIC 1425,Paris,,,France,1
"ClinicalTrials.gov processed this data on April 08, 2020",2020-03-24,NA,NA,2020-03-26,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,"February 24, 2020",Actual,2020-02-24,March 2020,2020-03-31,"June 17, 2021",Anticipated,2021-06-17,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,NA,,Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong,"Comprehensive Clinical, Virological, Microbiological, Immunological and Laboratory Monitoring of Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,NA,170,Anticipated,Chinese University of Hong Kong,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-09T09:14:43Z,2020-04-09T09:14:43Z,4926615,NCT04325919,Coronavirus Infections,coronavirus infections,Other,No intervention,No intervention,1,Recruiting,Prince of Wales Hospital,Sha Tin,,,Hong Kong,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-21,NA,NA,2020-04-23,2020-04-23,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Estimate,"April 24, 2020",Anticipated,2020-04-24,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,PassItOn II,,Passive Immunity Trial of Nashville II,"A Randomized, Controlled Clinical Trial to Test the Safety and Efficacy of Convalescent Donor Plasma to Treat COVID-19 in Hospitalized Adults",Not yet recruiting,NA,Phase 3,500,Anticipated,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:52:19Z,2020-04-27T08:52:19Z,5133033,NCT04362176,Coronavirus Infections,coronavirus infections,Biological|Biological,pathogen reduced SARS-CoV-2 convalescent plasma|Placebo,Convalescent COVID-19 donor plasma is the liquid part of blood that is collected from patients who have recovered from COVID-19 infection. This plasma contains SARS-CoV-2 specific antibodies that may help fight the infection.|Lactated Ringer's solution with multivitamins,2,,Vanderbilt University Medical Center,Nashville,Tennessee,37203,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-23,NA,NA,2020-04-23,2020-04-23,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Estimate,"April 17, 2020",Anticipated,2020-04-17,April 2020,2020-04-30,"December 21, 2024",Anticipated,2024-12-21,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,LIINC,,Long-term Impact of Infection With Novel Coronavirus (COVID-19),Long-term Impact of Infection With Novel Coronavirus (LIINC): An Observational Study,Not yet recruiting,NA,NA,800,Anticipated,"University of California, San Francisco",,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Whole blood, peripheral blood mononuclear cells, plasma, serum, and saliva.
    ",NA,NA,NA,No,NA,2020-04-27T08:52:20Z,2020-04-27T08:52:20Z,5133034,NCT04362150,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,,Zuckerberg San Francisco General Hospital (ZSFG),San Francisco,California,94110,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-14,NA,NA,2020-04-23,2020-04-23,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Estimate,"April 25, 2020",Anticipated,2020-04-25,April 2020,2020-04-30,"May 31, 2020",Anticipated,2020-05-31,"May 24, 2020",Anticipated,2020-05-24,NA,Observational,RESPIRE,,Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection,COVID-19: Ruxolitinib for the Treatment of cytokinE Storm resPiratory dIstREss Syndrome. RESPIRE Study,Not yet recruiting,NA,NA,13,Anticipated,Azienda USL Toscana Nord Ovest,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:52:27Z,2020-04-27T08:52:27Z,5133054,NCT04361903,Coronavirus Infections,coronavirus infections,Drug,Ruxolitinib Oral Tablet,Ruxolitinib Oral Tablet dosage of at least 20 mg x 2 / day in the first 48 hours,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-16,NA,NA,2020-04-23,2020-04-23,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Estimate,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,The COVID-19 ICU PRAYER Study,Impact of Multi-Denominational Prayer on Morbidity and Mortality of Patients Admitted to the Intensive Care Unite With Corona Virus Infection,Not yet recruiting,NA,N/A,1000,Anticipated,Kansas City Heart Rhythm Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:52:29Z,2020-04-27T08:52:29Z,5133067,NCT04361838,Coronavirus Infections,coronavirus infections,Behavioral,prayer,receive prayers daily while in ICU,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-21,NA,NA,2020-04-23,2020-04-23,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Estimate,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,CytokCOVID19,,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19),Recruiting,NA,N/A,40,Anticipated,Hospital Clinic of Barcelona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:52:38Z,2020-04-27T08:52:38Z,5133106,NCT04361526,Coronavirus Infections,coronavirus infections,Device,Cytokine Adsorption,"Cytokine adsorption will be performed through a venous hemodialysis catheter, preferably jugular or femoral. The filtration system will be established with a cytokine adsorption cartridge in an hemoperfusion system using a blood flow rate of 150 - 200 ml/min. Adsorbent therapy will last 72 hours, changing cartridges every 24 hours. Prior to start, heparinization will be stablished by a 1mg/Kg iv Na heparin bolus plus iv perfusion. Activated Partial Thromboplastin Time (aPTT) control will be performed every 6 hours, with a goal range between 60 and 80 seconds.",1,Recruiting,Hospital ClÃ­nic de Barcelona,Barcelona,,,Spain,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-22,NA,NA,2020-04-23,2020-04-23,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Estimate,"May 4, 2020",Anticipated,2020-05-04,April 2020,2020-04-30,"November 4, 2020",Anticipated,2020-11-04,"November 4, 2020",Anticipated,2020-11-04,NA,Interventional,NA,,Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),Hydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19),Not yet recruiting,NA,Phase 3,500,Anticipated,Apsen Farmaceutica S.A.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:52:40Z,2020-04-27T08:52:40Z,5133113,NCT04361461,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate + Azythromycin,"400 mg orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once daily, orally, for 10 days.|400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.",2,,Apsen FarmacÃªutica S.A.,SÃ£o Paulo,,04753-001,Brazil,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-22,NA,NA,2020-04-22,2020-04-22,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 23, 2020",Anticipated,2020-04-23,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,LAPTRANSCOV,,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum During an Emergency Laparoscopy Conducted on Confirmed or Suspected COVID-19 Patients,Not yet recruiting,NA,N/A,40,Anticipated,Centre Hospitalier RenÃ© Dubos,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:52:42Z,2020-04-27T08:52:42Z,5133118,NCT04361396,Coronavirus Infections,coronavirus infections,Other,Assessment of the presence of the SARS-COV-2 virus,Assessment of the presence of the SARS-COV-2 virus by RT-PCR in samples taken at different times of the emergency laparoscopy,1,|,"Department of General and Digestive Surgery, Hospital RenÃ© Dubos|Department of Gynecology-Obstetrics, Hospital RenÃ© Dubos",Pontoise|Pontoise,|,95300|95300,France|France,2
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-22,NA,NA,2020-04-22,2020-04-22,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,,Atrium COVID-19 Syndromic and Serologic Surveillance,"A Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records",Not yet recruiting,NA,NA,450000,Anticipated,Atrium Health,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:52:52Z,2020-04-27T08:52:52Z,5133150,NCT04361123,Coronavirus Infections,coronavirus infections,Other|Diagnostic Test,daily syndromic surveillance|monthly serologic IgM/G test,"Each volunteer will be securely linked to an Oracle developed, self-reporting online HIPAA-compliant data system through a secure app on their smartphone, tablet, or computer. Volunteers will report their illness symptoms daily, health seeking behavior and treatment, COVID-19 contacts, and, for health care workers, use of PPE.|At baseline to measure seroprevalence, and once every month after to detect seroconversions, we will use serological antibody tests for SARS-CoV-2 on a sample of volunteers demographically representative of populations served by Atrium Health.",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-20,NA,NA,2020-04-22,2020-04-22,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"October 27, 2020",Anticipated,2020-10-27,"October 27, 2020",Anticipated,2020-10-27,NA,Observational,NA,,Evaluation of Antibody Tests for COVID-19,Evaluation of Commerical Antibody Tests for COVID-19,Recruiting,NA,NA,1000,Anticipated,Washington University School of Medicine,,NA,4,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples Without DNA,"
      Plasma or serum.
    ",NA,NA,NA,NA,NA,2020-04-27T08:52:59Z,2020-04-27T08:52:59Z,5133170,NCT04360954,Coronavirus Infections,coronavirus infections,Diagnostic Test,Diagnostic test,There is no intervention. This study will test deidentified archived biosamples.,1,Recruiting,Washington University School of Medicine,Saint Louis,Missouri,63110,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-16,NA,NA,2020-04-22,2020-04-22,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"December 30, 2021",Anticipated,2021-12-30,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,COVID19 LTFU,,Long Term Outcomes of Patients With COVID-19,Long Term Outcomes of Patients With COVID-19,Recruiting,NA,NA,500,Anticipated,University of Chicago,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:53:13Z,2020-04-27T08:53:13Z,5133206,NCT04360538,Coronavirus Infections,coronavirus infections,Other|Other|Other,Quality of Life|Impact Event Score|Hospital anxiety and depression scale,Physical disability assessment tool|Psychological Sequelae assessment tool|Psychological Sequelae assessment tool,3,Recruiting,University of Chicago Medical Center,Chicago,Illinois,60637,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-20,NA,NA,2020-04-20,2020-04-20,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-24,Estimate,NA,NA,NA,April 2020,2020-04-30,NA,NA,NA,NA,NA,NA,NA,Expanded Access,NA,,Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP),Expanded Access Protocol For The Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP),Available,NA,NA,NA,NA,U.S. Army Medical Research and Development Command,,NA,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:53:14Z,2020-04-27T08:53:14Z,5133212,NCT04360486,Coronavirus Infections,coronavirus infections,Other,Anti-Sars-CoV-2 Convalescent Plasma,"Fresh frozen plasma, Plasma Frozen for 24 hours (PF-24), or Liquid plasma",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-15,NA,NA,2020-04-22,2020-04-22,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19,Impact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19,Not yet recruiting,NA,Phase 3,100,Anticipated,Ain Shams University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:53:26Z,2020-04-27T08:53:26Z,5133253,NCT04360122,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug,Levamisole|Isoprinosine|Levamisole and Isoprinosine,Levamisole (150 mg/day for two days per week for 2 months|Isoprinosine (1 g 3 times per day daily) for two months|Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months,3,,Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center,Cairo,Non-US,11566,Egypt,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-20,NA,NA,2020-04-20,2020-04-20,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-24,Estimate,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,September 2022,Anticipated,2022-09-30,May 2022,Anticipated,2022-05-31,NA,Observational,STOP COVID 19,,Sequencing and Tracking of Phylogeny in COVID-19 Study,Sequencing and Tracking of Phylogeny in COVID-19 Study,Recruiting,NA,NA,500,Anticipated,Portsmouth Hospitals NHS Trust,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:53:35Z,2020-04-27T08:53:35Z,5133293,NCT04359849,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,"Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital",Portsmouth,Hampshire,PO6 3LY,United Kingdom,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-20,NA,NA,2020-04-20,2020-04-20,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-24,Estimate,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"July 31, 2021",Anticipated,2021-07-31,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,NA,,A Study to Explore the Role of Gut Flora in COVID-19 Infection,A Non-Interventional Pilot Study to Explore the Role of Gut Flora in COVID-19 Infection,Recruiting,NA,NA,250,Anticipated,ProgenaBiome,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Stool samples.
    ",NA,NA,NA,No,NA,2020-04-27T08:53:35Z,2020-04-27T08:53:35Z,5133297,NCT04359836,Coronavirus Infections,coronavirus infections,Other,There is no intervention in this study,There is no intervention in this study,1,Recruiting,ProgenaBiome,Ventura,California,93003,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-21,NA,NA,2020-04-21,2020-04-21,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Plasma Therapy of COVID-19 in Critically Ill Patients,"A Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19",Not yet recruiting,NA,Phase 2,105,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:53:36Z,2020-04-27T08:53:36Z,5133302,NCT04359810,Coronavirus Infections,coronavirus infections,Biological|Biological,Convalescent Plasma (anti-SARS-CoV-2 plasma)|Non-convalescent Plasma (control plasma),Convalescent Plasma that contains antibody titers against SARS-CoV-2|Non-convalescent plasma (does not contain antibody titers against SARS-CoV-2),2,,Columbia University Irving Medical Center/NYP,New York,New York,10032,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-20,NA,NA,2020-04-22,2020-04-22,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"January 31, 2021",Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,COVID_EIT,,Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID Patients,The Effect of Prone Positioning on Lung Aeration and Ventilation-perfusion Matching in Mechanically Ventilated Patients With Coronavirus Disease Related Acute Respiratory Distress Syndrome,Not yet recruiting,NA,NA,16,Anticipated,"University Hospital, Geneva",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:53:49Z,2020-04-27T08:53:49Z,5133341,NCT04359407,Coronavirus Infections,coronavirus infections,Other,Prone positioning,Change the positioning of the COVID patients who are intubated and mechanically ventilated from supine to prone,1,,University Hospitals of Geneva,Geneva,,1206,Switzerland,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-21,NA,NA,2020-04-22,2020-04-22,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"May 30, 2021",Anticipated,2021-05-30,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,COP-COVID-19,,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia",Not yet recruiting,NA,Phase 2,30,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-27T08:54:09Z,2020-04-27T08:54:09Z,5133408,NCT04358783,Coronavirus Infections,coronavirus infections,Biological|Other,Plasma|Best Available Therapy,"The plasma unit will be fractionated in 200 mL aliquots for storage at -80Â°C until use. After thawing, it shall be administered in a single 200 mL dose to subjects who are randomized to that arm.|It shall include, but not be limited to, oxygen therapy by means of a nasal cannula; high-flow nasal cannula; invasive or non-invasive mechanical ventilation; intravenous hydration; antibiotic therapy; thrombus prophylaxis; pain and fever management.",2,,Hospital Universitario JosÃ© E. Gonzalez,Monterrey,Nuevo Leon,64460,Mexico,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-21,NA,NA,2020-04-21,2020-04-21,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"April 22, 2020",Anticipated,2020-04-22,"April 22, 2020",Anticipated,2020-04-22,NA,Observational,PSY_CO_CHU,,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,Recruiting,NA,NA,2000,Anticipated,Centre Hospitalier Universitaire de NÄ«mes,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:54:14Z,2020-04-27T08:54:14Z,5133423,NCT04358640,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,Intensive care unit CHU Nimes,NÃ®mes,,30029,France,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-21,NA,NA,2020-04-22,2020-04-22,2020-04-24,Estimate,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,NA,NA,NA,April 2020,2020-04-30,NA,NA,NA,NA,NA,NA,NA,Expanded Access,NA,,Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19,"Expanded Access: Pulsed, Inhaled Nitric Oxide (iNO) for the Treatment of Patients With Mild or Moderate Coronavirus Disease (COVID-19)",Available,NA,NA,NA,NA,Bellerophon,,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:54:16Z,2020-04-27T08:54:16Z,5133437,NCT04358588,Coronavirus Infections,coronavirus infections,Drug,iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System,"Patients will be treated by means of an INOpulse device and cannula. The active study drug, nitric oxide for inhalation (iNO), will be provided in size 0.074 liter aluminum cartridge at a concentration of 6.0 mg/L (4880 ppm).",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-20,NA,NA,2020-04-20,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,August 2020,Anticipated,2020-08-31,NA,Observational,NA,,A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device,A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device,Not yet recruiting,NA,NA,300,Anticipated,"Kaligia Biosciences, LLC",,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T08:54:37Z,2020-04-27T08:54:37Z,5133503,NCT04357977,Coronavirus Infections,coronavirus infections,Diagnostic Test,RBA-2,Collection of non-invasive in vivo saliva from confirmed cases of both infected and non-infected COVID-19 patients or site staff at the testing site and compare the test results using the RBA-2 against the standard test results used for diagnosis.,1,||,Tampa General Hospital|University of South Florida|AdventHealth Tampa,Tampa|Tampa|Tampa,Florida|Florida|Florida,33606|33612|33613,United States|United States|United States,3
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-20,NA,NA,2020-04-21,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,"April 20, 2020",Anticipated,2020-04-20,NA,Observational,SCout,,Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections,Risk Stratification With Chest Computed Tomography to Rule-out Suspected SARS-CoV-2 Infections of Unspecific Symptomatic Patients Before Hospital Admission,"Active, not recruiting",NA,NA,145,Anticipated,Jena University Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is not a plan to make IPD available.,2020-04-27T08:54:38Z,2020-04-27T08:54:38Z,5133508,NCT04357938,Coronavirus Infections,coronavirus infections,Device,CT-imaging,"Chest CT to rule out pneumonia in PCR negative, nonspecific symptomatic patients to prevent the spread of SARS-CoV-2 within the hospital.",1,,Jena University Hospital,Jena,Thuringia,07747,Germany,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-20,NA,NA,2020-04-22,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Observational,NA,,Comparison of New Coronavirus (COVID-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey,New Coronavirus Awareness,Not yet recruiting,NA,NA,1000,Anticipated,Istanbul University-Cerrahpasa,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:54:39Z,2020-04-27T08:54:39Z,5133514,NCT04357886,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,,Istanbul University-Cerrahpasa,Istanbul,,,Turkey,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-17,NA,NA,2020-04-20,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,AVoCaDO,,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Hunter Holmes Mcguire Veteran Affairs Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-27T08:54:43Z,2020-04-27T08:54:43Z,5133528,NCT04357782,Coronavirus Infections,coronavirus infections,Drug,L-ascorbic acid,50 mg/kg L-ascorbic acid infusion given every 6 hours for 4 days (16 total doses),1,Recruiting,Hunter Holmes Mcguire Veteran Affairs Medical Center,Richmond,Virginia,23249,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-18,NA,NA,2020-04-22,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,August 2020,Anticipated,2020-08-31,NA,Interventional,STARS,,STudy of Alteplase for Respiratory Failure in SARS-Cov2 (COVID-19),"STARS (""STudy of Alteplase for Respiratory Failure in SARS-Cov2 (COVID-19)"": A Phase IIa Clinical Trial",Not yet recruiting,NA,Phase 2,60,Anticipated,Denver Health and Hospital Authority,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T08:54:45Z,2020-04-27T08:54:45Z,5133535,NCT04357730,Coronavirus Infections,coronavirus infections,Drug|Drug,Alteplase 50 MG [Activase]|Alteplase 100 MG [Activase],"Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hours. Immediately following the Alteplase infusion, 5000 IU of unfracionated heparin (UFH) will be delivered intravenously and the heparin drip will be continued to maintain the activated partial thromboplastin time at 60-80sec (2.0 to 2.5 times the upper limit of normal).|Patients randomized to Alteplase-100 group will receive 100 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 90 mgs over a total time of 2 hours. Immediately following the Alteplase infusion, 5000 IU of unfracionated heparin (UFH) will be delivered intravenously and the heparin drip will be continued to maintain the activated partial thromboplastin time at 60-80sec (2.0 to 2.5 times the upper limit of normal).",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-19,NA,NA,2020-04-21,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 12, 2020",Actual,2020-04-12,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"July 31, 2020",Anticipated,2020-07-31,NA,Observational,NA,,Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives,Prognosis of Patients With Coronavirus Disease 2019 (COVID-19) Receiving Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Antagonists (ARBs),Recruiting,NA,NA,226,Anticipated,King Faisal Specialist Hospital & Research Center,,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,"On publication, according to the journal requirements",2020-04-27T08:54:51Z,2020-04-27T08:54:51Z,5133556,NCT04357535,Coronavirus Infections,coronavirus infections,Drug,Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB),ACE-I and ARB are a class of blood pressure lowering medications used to manage hypertension.,1,Recruiting,King Faisal Specialist Hospital & Research Centre,Riyadh,,11211,Saudi Arabia,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-20,NA,NA,2020-04-21,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"April 15, 2022",Anticipated,2022-04-15,"April 15, 2022",Anticipated,2022-04-15,NA,Interventional,SAVE,,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),"suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial",Recruiting,NA,Phase 2,100,Anticipated,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:54:59Z,2020-04-27T08:54:59Z,5133575,NCT04357366,Coronavirus Infections,coronavirus infections,Drug|Drug,Anakinra|trimethoprim/sulfamethoxazole,Treatment with 100mg Anakinra SC once daily for ten days|Treatment with 80/400 mgTrimethoprime/sulfamethoxazole p.o once daily for ten days,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis|Department of Internal Medicine, I PAMMAKARISTOS Hospital|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS|1st University Department of Internal Medicine, General Hospital of Athens LAIKO|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA|Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA|Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens|Department of Infectious Diseases, General Hospital of Kerkira|1st Department of Internal Medicine, General University Hospital of Ioannina|Department of Internal Medicine, University General Hospital of Larissa|Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki",Marousi|Alexandroupolis|Athens|Athens|Athens|Athens|Athens|Athens|Athens|Corfu|IoÃ¡nnina|Larissa|Patra|ThessalonÃ­ki,Athens|||||||||||||,15126|68100|11144|11527|11527|11527|11527|11527|11528|49100|45500|41334|26504|54621,Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece,14
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-15,NA,NA,2020-04-22,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study,Recruiting,NA,N/A,100,Anticipated,UniversitÃ  degli Studi dell'Insubria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Data will be available at the end of the study, once statistical analyses is conducted",Contact Principal Investigator,NA,Yes,"We could provide anamnestic, clinical and serological data of each participant at the end of the study, or at least at the end of the first phase.",2020-04-27T08:55:00Z,2020-04-27T08:55:00Z,5133581,NCT04357327,Coronavirus Infections,coronavirus infections,Diagnostic Test,rapid salivary test,a rapid salivary test to detect SARS-CoV-2 spike protein in saliva with a lateral flow immunoassay,1,Recruiting,ASST dei Sette Laghi,Varese,VA,21100,Italy,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-14,NA,NA,2020-04-21,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,COPLA,,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,NA,Phase 2,10,Anticipated,Centro de HematologÃ­a y Medicina Interna,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:55:09Z,2020-04-27T08:55:09Z,5133611,NCT04357106,Coronavirus Infections,coronavirus infections,Biological,Convalescent plasma,Convalescent plasma obtained by aphaeresis from recovered patients.,1,Recruiting,Centro de HematologÃ­a y Medicina Interna,Puebla,,72530,Mexico,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-11,NA,NA,2020-04-19,2020-04-19,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-19,2020-04-22,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"August 15, 2020",Anticipated,2020-08-15,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,COVERAGE,,Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19),"Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19): a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)",Not yet recruiting,NA,Phase 3,1057,Anticipated,"University Hospital, Bordeaux",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T08:55:34Z,2020-04-27T08:55:34Z,5133683,NCT04356495,Coronavirus Infections,coronavirus infections,Dietary Supplement|Drug|Drug|Drug|Drug,Vitamins|Hydroxychloroquine|Imatinib|Favipiravir|Telmisartan,2 tablets daily from the first day (day 0) to day 9|2 tablets twice a day on the first day (day 0) then 2 tablets daily from day 1 to day 9|1 tablet daily from the first day (day 0) to day 9|12 tablets twice a day the first day (day 0) then 6 tablets twice a day from day 1 to day 9|1 tablet daily from the first day (day 0) to day 9,5,,Bordeaux university Hospital,Bordeaux,,33000,France,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-17,NA,NA,2020-04-21,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"May 1, 2020",Anticipated,2020-05-01,April 2020,2020-04-30,"February 1, 2022",Anticipated,2022-02-01,"September 1, 2021",Anticipated,2021-09-01,NA,Observational,CAPACoV19,,Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation,Long Term Physical Functional Performance in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation: a Multicentric Observational Study,Not yet recruiting,NA,NA,300,Anticipated,CHU de Reims,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:55:38Z,2020-04-27T08:55:38Z,5133703,NCT04356378,Coronavirus Infections,coronavirus infections,Other,Data record,Data record,1,,Damien JOLLY,Reims,,,France,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-21,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,"April 17, 2020",Anticipated,2020-04-17,April 2020,2020-04-30,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,24,Anticipated,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:56:05Z,2020-04-27T08:56:05Z,5133793,NCT04355728,Coronavirus Infections,coronavirus infections,Biological|Other,Umbilical Cord Mesenchymal Stem Cells|Standard of Care,UC-MSC will be administered at 100x10^6 cells/infusion administered intravenously in addition to the standard of care treatment.|Standard of care treatment per the treating hospital protocol.,2,Recruiting,"Diabetes Research Institute, University of Miami Miller School of Medicine",Miami,Florida,33136,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-17,NA,NA,2020-04-17,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 30, 2020",Anticipated,2020-04-30,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19,"A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19",Not yet recruiting,NA,Phase 2,80,Anticipated,Karyopharm Therapeutics Inc,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T08:56:07Z,2020-04-27T08:56:07Z,5133802,NCT04355676,Coronavirus Infections,coronavirus infections,Drug,Selinexor,20 mg selinexor oral tablet.,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-15,NA,NA,2020-04-17,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 18, 2020",Anticipated,2020-04-18,April 2020,2020-04-30,"October 18, 2020",Anticipated,2020-10-18,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia,Not yet recruiting,NA,Phase 4,300,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:56:08Z,2020-04-27T08:56:08Z,5133809,NCT04355637,Coronavirus Infections,coronavirus infections,Drug,Inhaled budesonide,adding budesonide to standard of care for pneumonia in COVID19 positive patients,1,||||||,Hospital Universitari Germans Trias i Pujol|Hospital Universitari de Bellvitge|Hospital de Sabadell-Parc Tauli|Hospital del Mar|Hospital Universitari Vall d'Hebron|Hospital Clinic of Barcelona|Hospital de la Santa Creu i Sant Pau,Badalona|Hospitalet de Llobregat|Sabadell|Barcelona|Barcelona|Barcelona|Barcelona,Barcelona|Barcelona|Barcelona||||,08916|08907|08208|08003|08035|08036|08041,Spain|Spain|Spain|Spain|Spain|Spain|Spain,7
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-17,NA,NA,2020-04-20,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-21,Actual,"April 13, 2020",Anticipated,2020-04-13,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,CAPTOCOVID,,Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID),Efficacy of Captopril Nebulization in Covid-19 Patients Suffering of SARS CoV-2 Pneumonia. A Randomized Phase II Study,Not yet recruiting,NA,Phase 2,230,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:56:15Z,2020-04-27T08:56:15Z,5133831,NCT04355429,Coronavirus Infections,coronavirus infections,Drug,captopril 25mg,Drug administration,1,||||||||||,"CH Victor Dupuy- Argenteuil|HÃ´pital Avicenne,|HÃ´pital Avicenne|HÃ´pital Avicenne|HÃ´pital Antoine BÃ©clÃ¨re|CH de CompiÃ¨gne-Noyon|Groupe hospitalier Sud Ile de France|HÃ´pital de la PitiÃ©- SalpÃªtriÃ¨re|HÃ´pital Tenon|CHRU de Tours, HÃ´pital Bretonneau|HÃ´pital de Tours",Argenteuil|Bobigny|Bobigny|Bobigny|Clamart|CompiÃ¨gne|Melun|Paris|Paris|Tours|Tours,||||||||||,|93000|93000||||||||,France|France|France|France|France|France|France|France|France|France|France,11
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-17,NA,NA,2020-04-17,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,July 2020,Anticipated,2020-07-31,NA,Observational,NA,,Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.,AntikÃ¶rperseroprÃ¤valenz Und Hintergrundinfektionsrate Von SARS-CoV-2 in Einem Ã¶sterreichischen SchlÃ¼sselkollektiv an Arbeitnehmer*Innen,Not yet recruiting,NA,NA,4000,Anticipated,AUVA,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,IPD will be encrypted and anonymised.,2020-04-27T08:56:35Z,2020-04-27T08:56:35Z,5133893,NCT04354779,Coronavirus Infections,coronavirus infections,Diagnostic Test,a specifically designed self-administered questionnaire,"The questionnaire consists of the following items: questions related to personal health, traveling activities, living situation, as well as inquiries of symptoms and comorbidities.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-12,NA,NA,2020-04-16,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-21,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,"May 31, 2020",Anticipated,2020-05-31,"May 1, 2020",Anticipated,2020-05-01,NA,Observational,TARUS,,The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic,The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic: TARUS,Recruiting,NA,NA,3000,Anticipated,Ariel University,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T08:57:06Z,2020-04-27T08:57:06Z,5133988,NCT04353934,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,Ariel University,Ariel,,4070000,Israel,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-06,NA,NA,2020-04-21,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,3 Months,Observational [Patient Registry],NA,,Renal Outcome in Patients With COVID-19,Renal Outcome in Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,NA,NA,40,Anticipated,University of Giessen,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T08:57:19Z,2020-04-27T08:57:19Z,5134026,NCT04353583,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,,"University Hospital Giessen and Marburg, Giessen",Giessen,Hessen,35382,Germany,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-15,NA,NA,2020-04-15,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-20,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Observational,CALYPSO,,WGS ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS,WHOLE GENOME SEQUENCING ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS,Enrolling by invitation,NA,NA,5000,Anticipated,Vanda Pharmaceuticals,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-27T08:57:26Z,2020-04-27T08:57:26Z,5134047,NCT04353401,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,,"Vanda Pharmaceuticals, Inc.",Washington,District of Columbia,20037,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-15,NA,NA,2020-04-17,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-20,Actual,"April 17, 2020",Anticipated,2020-04-17,April 2020,2020-04-30,"December 1, 2030",Anticipated,2030-12-01,"December 1, 2030",Anticipated,2030-12-01,NA,Interventional,NA,,Efficacay of Chloroquine in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Chloroquine in COVID-19 Treatment,Not yet recruiting,NA,Phase 2/Phase 3,40,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:57:28Z,2020-04-27T08:57:28Z,5134056,NCT04353336,Coronavirus Infections,coronavirus infections,Drug,Chloroquine,Chloroquine,1,,Tanta University,Tanta,,35111,Egypt,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-25,NA,NA,2020-04-21,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,THICK,,Trial of Hydroxychloroquine In Covid-19 Kinetics,A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics,Recruiting,NA,Phase 2/Phase 3,58,Anticipated,University of South Alabama,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-27T08:57:32Z,2020-04-27T08:57:32Z,5134061,NCT04353271,Coronavirus Infections,coronavirus infections,Drug|Other,Hydroxychloroquine|Placebo,"Hydroxychloroquine 800 mg initial dose then 6-8 hours later HCQ 600 mg, then 200 mg three times per day for 4 days.|Placebo take 4 tabs, then 6-8 hours later take 3 tabs, then take 1 tab three times per day for 4 days.",2,Recruiting,University of South Alabama,Mobile,Alabama,36604,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-15,NA,NA,2020-04-15,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-20,Actual,"June 1, 2020",Anticipated,2020-06-01,April 2020,2020-04-30,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,12 Months,Observational [Patient Registry],PostCOVID19,,Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System,Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System: Effect of Hydroxychloroquine / Azithromycin Combined Therapy,Not yet recruiting,NA,NA,130,Anticipated,University of Sao Paulo General Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T08:57:33Z,2020-04-27T08:57:33Z,5134067,NCT04353245,Coronavirus Infections,coronavirus infections,Other,BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM,"Organize care follow-up for patients who have had COVID-19 coronavirus infection for scientific purposes. Thus, it is expected to obtain relevant data on cardiac sequelae and pulmonary. These data are important for understanding the long-term prognosis of patients surviving this infection.",1,,Instituto do CoraÃ§Ã£o - Hospital das ClÃ­nicas - Faculdade de Medicina da Universidade de SÃ£o Paulo,SÃ£o Paulo,SP,,Brazil,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-16,NA,NA,2020-04-21,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2021,Anticipated,2021-07-31,April 2021,Anticipated,2021-04-30,NA,Interventional,MeCOVID,,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.,Not yet recruiting,NA,Phase 2/Phase 3,450,Anticipated,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:57:37Z,2020-04-27T08:57:37Z,5134085,NCT04353128,Coronavirus Infections,coronavirus infections,Drug|Drug,Melatonin 2mg|Placebo oral tablet,2 mg of prolonged release melatonin tablets per os (P.O.) before bedtime for 12 weeks|Identically looking placebo tablets P.O. before bedtime for 12 weeks,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-09,NA,NA,2020-04-21,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,"April 7, 2020",Actual,2020-04-07,April 2020,2020-04-30,"June 15, 2021",Anticipated,2021-06-15,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) An Open Label Multi-arm Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19,Recruiting,NA,Phase 2,850,Anticipated,UnitedHealth Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,1 year,NA,NA,Yes,Data will be collected and managed by Optumcare and UnitedHealth Group Research & Development. Redacted/aggregate data will be shared with the University Of Penn using approved data sharing protocols.,2020-04-27T08:57:40Z,2020-04-27T08:57:40Z,5134102,NCT04353037,Coronavirus Infections,coronavirus infections,Drug|Drug,Group A HCQ|Group B Control,Enrolled participants randomized in Group A receive the HCQ drug|Enrolled participants randomized in Group B will receive a placebo drug,2,Recruiting,ProHealth New York,New York,New York,11042,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-15,NA,NA,2020-04-15,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-20,Actual,NA,NA,NA,April 2020,2020-04-30,NA,NA,NA,NA,NA,NA,NA,Expanded Access,NA,,Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19,Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19,Available,NA,NA,NA,NA,Spectral Diagnostics (US) Inc.,,NA,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:57:42Z,2020-04-27T08:57:42Z,5134109,NCT04352985,Coronavirus Infections,coronavirus infections,Device,Toraymyxin PMX-20R (PMX Cartridge),"The intervention is two (2) treatment sessions of PMX cartridge administration within approximately 24 hours of each other. Each treatment session will target 2 hours with a minimum of 1 Â½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute). In cases where the clinical status of the subject is improving, or if the subject suffers from a relapse and the treating physician believes an additional PMX treatment may improve the clinical outcome of the subject, they may administer an additional PMX treatment session (for a total of 3 treatment sessions) at their discretion. All subjects will continue to receive standard medical care for COVID 19 and septic shock.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-16,NA,NA,2020-04-18,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"February 19, 2020",Actual,2020-02-19,April 2020,2020-04-30,"April 6, 2020",Actual,2020-04-06,"April 4, 2020",Actual,2020-04-04,NA,Observational,NA,,Echocardiographic Manifestation in Patient With Coronavirus Disease 2019 (COVID-19),Cardiac Structural and Functional Characteristics in Coronavirus Disease 2019 (COVID-19): A Dynamic Echocardiographic Study,Completed,NA,NA,55,Actual,RenJi Hospital,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:57:46Z,2020-04-27T08:57:46Z,5134126,NCT04352842,Coronavirus Infections,coronavirus infections,Other,Echocardiography,"An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography",1,,"Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University",Shanghai,Shanghai,200127,China,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-16,NA,NA,2020-04-20,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"August 31, 2026",Anticipated,2026-08-31,"December 31, 2025",Anticipated,2025-12-31,NA,Observational,ReCovER,,Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room,Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room,Not yet recruiting,NA,NA,500,Anticipated,University of Cologne,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:58:21Z,2020-04-27T08:58:21Z,5134231,NCT04351854,Coronavirus Infections,coronavirus infections,Other,Retrospective data collection,Retrospective data collection to identify predicting factors in the clinical picture of COVID-19 patients presenting to the ED.,1,,University Hospital of Cologne,Cologne,,50937,Germany,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-16,NA,NA,2020-04-16,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"January 20, 2021",Anticipated,2021-01-20,"January 20, 2021",Anticipated,2021-01-20,NA,Observational,COR-DLUS,,CORonavirus (COVID-19) Diagnostic Lung UltraSound Study,CORonavirus (COVID-19) Diagnostic Lung UltraSound Study,Not yet recruiting,NA,NA,180,Anticipated,University Hospital Plymouth NHS Trust,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:58:23Z,2020-04-27T08:58:23Z,5134239,NCT04351802,Coronavirus Infections,coronavirus infections,Diagnostic Test,Lung ultrasound,Focused lung ultrasound examination,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-10,NA,NA,2020-04-21,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,ACOVACT,,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),"A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)",Recruiting,NA,Phase 2/Phase 3,500,Anticipated,Medical University of Vienna,,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Anonymized and pseudonymized data will be published in peer reviewed journals and may be presented at congresses and conferences,2020-04-27T08:58:25Z,2020-04-27T08:58:25Z,5134246,NCT04351724,Coronavirus Infections,coronavirus infections,Drug|Drug|Other|Drug|Drug|Drug|Drug|Drug|Drug,Chloroquine or Hydroxychloroquine|Lopinavir/Ritonavir|Best standard of care|Rivaroxaban|Thromboprophylaxis|Candesartan|non-RAS blocking antihypertensives|Clazakizumab|placebo for clazakizumab,"Hydroxychloroquine 200mg 2-0-2 on day 1 followed by 200mg 1-0-1, or Chloroquine 250mg 2-0-2, as available|Lopinavir/Ritonavir 200mg/50mg 2-0-2|best standard of care|2.5mg 2-0-2 or 10mg 1/2-0-1/2, as applicable|as local standard, most likely to be low molecular weight heparin|starting dose 4mg once daily, titrated to normotension|This excludes angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (AT-blockers, sartans) and includes alpha-receptor antagonists, calcium antagonists, amongst others|25mg i.v. single dose, possibly a repeated dose|sodium chloride bolus infusions as placebo for clazakizumab",9,Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,Medical University of Innsbruck|Medical University of Vienna|Wilhelminenspital|SMZ SÃ¼d Kaiser Franz Josef Spital|KH Hietzing|SMZ Baumgartner HÃ¶he Otto Wagner Spital|SMZ Ost Donauspital,Innsbruck|Vienna|Vienna|Vienna|Vienna|Vienna|Vienna,Tirol||||||,6020|1090|1090|1100|1130|1140|1220,Austria|Austria|Austria|Austria|Austria|Austria|Austria,7
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-15,NA,NA,2020-04-22,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Observational,NA,,A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19,A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City,Recruiting,NA,NA,10000,Anticipated,"University Hospital, Basel, Switzerland",,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T08:58:32Z,2020-04-27T08:58:32Z,5134265,NCT04351503,Coronavirus Infections,coronavirus infections,Other|Other|Other,Study A|Study B|Study C,"Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed. For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.|Study B: collection of epidemiological surveillance data to describe the epidemiology of the SARS-CoV-2 outbreak. The epidemic transmission of Influenza viruses in the City of Basel serves as an important reference to identify similarities and differences to the pandemic SARS-CoV-2 situation. In addition data collected during the Influenza projects - in particular data on statistical blocks of the city, e.g. population density, income and living space will be re-used. Already collected and stored samples such as serum and respiratory material (leftover material) will be (re-) used.|Study C: data collection for viral evolution. Respiratory materials and matching blood and tissue materials will be used to perform whole genome sequencing to study pathogen evolution between hosts as well as in-host evolution. No additional material will be collected.",3,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Viollier AG|University Hospital Basel|Biozentrum University of Basel|sciCore University of Basel|Department of Biosystems Science and Engineering ETH Zurich|Swiss Institute of Bioinformatics,Allschwil|Basel|Basel|Basel|Basel|Geneva,|||||,4123|4031|4056|4056|4058|1202,Switzerland|Switzerland|Switzerland|Switzerland|Switzerland|Switzerland,6
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-15,NA,NA,2020-04-15,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia,"A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia",Not yet recruiting,NA,Phase 3,238,Anticipated,"Humanigen, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-27T08:58:48Z,2020-04-27T08:58:48Z,5134302,NCT04351152,Coronavirus Infections,coronavirus infections,Biological|Drug,Lenzilumab|Standard of Care,Administered as an intravenous (IV) infusion|Standard of care therapy per local written policies or guidelines,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-17,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-20,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19,Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19,Not yet recruiting,NA,Phase 3,900,Anticipated,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:58:59Z,2020-04-27T08:58:59Z,5134332,NCT04350931,Coronavirus Infections,coronavirus infections,Biological|Other,intradermal injection of BCG Vaccine|placebo,0.10 mL intradermal injection of BCG Vaccine over the distal insertion of the deltoid muscle onto the humerus (approximately one third down the left upper arm) slowly over 10 seconds|placebo 0.10 mL intradermal normal saline (0.9% NaCl) over the distal insertion of the deltoid muscle onto the humerus,2,,Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center,Cairo,Non-US,11566,Egypt,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,COVI-PRONE,,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Not yet recruiting,NA,N/A,350,Anticipated,St. Joseph's Healthcare Hamilton,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:59:06Z,2020-04-27T08:59:06Z,5134354,NCT04350723,Coronavirus Infections,coronavirus infections,Procedure,Awake Proning,The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.,1,,St. Joseph's Healthcare Hamilton,Hamilton,Ontario,L8N 4A6,Canada,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore,"Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore: a Review of Process Feasibility, Safety, and Clinical Outcomes",Not yet recruiting,NA,Phase 2,100,Anticipated,Montefiore Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-04-27T08:59:14Z,2020-04-27T08:59:14Z,5134391,NCT04350450,Coronavirus Infections,coronavirus infections,Drug,Hydroxychloroquine,400 mg tablet,1,,Montefiore Medical Center,Bronx,New York,10467,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-17,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-20,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,FAV-001,,Efficacy and Safety of Favipiravir in Management of COVID-19,Efficacy and Safety of Favipiravir in Management of COVID-19,Not yet recruiting,NA,Phase 3,100,Anticipated,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:59:32Z,2020-04-27T08:59:32Z,5134426,NCT04349241,Coronavirus Infections,coronavirus infections,Drug|Drug,favipiravir|Standard of care therapy,"pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide), a new type of RNA-dependent RNA polymerase (RdRp) inhibitor|oseltamivir 75 mg 12 hourly for 5-10 days and hydroxychloroquine 400mg 12 hourly day -1 followed by 200mg 12 hourly daily on day- 2 to day-5-10",2,,Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center,Cairo,Non-US,11556,Egypt,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-14,NA,NA,2020-04-19,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-19,2020-04-21,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,Coronavirus,,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Recruiting,NA,Phase 2,230,Anticipated,Karyopharm Therapeutics Inc,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T08:59:33Z,2020-04-27T08:59:33Z,5134436,NCT04349098,Coronavirus Infections,coronavirus infections,Drug|Other,Selinexor|Placebo,Participants will receive 20 mg of selinexor.|Participants will receive 20 mg of placebo matched to selinexor.,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"UCLA|Norton Healthcare|Lehigh Valley Hospital|Baylor Scott & White Dallas|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases|Hadassah MC|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca",Los Angeles|Louisville|Allentown|Dallas|Vienna|Jerusalem|Salamanca,California|Kentucky|Pennsylvania|Texas|||,90095|40202|18103|75201|||37007,United States|United States|United States|United States|Austria|Israel|Spain,7
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-17,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-20,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,PRA-001,,Plasma Rich Antibodies From Recovered Patients From COVID19,Plasma Rich Antibodies From Recovered Patients From COVID19,Not yet recruiting,NA,N/A,20,Anticipated,Ain Shams University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:59:37Z,2020-04-27T08:59:37Z,5134460,NCT04348877,Coronavirus Infections,coronavirus infections,Other,Antibody-Rich Plasma from COVID-19 recovered patients,400 millimeter of Antibody-Rich Plasma from COVID-19 recovered patients will be transfused to patients with severe or immediately life-threatening COVID-19,1,,Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center,Cairo,Non-US,11556,Egypt,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-15,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 12, 2020",Actual,2020-04-12,April 2020,2020-04-30,"May 13, 2020",Anticipated,2020-05-13,"May 13, 2020",Anticipated,2020-05-13,NA,Interventional,Ruxo-Sim-20,,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.,Recruiting,NA,Phase 2,94,Anticipated,FundaciÃ³n de investigaciÃ³n HM,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T08:59:40Z,2020-04-27T08:59:40Z,5134469,NCT04348695,Coronavirus Infections,coronavirus infections,Drug|Other,Ruxolitinib plus simvastatin|Standard of Care,"Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.
Simvastatin 40 mg orally every 24 hours for 14 days|Patients will receive treatment according to usual clinical practice in the participant site.",2,Recruiting,Hospital Universitario Madrid Sanchinarro,Madrid,,28050,Spain,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-30,NA,NA,2020-04-21,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,November 2021,Anticipated,2021-11-30,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,BCG Vaccine for Health Care Workers as Defense Against SARS-COV2,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses,Not yet recruiting,NA,Phase 4,700,Anticipated,Baylor College of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,There is not a plan to make IPD available.,2020-04-27T08:59:44Z,2020-04-27T08:59:44Z,5134479,NCT04348370,Coronavirus Infections,coronavirus infections,Biological|Biological,BCG Vaccine|Placebo Vaccine,BCG vaccine will be administered by research nurses. Participants and investigators will be blinded.|Placebo vaccine will be administered by research nurses. Participants and investigators will be blinded.,2,|||||,Harvard T.H. Chan School of Public Health|Texas A&M University|Baylor College of Medicine|Baylor St. Luke's Medical Center|Harris Health System - Ben Taub Hospital|MD Anderson Cancer Center,Boston|Bryan|Houston|Houston|Houston|Houston,Massachusetts|Texas|Texas|Texas|Texas|Texas,02115|77807|77030|77030|77030|77030,United States|United States|United States|United States|United States|United States,6
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-17,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-20,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Observational,NA,,Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals,Screening and Risk Assessment of Healthcare Workers and Infection Control in University and COVID-19 Quarantine Hospitals Using Real-time Geospatial Mapping for Emergency Healthcare Resource Mobilization and Management,Not yet recruiting,NA,NA,3000,Anticipated,Ain Shams University,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:59:46Z,2020-04-27T08:59:46Z,5134484,NCT04348214,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,,Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center,Cairo,Non-US,11566,Egypt,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-11,NA,NA,2020-04-18,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"May 30, 2020",Anticipated,2020-05-30,"May 25, 2020",Anticipated,2020-05-25,NA,Interventional,WUHAN,,Efficacy of Nigella Sativa and Natural Honey Against COVID-19,"With Uncontroversial Honey And Nigella Sativa (WUHAN) Treatment for Novel Coronavirus Infection; Randomized, Controlled, Investigator Initiated Trial",Recruiting,NA,Phase 3,30,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T08:59:54Z,2020-04-27T08:59:54Z,5134507,NCT04347382,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug,Honey|Nigella Sativa / Black Cumin|Placebos,30ml Natural Honey orally BD|Capsule 2gm seed powder orally BD|Empty capsule with 250ml of distilled water,3,Recruiting,"Mayo Hospital, Kingedward Medical University",Lahore,Punjab,54600,Pakistan,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-09,NA,NA,2020-04-15,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,NA,N/A,10,Anticipated,A.O. Ospedale Papa Giovanni XXIII,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T09:00:00Z,2020-04-27T09:00:00Z,5134523,NCT04346589,Coronavirus Infections,coronavirus infections,Biological,Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients,"Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.",1,||||,IRFMN - Clinical Research Center for Rare Diseases|ASST HPG23 - Unit of Nephrology|ASST Papa Giovanni XXIII - Microbiology and Virology Unit|Asst Pg23 - S.I.M.T|ASST-PG23 - Intensive Care Unit,Ranica|Bergamo|Bergamo|Bergamo|Bergamo,BG||||,24020|24100|24100|24100|24100,Italy|Italy|Italy|Italy|Italy,5
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-17,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-20,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Observational,Explore,,Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19,Retrospective Study From November 2019 -Febrauary 2020 on Severe Respiratory Illness to Access the Presence or Absence of COVID-19 in Patients Samples by Real-time PcR,Recruiting,NA,NA,500,Anticipated,Ain Shams University,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Oropharyngeal and nasopharyngeal swabs for hospitalized SARI patients who meet the WHO
      standard SARI case definition.
    ",NA,NA,NA,No,NA,2020-04-27T09:00:04Z,2020-04-27T09:00:04Z,5134529,NCT04346056,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting|Recruiting,Faculty of Medicine Ain Shams University|Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center,Cairo|Cairo,Non-US|Non-US,11556|11566,Egypt|Egypt,2
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-17,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-20,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Observational,Strain,,To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database,Strain Study: To Access the Egyptian COVID-19 Whole Genome (Dominant Strain) by Next Generation Sequencing (NGS) and Compare to the International Worldwide Database,Not yet recruiting,NA,NA,100,Anticipated,Ain Shams University,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Nasopharyngeal & oropharyngeal swabs will be taken from patients with COVID-19
    ",NA,NA,NA,No,NA,2020-04-27T09:00:04Z,2020-04-27T09:00:04Z,5134530,NCT04346043,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,,Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center,Cairo,Non-US,11556,Egypt,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-05,NA,NA,2020-04-22,2020-04-09,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 11, 2020",Actual,2020-04-11,April 2020,2020-04-30,"April 6, 2021",Anticipated,2021-04-06,"September 6, 2020",Anticipated,2020-09-06,NA,Interventional,COVIDOC,,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,"University Hospital, Montpellier",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:00:06Z,2020-04-27T09:00:06Z,5134535,NCT04345861,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine + placebo|hydroxychloroquine + azithromycin,hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)|Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5),2,Recruiting,Montpellier University hospital,Montpellier,,34295,France,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-13,NA,NA,2020-04-22,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"May 15, 2020",Anticipated,2020-05-15,April 2020,2020-04-30,"April 1, 2025",Anticipated,2025-04-01,"July 1, 2024",Anticipated,2024-07-01,NA,Observational,NIAID,,COVID-19 Plasma Collection,A Pilot Study for Collection of Anti-SARS-CoV-2 Immune Plasma,Recruiting,NA,NA,1500,Anticipated,National Institutes of Health Clinical Center (CC),,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Serum, plasma
    ",NA,NA,NA,NA,NA,2020-04-27T09:00:11Z,2020-04-27T09:00:11Z,5134551,NCT04344977,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,Bloodworks Northwest,Seattle,Washington,98104,United States Minor Outlying Islands,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-09,NA,NA,2020-04-17,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Recruiting,NA,Phase 3,260,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T09:00:21Z,2020-04-27T09:00:21Z,5134564,NCT04344041,Coronavirus Infections,coronavirus infections,Drug|Drug,"cholecalciferol 200,000 IU|cholecalciferol 50,000 IU","Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.|Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose",2,Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,CHU Angers|CHU Bordeaux|CH Le Mans|CHU Lille|CHU Limoges|CHU Nantes|CHU Nice|CHU Saint Etienne|CH Saumur|CHU Tours,Angers|Bordeaux|Le Mans|Lille|Limoges|Nantes|Nice|Saint Etienne|Saumur|Tours,|||||||||,|||||||||,France|France|France|France|France|France|France|France|France|France,10
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-09,NA,NA,2020-04-18,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"April 18, 2020",Actual,2020-04-18,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,MetCOVID,,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Efficacy and Safety of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.",Recruiting,NA,Phase 2,420,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication.,upon formal request.,NA,Yes,all patient data will be shared after study publication,2020-04-27T09:00:23Z,2020-04-27T09:00:23Z,5134568,NCT04343729,Coronavirus Infections,coronavirus infections,Drug|Drug,Methylprednisolone Sodium Succinate|Placebo solution,injectable solution at a dose of 0.5mg/kg|injectable saline solution,2,Recruiting,Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz,Manaus,Amazonas,69093-415,Brazil,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-08,NA,NA,2020-04-16,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,COVIDAtoZ,,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Enrolling by invitation,NA,N/A,520,Anticipated,The Cleveland Clinic,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-27T09:00:29Z,2020-04-27T09:00:29Z,5134589,NCT04342728,Coronavirus Infections,coronavirus infections,Dietary Supplement|Dietary Supplement|Dietary Supplement|Other,Ascorbic Acid|Zinc Gluconate|Ascorbic Acid and Zinc Gluconate|Standard of Care,Readily available marketed open label ascorbic acid|Readily available marketed open label zinc gluconate|Readily available marketed open label ascorbic acid and zinc gluconate|Readily available prescribed medications/ supplements- None study supplements,4,,Cleveland Clinic,Cleveland,Ohio,44195,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-08,NA,NA,2020-04-16,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,August 2020,Anticipated,2020-08-31,NA,Interventional,SHARP COVID-19,,Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19,Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19- A Cluster Randomized Controlled Trial (SHARP COVID-19 RCT),Not yet recruiting,NA,Phase 3,1200,Anticipated,Tan Tock Seng Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-27T09:00:33Z,2020-04-27T09:00:33Z,5134599,NCT04342156,Coronavirus Infections,coronavirus infections,Drug,Hydroxychloroquine Sulfate 200 milligram (mg) Tab,Oral tablet of Hydroxychloroquine sulfate,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-07,NA,NA,2020-04-22,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"December 30, 2020",Anticipated,2020-12-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome,Recruiting,NA,Phase 4,86,Anticipated,Materno-Perinatal Hospital of the State of Mexico,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After finishing the study.,Requested by the journal or after publication if any researcher in the world express interest if the information of this survey.,NA,Yes,"If the final selected medical journal to send the paper of our research request it, we will add the full database of the studied population.",2020-04-27T09:00:35Z,2020-04-27T09:00:35Z,5134607,NCT04341493,Coronavirus Infections,coronavirus infections,Drug|Drug,Nitazoxanide 500 MG|Hydroxychloroquine,Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with two drugs|Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug,2,Recruiting,"Materno-Perinatal Hospital ""MÃ³nica Pretelini""",Toluca,,50130,Mexico,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-04,NA,NA,2020-04-20,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-21,Actual,"April 11, 2020",Actual,2020-04-11,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),"A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 1/Phase 2,144,Anticipated,I-Mab Biopharma Co. Ltd.,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:00:38Z,2020-04-27T09:00:38Z,5134610,NCT04341116,Coronavirus Infections,coronavirus infections,Drug|Drug,TJ003234|Placebo,patients receive a single infusion|patients receive a single infusion,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"OSF Healthcare Saint Francis Medical Center|Indiana University Health|Medpharmics, LLC|Oschner Medical Center|University of Mississippi Medical Center",Peoria|Indianapolis|Metairie|New Orleans|Jackson,Illinois|Indiana|Louisiana|Louisiana|Mississippi,61637|46202|70006|70121|39216,United States|United States|United States|United States|United States,5
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-01,NA,NA,2020-04-21,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,ESCAPE,,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial,Recruiting,NA,Phase 2,40,Anticipated,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:00:42Z,2020-04-27T09:00:42Z,5134630,NCT04339712,Coronavirus Infections,coronavirus infections,Drug|Drug,Anakinra|Tocilizumab,In case of diagnosis of MAS treatment with anakinra|In case of diagnosis of immune dysregulation treatment with tocilizumab,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"2nd Department of Critical Care Medicine, ATTIKON University Hospital|Intensive Care Unit, Ioannina University Hospital|Department of Internal Medicine, Patras University Hospital|Department of Internal Medicine, I PAMMAKARISTOS Hospital|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S.|1st Department of Pulmonary Medicine and Intensive Care Unit|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO|4th Department of Internal Medicine, Attikon University Hospital|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas|Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital|Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital|Department of Internal Medicine, Larissa University Hospital|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA",Athens|IoÃ¡nnina|Patras|Athens|Athens|Athens|Athens|Athens|Athens|ElefsÃ­na|Larissa|Larissa|Thessaloniki|Thessaloniki|Thessaloniki|Thessaloniki|Thessaloniki,Haidari|Ioannina|Rion||||||||||||||,12462|45500|26504|11144|11526|11527|11527|12462|16673|19600|41221|41334|54 634|546 35|546 39|546 42|54636,Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece|Greece,17
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-01,NA,NA,2020-04-22,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,REPLACECOVID,,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019,Enrolling by invitation,NA,N/A,152,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Not making it available,2020-04-27T09:00:48Z,2020-04-27T09:00:48Z,5134647,NCT04338009,Coronavirus Infections,coronavirus infections,Other|Other,Discontinuation of ARB/ACEI|Continuation of ARB/ACEI,"The randomized intervention will be the discontinuation of ACEI/ARBs. In all participants randomized to discontinuation, treating clinicians will be reminded about the medication discontinuation upon discharge and will be prompted to consider re-initiation of the medication at that time if appropriate, per the clinician's discretion.|The randomized intervention will be the continuation of ACEI/ARBs at the doses previously prescribed for patients during their routine care. Clinicians will be encouraged to continue the randomized treatment but will be allowed to change the dose of ACEI/ARB or discontinue these medications if any compelling clinical reasons are identified (such as hypotension, hyperkalemia, acute kidney injury).",2,,University of Pennsylvania Health System,Philadelphia,Pennsylvania,19104,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-06,NA,NA,2020-04-22,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NOCOVID,,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection",Not yet recruiting,NA,Phase 2,200,Anticipated,Sanotize Research and Development corp.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:00:48Z,2020-04-27T09:00:48Z,5134650,NCT04337918,Coronavirus Infections,coronavirus infections,Drug|Drug,NORS (Nitric Oxide Releasing Solution)|NORS (Nitric Oxide Releasing Solution),"NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.|Up to ten volunteers who are found to be COVID-19 positive during screening will be eligible to enroll in the 21-day Treatment sub-study and receive daily NORS treatment for 14 days. NORS treatment will consist of daily self-administration of three routes; Nitric Oxide Gargle (NOG) every morning, Nitric Oxide Nasophyaryngeal Irrigation (NONI) every evening, and Nitric Oxide Nasal Spray (NONS) up to 5 times per day.
Any participants enrolled in the Prevention study who meet the criteria for the sub study will roll over into the Treatment Sub-Study but must remain in their randomly assigned group.",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-03,NA,NA,2020-04-21,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 3, 2020",Anticipated,2020-06-03,NA,Interventional,SRA-COV,,Renin Angiotensin System - CoronaVirus,Renin Angiotensin System - CoronaVirus,Recruiting,NA,N/A,50,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:00:49Z,2020-04-27T09:00:49Z,5134654,NCT04337008,Coronavirus Infections,coronavirus infections,Other,blood draw,20 mL blood draw will be performed at J1 et J7,1,Recruiting,ASSISTANCE PUBLIQUE HÃ–PITAUX de MARSEILLE,Marseille,,13005,France,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-03,NA,NA,2020-04-21,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1,40,Anticipated,Inovio Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2020-04-27T09:00:51Z,2020-04-27T09:00:51Z,5134658,NCT04336410,Coronavirus Infections,coronavirus infections,Drug|Device,INO-4800|CELLECTRAÂ® 2000,INO-4800 will be administered ID on Day 0 and Week 4.|EP using the CELLECTRAÂ® 2000 device will be administered following ID delivery of INO-4800 on Day 0 and Week 4.,2,Recruiting|Recruiting,Center for Pharmaceutical Research|University of Pennsylvania,Kansas City|Philadelphia,Missouri|Pennsylvania,64114|19104,United States|United States,2
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-02,NA,NA,2020-04-22,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"May 30, 2020",Anticipated,2020-05-30,"April 30, 2020",Anticipated,2020-04-30,1 Month,Observational [Patient Registry],MexCOVID-19,,Outcomes of Patients With COVID-19 in the Intensive Care Unit,Outcomes of Patients With COVID-19 in the Intensive Care Unit: A National Observational Study (Mexico COVID-19 ICU Study),Recruiting,NA,NA,150,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,All IPD that underlie could results in a publication.,2020-04-27T09:00:51Z,2020-04-27T09:00:51Z,5134660,NCT04336345,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting|Recruiting,Instituto Nacional de Ciencias MÃ©dicas y NutriciÃ³n Salvador ZubirÃ¡n|All centres from Mexico willing to contribute are Welcome.,Mexico City|Mexico,|,14000|,Mexico|Mexico,2
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-02,NA,NA,2020-04-20,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,July 2021,Anticipated,2021-07-31,April 2021,Anticipated,2021-04-30,NA,Interventional,HELPCOVID-19,,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","An Open Label Phase II Pilot Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Not yet recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-27T09:00:57Z,2020-04-27T09:00:57Z,5134684,NCT04335084,Coronavirus Infections,coronavirus infections,Drug|Dietary Supplement|Dietary Supplement|Dietary Supplement,Hydroxychloroquine|Vitamin C|Vitamin D|Zinc,Prophylaxis treatment for COVID-19|Prophylaxis treatment for COVID-19|Prophylaxis treatment for COVID-19|Prophylaxis treatment for COVID-19,4,,ProgenaBiome,Ventura,California,93003,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-02,NA,NA,2020-04-22,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 22, 2020",Anticipated,2020-04-22,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,CORON-ACT,,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),"CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)",Recruiting,NA,Phase 2,100,Anticipated,"University Hospital Inselspital, Berne",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:00:57Z,2020-04-27T09:00:57Z,5134687,NCT04335071,Coronavirus Infections,coronavirus infections,Drug|Drug,Tocilizumab (TCZ)|Placebo,"Patients get one dose (= 8 mg/kg bodyweight, max. single dose 800 mg) ActemraÂ® (active ingredient: TCZ) intravenously in 100 mL NaCl 0.9% after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.|The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.",2,Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,University Hospital Bern (Inselspital)|Centre Hospitalier Universitaire Vaudois (CHUV)|Ospedale Regionale di Lugano (EOC)|University Hospital Zurich,Bern|Lausanne|Viganello|Zurich,|||,3010|1011|6962|8091,Switzerland|Switzerland|Switzerland|Switzerland,4
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-02,NA,NA,2020-04-20,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,EPICOS,,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,"Active, not recruiting",NA,Phase 3,4000,Anticipated,Plan Nacional sobre el Sida (PNS),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:01:00Z,2020-04-27T09:01:00Z,5134689,NCT04334928,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug|Drug,Emtricitabine/tenofovir disoproxil|Hydroxychloroquine|Placebo: Emtricitabine/tenofovir disoproxil Placebo|Placebo: Hydroxychloroquine,"Emtricitabine/tenofovir disoproxil, 200 mg/245 mg tablets. A dose of one tablet once a day will be administered.|Hydroxychloroquine, 200 mg tablets. A dose of one tablet once a day will be administered.|Placebo: Tablets similar in appearance to Emtricitabine/tenofovir disoproxil|Placebo: Tablets similar in appearance to Hydroxychloroquine",4,|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||,Hospital Universitario de Ferrol|Hospital ClÃ­nico Universitario de Santiago|Hospital General de Elche|Hospital Universitario Central de Asturias|Hospital Sant Joan de Deu de Esplugues|Parc Sanitari Sant Joan de DÃ©u de Sant Boi|Hospital Infanta Margarita|Hospital Insular de Las Palmas|Hospital Universitario de Canarias|Hospital de Donostia|Hospital San Pedro|Hospital Principe de Asturias|Hospital FundaciÃ³n de AlcorcÃ³n|Hospital Colllado Villalba|Hospital Severo Ochoa|Hospital Rey Juan Carlos|Hospital QuirÃ³n Pozuelo|Hospital de TorrejÃ³n|Hospital Infanta Elena|Hospital Virgen del Castillo|Hospital Costa del Sol|Complejo Hospitalario de Navarra|Hospital Arnau de Vilanova|Hospital de Araba|Hospital General Universitario de Albacete|Centro MÃ©dico Teknon|Hospital Clinic|Hospital del Mar|Hospital Dexeus|Hospital QuirÃ³n Barcelona|Hospital Sant Pau|Hospital Universitario Sagrat Cor|Hospital Universitario de Burgos|Hospital Virgen de la Luz|Hospital ClÃ­nico San Cecilio|Hospital Universitario de LeÃ³n|Hospital Universitario RamÃ³n y Cajal|FundaciÃ³n JimÃ©nez DÃ­az|Hospital Clinico San Carlos|Hospital Infanta Leonor|Hospital La Princesa|Hospital Universitario 12 de Octubre|Hospital Universitario Gregorio MaraÃ±on|Hospital Universitario La Paz|Hospital Universitario Puerta de Hierro|Hospital Reina SofÃ­a|Hospital Universitario Virgen de la Arrixaca|Hospital Virgen de la Victoria|Complejo Asistencial de Palencia|Hospital Universitario de Salamanca|Hospital General de Segovia|Hospital Virgen del Rocio|Hospital Virgen Macarena|Hospital Clinico Universitario|Hospital Dr. Peset|Hospital General de Valencia|Hospital La Fe|Hospital de Valladolid|Hospital Rio Hortega|Hospital Lozano Blesa|Hospital Miguel Servet|Hospital Nuestra SeÃ±ora de Sonsoles,Ferrol|Santiago De Compostela|Elche|Oviedo|Esplugues De Llobregat|Sant Boi De Llobregat|Cabra|Las Palmas De Gran Canaria|Las Palmas De Gran Canaria|San SebastiÃ¡n|LogroÃ±o|AlcalÃ¡ De Henares|AlcorcÃ³n|Collado-Villalba|LeganÃ©s|MÃ³stoles|Pozuelo De AlarcÃ³n|TorrejÃ³n De Ardoz|Valdemoro|Yecla|Marbella|Pamplona|LlÃ­ria|Alava|Albacete|Barcelona|Barcelona|Barcelona|Barcelona|Barcelona|Barcelona|Barcelona|Burgos|Cuenca|Granada|LeÃ³n|Madrid|Madrid|Madrid|Madrid|Madrid|Madrid|Madrid|Madrid|Madrid|Murcia|Murcia|MÃ¡laga|Palencia|Salamanca|Segovia|Sevilla|Sevilla|Valencia|Valencia|Valencia|Valencia|Valladolid|Valladolid|Zaragoza|Zaragoza|Ãvila,A CoruÃ±a|A CoruÃ±a|Alicante|Asturias|Barcelona|Barcelona|CÃ³rdoba|Gran Canaria|Gran Canaria|Guipuzcoa|La Rioja|Madrid|Madrid|Madrid|Madrid|Madrid|Madrid|Madrid|Madrid|Murcia|MÃ¡laga|Navarra|Valencia|Vitoria||||||||||||||||||||||||||||||||||||||,||||||||||||||||||||||||||||||||||||28034|||||||||||||||||||||||||,Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain|Spain,62
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-02,NA,NA,2020-04-23,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Estimate,"April 27, 2020",Anticipated,2020-04-27,March 2020,2020-03-31,"November 26, 2020",Anticipated,2020-11-26,"August 26, 2020",Anticipated,2020-08-26,NA,Interventional,LIBA,,LIBA Trial in COVID-19,"Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial",Not yet recruiting,NA,Phase 4,230,Anticipated,King's College London,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-27T09:01:00Z,2020-04-27T09:01:00Z,5134691,NCT04334629,Coronavirus Infections,coronavirus infections,Drug,Ibuprofen,Lipid ibuprofen 200 mg,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-01,NA,NA,2020-04-16,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib,Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Grupo Cooperativo de HemopatÃ­as Malignas,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:01:02Z,2020-04-27T09:01:02Z,5134696,NCT04334044,Coronavirus Infections,coronavirus infections,Drug,Ruxolitinib Oral Tablet,Ruxolitinib 5 mg twice a day,1,Recruiting,Grupo Cooperativo de HemopatÃ­as Malignas,Huixquilucan,Estado De MÃ©xico,52763,Mexico,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-04-01,NA,NA,2020-04-22,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 12, 2020",Actual,2020-04-12,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Hydroxychloroquine in Outpatient Adults With COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19",Recruiting,NA,Phase 1,210,Anticipated,Sanofi,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-04-27T09:01:04Z,2020-04-27T09:01:04Z,5134703,NCT04333654,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine SAR321068|Placebo,Pharmaceutical form:Tablet Route of administration: Oral|Pharmaceutical form:Tablet Route of administration: Oral,2,Recruiting|Recruiting|Recruiting|Recruiting,Investigational Site Number 8400001|Investigational Site Number 2501001|Investigational Site Number 2501002|Investigational Site Number 5281001,Boston|Bordeaux Cedex|Paris|Groningen,Massachusetts|||,02115|33076|75005|9728 NZ,United States|France|France|Netherlands,4
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-31,NA,NA,2020-04-22,2020-03-31,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,July 2021,Anticipated,2021-07-31,April 2021,Anticipated,2021-04-30,NA,Interventional,ORCHID,,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Recruiting,NA,Phase 3,510,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T09:01:05Z,2020-04-27T09:01:05Z,5134713,NCT04332991,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine|Placebo,"Hydroxychloroquine is available in 200 mg oral tablets of hydroxychloroquine sulfate.
For this COVID-19 trial, we will use an oral or enteral dose of hydroxychloroquine 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.",2,Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting,University of Arizona|UCSF Fresno|Cedars-Sinai Medical Center|Ronald Reagan UCLA Medical Center|UC Davis Medical Center|UCSF Medical Center|Stanford University|Medical Center of Aurora|University of Colorado Hospital|Denver Health Medical Center|St. Joseph Hospital|University of Florida|University of Kentucky|University Medical Center|Maine Medical Center|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Baystate Medical Center|St. Vincent's Hospital|University of Michigan Medical Center|Henry Ford Medical Center|University of Mississippi Medical Center|Montefiore Medical Center-Weiler|Montefiore Medical Center-Moses|University of North Carolina at Chapel Hill|Wake Forest Baptist Medical Center|University of Cincinnati Medical Center|Cleveland Clinic Foundation|Ohio State University Wexner Medical Center|Oregon Health and Science University|Penn State Hershey Medical Center|Temple University Hospital|UPMC Presbyterian/Mercy/Shadyside|Medical University of South Carolina|Vanderbilt University Medical Center|University of Texas Health Science Center|Intermountain Medical Center|University of Utah Hospital|University of Virginia Health System|VCU Medical Center|Harborview Medical Center|Swedish Hospital First Hill,Tucson|Fresno|Los Angeles|Los Angeles|Sacramento|San Francisco|Stanford|Aurora|Aurora|Denver|Denver|Gainesville|Lexington|New Orleans|Portland|Boston|Boston|Boston|Springfield|Worcester|Ann Arbor|Detroit|Jackson|Bronx|Bronx|Chapel Hill|Winston-Salem|Cincinnati|Cleveland|Columbus|Portland|Hershey|Philadelphia|Pittsburgh|Charleston|Nashville|Houston|Murray|Salt Lake City|Charlottesville|Richmond|Seattle|Seattle,Arizona|California|California|California|California|California|California|Colorado|Colorado|Colorado|Colorado|Florida|Kentucky|Louisiana|Maine|Massachusetts|Massachusetts|Massachusetts|Massachusetts|Massachusetts|Michigan|Michigan|Mississippi|New York|New York|North Carolina|North Carolina|Ohio|Ohio|Ohio|Oregon|Pennsylvania|Pennsylvania|Pennsylvania|South Carolina|Tennessee|Texas|Utah|Utah|Virginia|Virginia|Washington|Washington,85721|93701|90048|90095|95817|94143|94305|80045|80045|80204|80218|32608|40506|70112|04102|02114|02115|02445|01199|01608|48109|48025|39216|10461|10467|27514|27157|45219|44195|43210|97239|17033|19140|15261|29425|37221|77030|84107|84132|22903|23298|98104|98122,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,43
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-31,NA,NA,2020-04-16,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,COVID-19,,An Observational Study of Patients With Coronavirus Disease 2019,An Observational Study of Patients With Coronavirus Disease 2019,Not yet recruiting,NA,NA,5000,Anticipated,"Target PharmaSolutions, Inc.",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T09:01:08Z,2020-04-27T09:01:08Z,5134718,NCT04331886,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,,University of Washington,Seattle,Washington,98195,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-23,NA,NA,2020-04-16,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Hydroxychloroquine for COVID-19 PEP,"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Recruiting,NA,Phase 2/Phase 3,2000,Anticipated,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2020-04-27T09:01:17Z,2020-04-27T09:01:17Z,5134738,NCT04328961,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine Sulfate|Ascorbic Acid,Eligible participants in a household randomized to this study arm will receive hydrochloroquine therapy|Eligible participants in a household randomized to this study arm will receive ascorbic acid therapy.,2,"Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Active, not recruiting|Recruiting","University of California Los Angeles|Tulane|University of Maryland, Baltimore|Boston University|NYU Langone Health|SUNY Upstate Medical University|University of Washington, Coordinating Center|UW Virology Research Clinic",Los Angeles|New Orleans|Baltimore|Boston|New York|Syracuse|Seattle|Seattle,California|Louisiana|Maryland|Massachusetts|New York|New York|Washington|Washington,90095|70118|21201|02215|10016|13210|98104|98104,United States|United States|United States|United States|United States|United States|United States|United States,8
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-26,NA,NA,2020-04-22,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"March 29, 2020",Actual,2020-03-29,April 2020,2020-04-30,June 2021,Anticipated,2021-06-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Sarilumab COVID-19,"An Adaptive Phase 2/3, Randomized, Double-blind, Placebo Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-04-27T09:01:22Z,2020-04-27T09:01:22Z,5134749,NCT04327388,Coronavirus Infections,coronavirus infections,Drug|Drug,Sarilumab SAR153191|Placebo,Pharmaceutical form:Solution for injection Route of administration: Intravenous infusion|Pharmaceutical form:Solution for injection Route of administration: Intravenous infusion,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Investigational Site Number 1240001|Investigational Site Number 1240002|Investigational Site Number 1240003|Investigational Site Number 2500001|Investigational Site Number 2500006|Investigational Site Number 2500002|Investigational Site Number 2500005|Investigational Site Number 2500003|Investigational Site Number 2500004|Investigational Site Number 2760003|Investigational Site Number 2760002|Investigational Site Number 2760004|Investigational Site Number 2760001|Investigational Site Number 3760003|Investigational Site Number 3760001|Investigational Site Number 3800005|Investigational Site Number 3800001|Investigational Site Number 3800002|Investigational Site Number 3800003|Investigational Site Number 3800004|Investigational Site Number 3920002|Investigational Site Number 6430002|Investigational Site Number 7240003|Investigational Site Number 7240004|Investigational Site Number 7240002|Investigational Site Number 7240005|Investigational Site Number 7240001,Montreal|Toronto|Vancouver|Bordeaux Cedex|La Roche Sur Yon Cedex 9|Nantes|Paris Cedex 18|Strasbourg|Suresnes|Bonn|Essen|KÃ¶ln|MÃ¼nster|Ashdod|Ramat Gan|Milano|Milano|Milano|Modena|Parma|Fuchu-Shi|Moscow|Barcelona|Barcelona|Madrid|Madrid|Madrid,||||||||||||||||||||||||||,H2X3E4|M5G 2N2|V5Z 1M9|33076|85925|44093|75877|67098|92151|53127|45147|50937|48149|7747629|52662|20122|20132|20157|41100|43100||123182|08035|08036|28007|28034|28046,Canada|Canada|Canada|France|France|France|France|France|France|Germany|Germany|Germany|Germany|Israel|Israel|Italy|Italy|Italy|Italy|Italy|Japan|Russian Federation|Spain|Spain|Spain|Spain|Spain,27
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-26,NA,NA,2020-04-16,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,"ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection",Enrolling by invitation,NA,Phase 3,300,Anticipated,Vanda Pharmaceuticals,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-27T09:01:23Z,2020-04-27T09:01:23Z,5134760,NCT04326426,Coronavirus Infections,coronavirus infections,Drug|Drug,Tradipitant|Placebo,Neurokinin-1 antagonist|Matching placebo,2,,Lenox Hill Hospital Northwell Health,New York,New York,10075,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-26,NA,NA,2020-04-20,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,Recruiting,NA,N/A,346,Anticipated,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:01:24Z,2020-04-27T09:01:24Z,5134765,NCT04325906,Coronavirus Infections,coronavirus infections,Device|Procedure,high flow nasal cannula (HFNC)|Prone positioning (PP),"HFNC will be initiated at 50 L/min (AIRVO2 or Optiflow, Fisher &Paykel Health care Limited., Auckland, New Zealand) with temperature set at 37 oC. Nasal cannula size will be determined by the patient's nostril size (â‰¤ 50%). FIO2 will be adjusted to maintain SpO2 at 92% to 95%. Flow and temperature will be adjusted based on patient's comfort and clinical response.|PP will be performed before or 1 hour after meal. Before PP, all the I.V. lines and nasal cannula will be checked by clinicians. PP will be performed by patient under the supervision of clinicians. Assistance will be offered if needed. If tolerated, PP will be maintained for at least 30 minutes, until the patients feel tired to keep that position. PP will be performed twice a day for the first 3 days after the patient's enrollment. FIO2 will be adjusted to maintain SpO2 at 92-95%.",2,Recruiting,Rush University Medical Center,Chicago,Illinois,60612,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-20,NA,NA,2020-04-22,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers",Recruiting,NA,Phase 1/Phase 2,1112,Anticipated,University of Oxford,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T09:01:26Z,2020-04-27T09:01:26Z,5134775,NCT04324606,Coronavirus Infections,coronavirus infections,Biological|Biological|Biological,ChAdOx1 nCoV-19|MenACWY|ChAdOx1 nCoV-19 boost,A single dose of 5x10^10vp of ChAdOx1 nCoV-19|Standard single dose of MenACWY vaccine delivered intramuscularly|A single dose of 5x10^10vp of ChAdOx1 nCoV-19 followed by a boost dose of 2.5x10^10vp of ChAdOx1 nCoV-19,3,Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting,"NIHR WTCRF, University Hospital Southampton NHS Foundation Trust|St Georges University Hospital NHS Foundation Trust|University Hospitals Bristol and Weston NHS Foundation Trust|Imperial College Healthcare NHS Trust|CCVTM, University of Oxford, Churchill Hospital|John Radcliffe Hospital",Southampton|London|Bristol|London|Oxford|Oxford,Hampshire|Tooting||||,SO16 6YD|SW17 0QT|BS1 3NU|W2 1NY|OX3 7LE|OX3 9DU,United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom,6
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-25,NA,NA,2020-04-21,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,"April 21, 2020",Actual,2020-04-21,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,ACT COVID19,,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",Recruiting,NA,Phase 3,1500,Anticipated,Population Health Research Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-27T09:01:27Z,2020-04-27T09:01:27Z,5134776,NCT04324463,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug,Azithromycin|Hydoxychloroquine or Chloroquine|Interferon-Beta,oral medication|oral medication|subcutaneous injection,3,Recruiting,Hamilton Health Sciences,Hamilton,Ontario,L8L2X2,Canada,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-24,NA,NA,2020-04-22,2020-03-24,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"March 31, 2024",Anticipated,2024-03-31,"March 31, 2024",Anticipated,2024-03-31,12 Months,Observational [Patient Registry],PRIORITY,,COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),PRIORITY (Pregnancy Coronavirus Outcomes Registry),Recruiting,NA,NA,2000,Anticipated,"University of California, San Francisco",,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:01:29Z,2020-04-27T09:01:29Z,5134786,NCT04323839,Coronavirus Infections,coronavirus infections,Other|Other,Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Postpartum women under investigation for Coronavirus or diagnosed with COVID-19,This is an observational study with no intervention|This is an observational study with no intervention,2,Recruiting,"University of California, San Francisco",San Francisco,California,94143,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-23,NA,NA,2020-04-18,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"January 15, 2021",Anticipated,2021-01-15,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,NA,,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial",Recruiting,NA,Phase 3,1000,Anticipated,Misr University for Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:01:32Z,2020-04-27T09:01:32Z,5134797,NCT04323345,Coronavirus Infections,coronavirus infections,Dietary Supplement|Other,Natural Honey|Standard Care,Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.|Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.,2,Recruiting,Mahmoud Tantawy,Cairo,,,Egypt,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-23,NA,NA,2020-04-22,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"March 23, 2020",Actual,2020-03-23,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,COVID-19,,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Recruiting,NA,Phase 3,6000,Anticipated,Montreal Heart Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-27T09:01:33Z,2020-04-27T09:01:33Z,5134798,NCT04322682,Coronavirus Infections,coronavirus infections,Drug|Drug,Colchicine|Placebo oral tablet,"Patients in this arm will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.|Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.",2,Recruiting|Recruiting|Recruiting|Recruiting,"University of California, San Francisco - San Francisco General Hospital|New York University School of Medecine|Montreal Heart Institute|Hospital Universitario La Paz, IdiPaz",San Francisco|New York|Montreal|La Paz,California|New York|Quebec|Madrid,94110|10010|H1T 1C8|28046,United States|United States|Canada|Spain,4
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-24,NA,NA,2020-04-22,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Estimate,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,July 2021,Anticipated,2021-07-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Enrolling by invitation,NA,Phase 2,1000,Anticipated,Nova Scotia Health Authority,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-27T09:01:39Z,2020-04-27T09:01:39Z,5134820,NCT04321993,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug,Lopinavir/ritonavir|Hydroxychloroquine sulfate|Baricitinib (janus kinase inhibitor),Lopinavir/ritonavir tablet 200mg/50mg 2 tables by mouth twice daily for 10 days|Hydroxychloroquine sulfate tablet 200 mg 2 tablets by mouth twice daily for 10 days|Baricitinib 2 mg po daily for 10 days,3,,Nova Scotia Health Authority,Halifax,Nova Scotia,B3H 1V7,Canada,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-23,NA,NA,2020-04-20,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"March 28, 2020",Actual,2020-03-28,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - Severely-ill Patients,Recruiting,NA,Phase 3,440,Anticipated,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-27T09:01:40Z,2020-04-27T09:01:40Z,5134822,NCT04321278,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine + azithromycin|Hydroxychloroquine,"Intervention Group: Hydroxychloroquine + azithromycin. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] + azithromycin [500mg 1x/day]) for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.|Active Control Group: Hydroxychloroquine. After randomization, Hydroxychloroquine [400mg 2x/day, 12/12h] for 10 days. Standard treatment is according to the treatment protocol for 2019-nCoV infection.",2,Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting,"Instituto de Cardiologia do Distrito Federal|FundaÃ§Ã£o Social Rural de Colatina|Hospital Vera Cruz AS|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda|Universidade Estadual de Londrina|Hospital Adventista de BelÃ©m|Hospital Giselda Trigueiro|Hospital UniversitÃ¡rio Onofre Lopes|Hospital Moinhos de Vento|Irmandade da Santa Casa de Misericordia de Porto Alegre|Maestri E Kormann Consultoria Medico-Cientifica|Sociedade Literaria e Caritativa Santo Agostinho|FundaÃ§Ã£o Pio XII|Santa Casa de Misericordia de Votuporanga|Hospital Israelita Albert Einstein|AMICO Saude LTDA|Associacao Beneficente Siria|Hospital Vila Santa Catarina|Prevent Senior Private Operadora de Saude Ltda|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP|Santa Casa de MisericÃ³rdia|Secretaria de SaÃºde do Estado de SÃ£o Paulo|Serv Social da Industria do papel, papelÃ£o e cortiÃ§a do estado de SP|Sociedade Beneficente de Senhoras Hospital SÃ­rio-LibanÃªs|Universidade Federal de SÃ£o Paulo",BrasÃ­lia|Colatina|Belo Horizonte|PoÃ§os De Caldas|Londrina|BelÃ©m|Natal|Natal|Porto Alegre|Porto Alegre|Blumenau|CriciÃºma|Barretos|Votuporanga|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo,Distrito Federal|Espirito Santo|Minas Gerais|Minas Gerais|ParanÃ¡|ParÃ¡|Rio Grande Do Norte|Rio Grande Do Norte|Rio Grande Do Sul|Rio Grande Do Sul|Santa Catarina|Santa Catarina|SÃ£o Paulo|SÃ£o Paulo||||||||||||,||||||||||||||05652-900|||||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,26
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-18,NA,NA,2020-04-17,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIPREV-LR,,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,NA,Phase 3,1220,Anticipated,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,TBA,2020-04-27T09:01:40Z,2020-04-27T09:01:40Z,5134826,NCT04321174,Coronavirus Infections,coronavirus infections,Drug,Lopinavir/ritonavir,"The intervention is a 14-day course of LPV/r 400/100 mg orally twice daily, or equivalent weight-based dosing, to be initiated as soon as possible (within 1-7 days) after the last exposure.",1,Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting,St. Paul's Hospital|Sunnybrook Hospital|St. Michael's Hospital|Toronto General Hospital,Vancouver|Toronto|Toronto|Toronto,British Columbia|Ontario|Ontario|Ontario,V6Z 1Y6|M4N 3M5|M5B 1W8|M5G 2N2,Canada|Canada|Canada|Canada,4
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-19,NA,NA,2020-04-15,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,PHYDRA,,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial),Recruiting,NA,Phase 3,400,Anticipated,"National Institute of Respiratory Diseases, Mexico",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-27T09:01:47Z,2020-04-27T09:01:47Z,5134852,NCT04318015,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,All treatment will be administered orally.|All placebo will be administered orally,2,Recruiting,"Instituto Nacional de Enfermedades Respiratorias, ""Ismael CosÃ­o Villegas""","Mexico, City",,14080,Mexico,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-19,NA,NA,2020-04-21,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,May 2022,Anticipated,2022-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,SAC-COVID,,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Recruiting,NA,Phase 3,230,Anticipated,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-27T09:01:50Z,2020-04-27T09:01:50Z,5134861,NCT04317040,Coronavirus Infections,coronavirus infections,Drug|Drug,CD24Fc|Placebo,CD24Fc is given on Day 1.|Placebo is given on Day 1.,2,Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting,"Baptist Health Research Institute|Martin Army Community Hospital|Anne Anundel Medical Center|Institute of Human Virology, University of Maryland Baltimore|White Oak Medical Center|Cooper University Hospital|University Hospitals of Cleveland|The Ohio State University Medical Center|Thomas Jefferson University Medical Center|University of Vermont Medical Center",Jacksonville|Fort Benning|Annapolis|Baltimore|Silver Spring|Camden|Cleveland|Columbus|Philadelphia|Burlington,Florida|Georgia|Maryland|Maryland|Maryland|New Jersey|Ohio|Ohio|Pennsylvania|Vermont,32207|31905|21401|21201|20904|08103|44106|43210|19107|05401,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,10
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-18,NA,NA,2020-04-15,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"March 22, 2021",Anticipated,2021-03-22,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,HYDRA,,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial),Recruiting,NA,Phase 3,500,Anticipated,"National Institute of Respiratory Diseases, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,As requested by other investigators.,2020-04-27T09:01:53Z,2020-04-27T09:01:53Z,5134867,NCT04315896,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine|Placebo oral tablet,hydroxychloroquine 400mg day for 10 days|Placebo oral tablet,2,Recruiting,"Instituto Nacional de Enfermedades Respiratorias, ""Ismael CosÃ­o Villegas""","Mexico, City",,14080,Mexico,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-13,NA,NA,2020-04-21,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Recruiting,NA,Phase 2,200,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-27T09:01:57Z,2020-04-27T09:01:57Z,5134885,NCT04312009,Coronavirus Infections,coronavirus infections,Drug|Other,Losartan|Placebo,"Losartan; 50 mg daily; oral administration|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration",2,Recruiting|Recruiting|Recruiting,Hennepin County Medical Center|M Health Fairview University of Minnesota Medical Center|University of Minnesota,Minneapolis|Minneapolis|Minneapolis,Minnesota|Minnesota|Minnesota,55415|55455|55455,United States|United States|United States,3
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-14,NA,NA,2020-04-21,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Estimate,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,COVID-AIV,,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Not yet recruiting,NA,Phase 2,120,Anticipated,"NeuroRx, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-27T09:01:59Z,2020-04-27T09:01:59Z,5134893,NCT04311697,Coronavirus Infections,coronavirus infections,Drug|Drug,Aviptadil by intravenous infusion + maximal intensive care|Normal Saline Infusion + Maximal intensive care,Aviptadil by intravenous infusion + maximal intensive care (MIC). MIC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.|Maximal intensive care (MIC). MIC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.,2,|||,Miller School of Medicine / University of Miami Medical Center|Robert I Grossman School of Medicine / NYU Langone Medical Center|Thomas Jefferson University Hospital|Rambam Health Care Campus,Miami|New York|Philadelphia|Haifa,Florida|New York|Pennsylvania|,33136|10016|19107|3109601,United States|United States|United States|Israel,4
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-13,NA,NA,2020-04-23,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Estimate,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Recruiting,NA,Phase 2,580,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-27T09:02:01Z,2020-04-27T09:02:01Z,5134903,NCT04311177,Coronavirus Infections,coronavirus infections,Drug|Other,Losartan|Placebo,"Losartan; 25 mg daily; oral administration|Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration",2,Recruiting|Recruiting|Recruiting|Recruiting,Hennepin County Medical Center|M Health Fairview University of Minnesota Medical Center|University of Minnesota|Mayo Clinic Health System,Minneapolis|Minneapolis|Minneapolis|Rochester,Minnesota|Minnesota|Minnesota|Minnesota,55415|55455|55455|55415,United States|United States|United States|United States,4
"ClinicalTrials.gov processed this data on April 24, 2020",2020-02-20,NA,NA,2020-04-16,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"February 21, 2020",Actual,2020-02-21,"April 8, 2020",2020-04-08,"April 1, 2023",Anticipated,2023-04-01,"April 1, 2023",Anticipated,2023-04-01,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,572,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-27T09:02:40Z,2020-04-27T09:02:40Z,5135031,NCT04280705,Coronavirus Infections,coronavirus infections,Other|Drug,Placebo|Remdesivir,"The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a matching placebo of normal saline of equal volume may be given if there are limitations on placebo supplies.|Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.",2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"University of Alabama at Birmingham School of Medicine - Infectious Disease|University of California San Diego Health - Jacobs Medical Center|University of California Los Angeles Medical Center - Westwood Clinic|University of California Irvine Medical Center - Infectious Disease|VA Palo Alto Health Care System - Infectious Diseases|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases|University of California Davis Medical Center - Internal Medicine - Infectious Disease|Naval Medical Center San Diego - Infectious Disease Clinic|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine|Cedars Sinai Medical Center|Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases|Denver Health Division of Hospital Medicine - Main Campus|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine|Emory Vaccine Center - The Hope Clinic|Northwestern Hospital - Infectious Disease|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore|Johns Hopkins Hospital - Medicine - Infectious Diseases|Walter Reed National Military Medical Center|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section|Massachusetts General Hospital - Infectious Diseases|University of Massachusetts Medical School - Infectious Diseases and Immunology|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine|Saint Louis University - Center for Vaccine Development|University of Nebraska Medical Center - Infectious Diseases|Montefiore Medical Center - Infectious Diseases|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology|University of Rochester Medical Center - Vaccine Research Unit|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases|Hospital of the University of Pennsylvania - Infectious Diseases|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology|Vanderbilt University Medical Center - Infectious Diseases|Brooke Army Medical Center|University of Texas Medical Branch - Division of Infectious Disease|Baylor College of Medicine - Molecular Virology and Microbiology|University of Texas Health Science Center at San Antonio - Infectious Diseases|University of Virginia - Acute Care Surgery|Naval Medical Center Portsmouth - Infectious Disease Division|EvergreenHealth Infectious Disease Service|The University of Washington - Virology Research Clinic|Providence Sacred Heart Medical Center|Madigan Army Medical Center - Infectious Disease Clinic|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I|UniversitÃ¤tsklinikum Frankfurt -Medizinische Klinik II - Infektiologie|AHEPA University Hospital - 1st Department of Internal Medicine|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center|Seoul National University Bundang Hospital - Division of Infectious Diseases|Seoul National University Hospital|Instituto Nacional de Ciencias Medicas y NutriciÃ³n Salvador ZubirÃ¡n - Departamento de Infectologia|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael CosÃ­o Villegas|National University Health System - Division of Infectious Diseases|Singapore General Hospital - Department of Infectious Diseases|National Centre for Infectious Diseases (NCID)|Changi General Hospital - Clinical Trials and Research Unit (CTRU)|Ng Teng Fong General Hospital - Infectious Disease Service|Khoo Teck Puat Hospital - Clinical Research Unit|Hospital Clinic Barcelona, Servicio de Salud Internacional|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses|Royal Sussex County Hospital - Department of Intensive Care Medicine|Saint Thomas' Hospital - Directorate of Infection|St. James's University Hospital - Infectious Diseases|John Radcliffe Hospital|Royal Victoria Infirmary - Department of Infectious Diseases","Birmingham|La Jolla|Los Angeles|Orange|Palo Alto|Palo Alto|Sacramento|San Diego|San Francisco|West Hollywood|Aurora|Denver|Gainesville|Decatur|Chicago|Chicago|New Orleans|Annapolis|Baltimore|Bethesda|Bethesda|Boston|Worcester|Minneapolis|Saint Louis|Omaha|Bronx|New York|Rochester|Durham|Hershey|Philadelphia|Philadelphia|Nashville|Fort Sam Houston|Galveston|Houston|San Antonio|Charlottesville|Portsmouth|Kirkland|Seattle|Spokane|Tacoma|Copenhagen|Bonn|Cologne|Frankfurt|Thessaloniki|Athens|Tokyo|Bundang-gu Seongnam-si|Seoul|Mexico City|Mexico City|Singapore|Singapore|Singapore|Singapore|Singapore|Singapore|Barcelona|Barcelona|East Sussex|London|Leeds|Headington, Oxford|Newcastle Upon Tyne","Alabama|California|California|California|California|California|California|California|California|California|Colorado|Colorado|Florida|Georgia|Illinois|Illinois|Louisiana|Maryland|Maryland|Maryland|Maryland|Massachusetts|Massachusetts|Minnesota|Missouri|Nebraska|New York|New York|New York|North Carolina|Pennsylvania|Pennsylvania|Pennsylvania|Tennessee|Texas|Texas|Texas|Texas|Virginia|Virginia|Washington|Washington|Washington|Washington||Nordrhein-Westfalen|||Central Macedonia|||Gyeonggi-do|Jongno-gu|||||||||CataluÃ±a|CataluÃ±a|Brighton|London, City Of|West Yorkshire||",35233|29037|90095|92868-3298|94304-1207|94304-1503|95817-1460|92314|94110-2859|90048-1804|80045|80204|32610|30030-1705|60611-2908|60612|70119|21401-1527|21287-0005|20889|20892-1504|02114-2621|01655-0002|55455-0341|63104-1015|68198-5400|10467-2401|10016-6402|14642-0001|27704|17033|19104-4238|19104-4863|37232-0011|78234|77555-0435|77030-3411|78229-3901|22908-0816|23708|98034|98104-2433|99204|98431|2100|53127|50937|60590|P.O. 54636|GR-10675|162-8655|13620|03080|14080|14080|119228|169608|308442|529889|609606|768828|08036|08916|BN2 5BE|SE1 7EH|LS9 7TK|OX3 9DU|NE1 4LP,"United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|Denmark|Germany|Germany|Germany|Greece|Greece|Japan|Korea, Republic of|Korea, Republic of|Mexico|Mexico|Singapore|Singapore|Singapore|Singapore|Singapore|Singapore|Spain|Spain|United Kingdom|United Kingdom|United Kingdom|United Kingdom|United Kingdom",68
"ClinicalTrials.gov processed this data on April 24, 2020",2020-02-18,NA,NA,2020-04-15,2020-02-18,2020-02-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 5, 2020",Actual,2020-03-05,October 2019,2019-10-31,"April 24, 2024",Anticipated,2024-04-24,"April 24, 2024",Anticipated,2024-04-24,NA,Observational,POPS or POP02,,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs",Recruiting,NA,NA,5000,Anticipated,Duke University,,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Whole blood, effluent samples, and plasma.
    ",NA,NA,NA,No,NA,2020-04-27T09:02:43Z,2020-04-27T09:02:43Z,5135048,NCT04278404,Coronavirus Infections,coronavirus infections,Drug,"The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:",The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.,1,Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,Arkansas Children's Hospital Research Institute|Colorado University Denver|Alfred I. DuPont Hospital for Children|University of Florida Jacksonville Shands Medical Center|Kapiolani Womens and Childrens Medical Center|Ann and Robert H. Lurie Childrens Hospital of Chicago|Riley Hospital for Children at Indiana University|University of Kansas Medical Center|Wesley Medical Center|University of Louisville Norton Childrens Hospital|Tulane University Health Science Center|Ochsner Baptist Clinical Trials Unit|University of Mississippi Medical Center|Childrens Mercy Hospital|University of Nebraska Medical Center|Dartmouth-Hitchcock Medical Center|University of New Mexico Health Science Center|Kravis Children's Hospital at Mt. Sinai|University of North Carolina at Chapel Hill|Duke University Health System|Cincinnati Childrens Hospital Medical Center|Board of Regents of the University of Oklahoma|Oregon Health and Science University|Rhode Island Hospital|Medical University of South Carolina Children's Hospital|University of South Carolina|University of South Carolina|Monroe Carell Jr. Children's Hospital at Vanderbilt|Dell Children's Medical Center of Central Texas|Seattle Children's Hospital|University Wisconsin|Medical College of Wisconsin,Little Rock|Aurora|Wilmington|Jacksonville|Honolulu|Chicago|Indianapolis|Kansas City|Wichita|Louisville|New Orleans|New Orleans|Jackson|Kansas City|Omaha|Lebanon|Albuquerque|New York|Chapel Hill|Durham|Cincinnati|Oklahoma City|Portland|Providence|Charleston|Columbia|Columbia|Nashville|Austin|Seattle|Madison|Milwaukee,Arkansas|Colorado|Delaware|Florida|Hawaii|Illinois|Indiana|Kansas|Kansas|Kentucky|Louisiana|Louisiana|Mississippi|Missouri|Nebraska|New Hampshire|New Mexico|New York|North Carolina|North Carolina|Ohio|Oklahoma|Oregon|Rhode Island|South Carolina|South Carolina|South Carolina|Tennessee|Texas|Washington|Wisconsin|Wisconsin,72202|80045|19803|32209|96826|60614|46202|66160|67214|40202|70112|70115|39216|64111|68114|03756|87131|10029|27599|27710|45229|73104|97239|02903|29425|29203|29203|37232|78723|98105|53705|53226,United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States|United States,32
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-13,NA,NA,2020-03-15,2020-02-20,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"February 21, 2020",Actual,2020-02-21,March 2020,2020-03-31,"July 30, 2020",Anticipated,2020-07-30,"May 30, 2020",Anticipated,2020-05-30,NA,Observational,NA,,Study for Novel Coronavirus Pneumonia (NCP),Study for Clinical Epidemiology and Methods of Diagnosis and Treatment of Novel Coronavirus Pneumonia (NCP),Recruiting,NA,NA,2000,Anticipated,"Wuhan Union Hospital, China",,NA,NA,NA,FALSE,NA,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:23:13Z,2020-04-01T09:23:13Z,4278041,NCT04283396,Coronavirus Infections,coronavirus infections,Combination Product,systemic treatment,"Oxygen therapy, antiviral therapy, antibiotics, hormones, globulin",1,Recruiting,Union hospital,Wuhan,Hubei,430000,China,1
"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-06,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-09,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Observational,NA,,Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),Not yet recruiting,NA,NA,500,Anticipated,University of Minnesota,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-19T09:01:58Z,2020-04-19T09:01:58Z,5047273,NCT04339998,Coronavirus Infections,coronavirus infections,Diagnostic Test,Point-of-Care Ultrasonography (POCUS),"The POCUS exam of the heart will capture 2 standard views commonly used to assess general cardiac function at the point of care. The details of POCUS views and exam findings of interest are outline below:
Pulmonary POCUS Evaluation:
B lines: absent (< 3 lines), present (> 3 lines), fused
Consolidation: yes or no
a. Bilateral: yes or no
Pleural Effusion: yes or no
Other pleural abnormalities: yes or no Score each finding based on degree of abnormalities and number of sites with abnormalities
Cardiac POCUS Evaluation:
Parasternal long axis
Parasternal short axis
Qualitative LVEF: Normal, hyperdynamic, mild-moderately depressed, severely depressed
EPSS (E-point septal separation): normal (<10 mm), abnormal (>10 mm)
Left ventricular (LV) mass approximation by septal thickness
Left Ventricular Chamber Size by internal diameter at diastole",1,|,University of Minnesota Medical Center (UMMC)|M Health Fairview Bethesda Hospital,Minneapolis|Saint Paul,Minnesota|Minnesota,55455|55103,United States|United States,2
"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-06,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-09,Actual,"March 1, 2020",Actual,2020-03-01,April 2020,2020-04-30,"April 15, 2020",Anticipated,2020-04-15,"April 15, 2020",Anticipated,2020-04-15,NA,Observational,NA,,COVID-19 Risk Stratification,COVID-19 Risk Stratification,Recruiting,NA,NA,1500,Anticipated,Brigham and Women's Hospital,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Investigators may provide reasonable requests for IPD. These requests will be reviewed by the study team and institution on a case by case basis.,2020-04-19T09:02:22Z,2020-04-19T09:02:22Z,5047344,NCT04339387,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,Brigham and Women's Hospital,Boston,Massachusetts,02115,United States,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-14,NA,NA,2020-03-14,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"March 14, 2020",Anticipated,2020-03-14,March 2020,2020-03-31,"December 1, 2020",Anticipated,2020-12-01,"June 1, 2020",Anticipated,2020-06-01,NA,Observational,NA,,Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System,Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System,Not yet recruiting,NA,NA,100,Anticipated,Huashan Hospital,,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:19:39Z,2020-04-01T09:19:39Z,4274500,NCT04311398,Coronavirus Infections,coronavirus infections,Diagnostic Test,New QIAstat-Dx fully automatic multiple PCR detection platform,We use the New QIAstat-Dx fully automatic multiple PCR detection platform to test the enrolled patients,1,,Huashan Hospital of Fudan University,Shanghai,Shanghai,200040,China,1
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-23,NA,NA,2020-03-30,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,NA,,Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2,"COVID CT, Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2",Not yet recruiting,NA,NA,25,Anticipated,William Beaumont Hospitals,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-10T09:16:55Z,2020-04-10T09:16:55Z,4940269,NCT04320511,Coronavirus Infections,coronavirus infections,Device,CT-V,"CT-V is an image processing-based modality that recovers changes in local tissue volumes, induced by respiratory motion, from an inspiration-expiration CT (IE-CT) scan or a standard non-contrast 4D CT scan",1,,Beaumont Health,Royal Oak,Michigan,48073,United States,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-14,NA,NA,2020-03-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-20,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19,Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19,Not yet recruiting,NA,N/A,200,Anticipated,"Centro Studi Internazionali, Italy",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months,Still under development,NA,Yes,Still under development,2020-04-01T09:19:01Z,2020-04-01T09:19:01Z,4273817,NCT04316728,Coronavirus Infections,coronavirus infections,Device,VivaDiagâ„¢ COVID-19 lgM/IgG Rapid Test,"VivaDiagâ„¢ COVID-19 lgM/IgG Rapid Test is an in vitro diagnostic for the qualitative determination of COVID-19 IgM and IgG antibodies in human whole blood (from vein or fingertip), serum or plasma",1,,"UnitÃ ' Complesse di cure primarie (UCCP), ASP Catanzaro",Catanzaro,,88100,Italy,1
"ClinicalTrials.gov processed this data on April 08, 2020",2020-02-27,NA,NA,2020-03-26,2020-02-27,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,NA,NA,NA,March 2020,2020-03-31,NA,NA,NA,NA,NA,NA,NA,Expanded Access,SOLID-C19,,Eculizumab (Soliris) in Covid-19 Infected Patients,Soliris to Stop Immune Mediated Death In Covid 19 Infected Patients. A Trial of Distal Complement Inhibition.,Available,NA,NA,NA,NA,Hudson Medical,,NA,NA,NA,FALSE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-09T09:17:15Z,2020-04-09T09:17:15Z,4927221,NCT04288713,Coronavirus Infections,coronavirus infections,Drug,Eculizumab,A distal complement inhibitor.,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-13,NA,NA,2020-03-23,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-25,Actual,"March 22, 2020",Actual,2020-03-22,March 2020,2020-03-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,DisCoVeRy,,Trial of Treatments for COVID-19 in Hospitalized Adults,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,3100,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-04T09:18:48Z,2020-04-04T09:18:48Z,4870258,NCT04315948,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug|Drug|Other,Remdesivir|Lopinavir/ritonavir|Interferon Beta-1A|Hydroxychloroquine|Standard of care,"The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.|The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the ""a"" logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).|IFN-ÃŸ-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 Âµg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.|Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).|Standard of care.",5,Recruiting|Recruiting|Recruiting,CHRU Lille|CHU Nantes|APHP - Bichat Claude Bernard,Lille|Nantes|Paris,||,59000|44000|75018,France|France|France,3
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-13,NA,NA,2020-03-14,2020-03-14,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-18,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,February 2021,Anticipated,2021-02-28,October 2020,Anticipated,2020-10-31,NA,Observational,SOTSPC,,Sequential Oxygen Therapy Strategy for Patients With COVID-19,Sequential Oxygen Therapy Strategy for Patients With COVID-19,Recruiting,NA,NA,30,Anticipated,Henan Provincial People's Hospital,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-01T09:19:34Z,2020-04-01T09:19:34Z,4274415,NCT04312100,Coronavirus Infections,coronavirus infections,Other,oxygen treatment,different kinds of oxygen treatments will be given to patients according to their state of illness,1,Recruiting,Henan Provincial People's Hospital,Zhengzhou,Henan,450000,China,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-05,NA,NA,2020-02-13,2020-02-05,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-02-13,2020-02-17,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"February 4, 2021",Anticipated,2021-02-04,"October 4, 2020",Anticipated,2020-10-04,NA,Observational,Cov-CONTACT,,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection,Recruiting,NA,NA,300,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      Nasopharyngeal swabs
    ",NA,NA,NA,Undecided,NA,2020-04-01T09:26:21Z,2020-04-01T09:26:21Z,4280975,NCT04259892,Coronavirus Infections,coronavirus infections,Biological,2019-nCoV PCR,Nasopharyngeal swabs,1,Recruiting,CIC 1425,Paris,,75018,France,1
"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-07,NA,NA,2020-04-07,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-10,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,SOS-COVID19,,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.,Not yet recruiting,NA,N/A,60,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-20T08:50:05Z,2020-04-20T08:50:05Z,5057401,NCT04341415,Coronavirus Infections,coronavirus infections,Procedure|Procedure,Auricular neuromodulation|Control,"The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.
Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELECÂ®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient.
Compress soaked with Oxygenated water on the concha (to stop potential bleeding).
Placing an opaque dressing on the ear and a non-occlusive Band-Aid|The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.
Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle).
Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid.",2,,Fondation Adolphe de Rothschild,Paris,,75019,France,1
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-25,NA,NA,2020-03-27,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"November 26, 2020",Anticipated,2020-11-26,"September 26, 2020",Anticipated,2020-09-26,NA,Interventional,CYCOV,,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,NA,N/A,30,Anticipated,University Hospital Freiburg,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-10T09:16:23Z,2020-04-10T09:16:23Z,4940151,NCT04324528,Coronavirus Infections,coronavirus infections,Device|Device,vv-ECMO + cytokine adsorption (Cytosorb adsorber)|vv-ECMO only (no cytokine adsorption),in COVID-19-diseased vv-ECMO patients additional treatment with cytokine adsorption using a Cytosorb adsorber will be randomized (vs. control group)|COVID-19-diseased treated with vv-ECMO,2,Recruiting,University Clinic Freiburg,Freiburg,,79108,Germany,1
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-31,NA,NA,2020-04-01,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,CP-COVID-19,,"Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study",Not yet recruiting,NA,Phase 2/Phase 3,80,Anticipated,Universidad del Rosario,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-13T08:59:50Z,2020-04-13T08:59:50Z,4977946,NCT04332835,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug,Plasma|Hydroxychloroquine|Azithromycin,"Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.|400 milligrams each 12 hours for 10 days|500 milligrams daily for 10 days",3,,Universidad del Rosario,Bogota,Cundinamarca,11100,Colombia,1
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-24,NA,NA,2020-03-28,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-28,2020-03-31,Actual,"March 19, 2020",Actual,2020-03-19,March 2020,2020-03-31,"May 19, 2020",Anticipated,2020-05-19,"May 19, 2020",Anticipated,2020-05-19,NA,Observational,SISCO,,An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection,An Observational Case-control Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications,Recruiting,NA,NA,50,Anticipated,A.O. Ospedale Papa Giovanni XXIII,,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-10T09:16:44Z,2020-04-10T09:16:44Z,4940219,NCT04322188,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,ASST - Papa Giovanni XXIII,Bergamo,,24127,Italy,1
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-23,NA,NA,2020-03-27,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"March 20, 2030",Anticipated,2030-03-20,"March 27, 2022",Anticipated,2022-03-27,NA,Observational,NA,,Risk Factors for Community- and Workplace Transmission of COVID-19,Risk Factors for Community- and Workplace Transmission of COVID-19,Recruiting,NA,NA,50000,Anticipated,Oslo University Hospital,,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood and upper repiratory samples will be collected from some participants.
    ",NA,NA,NA,No,"European GDPR regulations severely limits IPD, but the study will share data to the largest extent possible within GDPR.",2020-04-10T09:16:51Z,2020-04-10T09:16:51Z,4940261,NCT04320732,Coronavirus Infections,coronavirus infections,Behavioral,Observation of behavior and COVID-19 infection will be conducted.,"No intervention, only prospective observation of behavior will be conducted by a questionnaire.",1,Recruiting,Oslo University Hospital,Oslo,,0424,Norway,1
"ClinicalTrials.gov processed this data on April 10, 2020",2020-02-14,NA,NA,2020-04-01,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,May 2020,Anticipated,2020-05-31,April 2020,Anticipated,2020-04-30,NA,Interventional,BEST-CP,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP),Recruiting,NA,Phase 2/Phase 3,20,Anticipated,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-13T09:02:44Z,2020-04-13T09:02:44Z,4978590,NCT04275414,Coronavirus Infections,coronavirus infections,Drug,Bevacizumab Injection,"Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip â‰¥90min",1,Recruiting|Recruiting|Recruiting,Renmin Hospital of Wuhan University|Qilu Hospital of Shandong University|Moriggia-Pelascini Gravedona Hospital,Wuhan|Jinan|Gravedona,Hubei|Shandong|,|250012|,China|China|Italy,3
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-27,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"January 30, 2020",Actual,2020-01-30,March 2020,2020-03-31,"April 15, 2020",Anticipated,2020-04-15,"April 2, 2020",Anticipated,2020-04-02,NA,Observational,NA,,Clinical Characteristics and Prognostic Factors of Patients With COVID-19,Clinical Characteristics and Prognostic Factors of Patients With COVID-19 in Chibi Hospital of Hubei Province,Recruiting,NA,NA,120,Anticipated,Shanghai 10th People's Hospital,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-10T09:15:14Z,2020-04-10T09:15:14Z,4939855,NCT04328454,Coronavirus Infections,coronavirus infections,Other,retrospective analysis,The investigators retrospectively analyzed the hospitalized patients with COVID-19,1,Recruiting,Shanghai 10th People's Hospital,Shanghai,Shanghai,+86200072,China,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-08,NA,NA,2020-03-16,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-17,Actual,"March 8, 2020",Actual,2020-03-08,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"May 31, 2020",Anticipated,2020-05-31,NA,Observational,NA,,Social Media Use During COVID-19,Getting it Right: Towards Responsible Social Media Use During a Pandemic,Recruiting,NA,NA,5000,Anticipated,Yale-NUS College,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Due to stipulations by the Institutional Review Board, data cannot be shared.",2020-04-01T09:20:25Z,2020-04-01T09:20:25Z,4275274,NCT04305574,Coronavirus Infections,coronavirus infections,Behavioral,Use of social media during COVID-19,Participants' self-reported use of social media to receive and share news about COVID-19,1,Recruiting,Yale-NUS College,Singapore,,138527,Singapore,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-19,NA,NA,2020-02-24,2020-02-24,2020-02-26,Actual,NA,NA,NA,NA,NA,NA,2020-02-24,2020-02-26,Actual,"February 26, 2020",Anticipated,2020-02-26,February 2020,2020-02-29,"September 15, 2020",Anticipated,2020-09-15,"June 15, 2020",Anticipated,2020-06-15,NA,Interventional,NA,,The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19,A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19),Not yet recruiting,NA,N/A,120,Anticipated,"Tasly Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No plan to share,2020-04-01T09:23:00Z,2020-04-01T09:23:00Z,4277768,NCT04285190,Coronavirus Infections,coronavirus infections,Drug,T89,"The subjects in the T89 treatment group will receive 30 pills of T89 orally, bid., for 10 days, except a standard background treatment (antiviral drug + antibacterial + oxygen therapy+ Traditional Chinese Medicine decoction). The subjects in the blank control group will only receive a standard background treatment.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-10,NA,NA,2020-02-21,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"June 1, 2020",Anticipated,2020-06-01,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Recruiting,NA,Phase 3,294,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:23:17Z,2020-04-01T09:23:17Z,4278107,NCT04282902,Coronavirus Infections,coronavirus infections,Drug,pirfenidone,"Pirfenidone is administered orally 3 times a day, 2 tablets each time, for a period of 4 weeks or longer",1,Recruiting,Tongji hospital affiliated to huazhong university of science and technology,Wuhan,Hubei,,China,1
"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-23,NA,NA,2020-03-25,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"August 30, 2020",Anticipated,2020-08-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,add-on-COV2,,Escin in Patients With Covid-19 Infection,Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,University of Catanzaro,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-06T08:55:58Z,2020-04-06T08:55:58Z,4894413,NCT04322344,Coronavirus Infections,coronavirus infections,Drug|Drug,Escin|standard therapy,treatment with escin or escinate sodium|antiviral drugs,2,Recruiting,Luca Gallelli,Catanzaro,,88100,Italy,1
"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-20,NA,NA,2020-03-25,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"August 21, 2021",Anticipated,2021-08-21,"April 21, 2021",Anticipated,2021-04-21,NA,Interventional,PROACTIVE-19,,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19),Not yet recruiting,NA,N/A,7576,Anticipated,University of Pecs,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-06T08:56:05Z,2020-04-06T08:56:05Z,4894434,NCT04321928,Coronavirus Infections,coronavirus infections,Behavioral|Behavioral,Personalized health education|General health education,"Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive detailed individualized education regarding lifestyle changes based on their current habits.|Subjects will go through questioning and recommendations in 5 domains: (1) mental health (2) smoking habits, (3) physical activity, (4) dietary habits and (5) alcohol consumption. Then they will receive general health education aiming towards improvement of these factors with general recommendations following the WHO principles.",2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-10,NA,NA,2020-03-14,2020-03-10,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"March 19, 2020",Anticipated,2020-03-19,March 2020,2020-03-31,"December 31, 2020",Anticipated,2020-12-31,"April 19, 2020",Anticipated,2020-04-19,NA,Observational,NA,,Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life,Acute Respiratory Failure and Continuous Positive Airway Pressure Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: a Real Life Evaluation,Not yet recruiting,NA,NA,50,Anticipated,University of Milan,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:12Z,2020-04-01T09:20:12Z,4275055,NCT04307459,Coronavirus Infections,coronavirus infections,Other,standard operating procedures,"standard operating procedures represented by continuous positive airway pressure (CPAP) therapy or non invasive ventilation, pharmacological treatment as antiviral and antibiotic drugs, bronchodilators, xanthines, enteral nutrition, hydration.",1,,Luigi Sacco University Hospital,Milan,Lombardia,20157,Italy,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-25,NA,NA,2020-02-28,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-02-28,2020-03-03,Actual,"February 1, 2020",Actual,2020-02-01,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"July 31, 2020",Anticipated,2020-07-31,NA,Observational,NA,,Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19,The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study,Recruiting,NA,NA,15,Anticipated,Shanghai Public Health Clinical Center,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:22:05Z,2020-04-01T09:22:05Z,4276857,NCT04292340,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,Shanghai Public Health Clinical Center,Shanghai,Shanghai,201508,China,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-23,NA,NA,2020-02-29,2020-02-29,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-02-29,2020-03-03,Actual,"January 1, 2020",Actual,2020-01-01,February 2020,2020-02-29,"July 31, 2020",Anticipated,2020-07-31,"April 30, 2020",Anticipated,2020-04-30,NA,Observational,2019-nCoV,,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus(2019-nCoV),"Active, not recruiting",NA,NA,400,Anticipated,Fujian Provincial Hospital,,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:22:05Z,2020-04-01T09:22:05Z,4276858,NCT04292327,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,,Fujian Provincial Hospital,Fuzhou,Fujian,350000,China,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-01-30,NA,NA,2020-01-31,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-01-31,2020-02-05,Actual,"January 28, 2020",Anticipated,2020-01-28,January 2020,2020-01-31,"July 31, 2020",Anticipated,2020-07-31,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,ELACOI,,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Recruiting,NA,Phase 4,125,Anticipated,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-01T09:27:18Z,2020-04-01T09:27:18Z,4281796,NCT04252885,Coronavirus Infections,coronavirus infections,Drug|Drug,Lopinavir and Ritonavir Tablets|Arbidol,As indicated in arm/group descriptions|As indicated in arm/group descriptions,2,Recruiting,Guangzhou Eighth People's Hospital,Guangzhou,Guangdong,510060,China,1
"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-22,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"June 25, 2020",Anticipated,2020-06-25,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,Beijing Chao Yang Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:19:32Z,2020-04-03T09:19:32Z,4856286,NCT04319900,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug,favipiravir tablets+chloroquine phosphatetablets tablets|Favipiravir tablets|Placebo,"Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).
Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.
Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug.|Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.|Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.",3,Recruiting,Beijing Chaoyang hospital,Beijing,Beijing,100020,China,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-19,NA,NA,2020-02-19,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"January 20, 2020",Actual,2020-01-20,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,NA,,Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations,Study on Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations in Patients,Recruiting,NA,NA,20,Anticipated,"Third Affiliated Hospital, Sun Yat-Sen University",,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:23:39Z,2020-04-01T09:23:39Z,4278532,NCT04279795,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,510630,China,1
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-13,NA,NA,2020-03-30,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-03,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"March 3, 2025",Anticipated,2025-03-03,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NO COVID-19,,Norwegian Coronavirus Disease 2019 Study,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection,Recruiting,NA,Phase 4,202,Anticipated,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-13T09:01:21Z,2020-04-13T09:01:21Z,4978273,NCT04316377,Coronavirus Infections,coronavirus infections,Drug,Hydroxychloroquine Sulfate,400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days,1,Recruiting,Akershus University Hospital,LÃ¸renskog,,1478,Norway,1
"ClinicalTrials.gov processed this data on April 15, 2020",2020-03-23,NA,NA,2020-04-02,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,CamoCO-19,,The Impact of Camostat Mesilate on COVID-19 Infection,"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial",Recruiting,NA,Phase 1/Phase 2,180,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposals should be addressed to olesoega@rm.dk.,NA,Yes,"Data sharing plan: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan). Data will become available following publication with no planned end date.",2020-04-16T09:16:53Z,2020-04-16T09:16:53Z,5010564,NCT04321096,Coronavirus Infections,coronavirus infections,Drug|Drug,Camostat Mesilate|Placebo oral tablet,Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2|Placebo,2,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,"Department of Infectious Diseases|Department for Infectious Diseases, Aarhus University Hospital|Herning Regional Hospital|Northzealands hospital - HillerÃ¸d|Horsens Regional Hospital|Bispebjerg hospital|Dept. of Infectious Diseases, Odense University Hospital|Randers Regional Hospital|Silkeborg Hospital",Aalborg|Aarhus N|Herning|HillerÃ¸d|Horsens|KÃ¸benhavn|Odense|Randers|Silkeborg,||||||||,|8200|7400|3400|8700|2400|5000|8900|8600,Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark,9
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-30,NA,NA,2020-03-31,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Observational,NA,,Impact of the Coronavirus (COVID-19) on Patients With Cancer,Impact of the Coronavirus (COVID-19) on Patients With Cancer,Not yet recruiting,NA,NA,50,Anticipated,Stanford University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-11T09:12:30Z,2020-04-11T09:12:30Z,4953200,NCT04330521,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-15,NA,NA,2020-04-01,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"April 2, 2020",Anticipated,2020-04-02,April 2020,2020-04-30,"March 20, 2022",Anticipated,2022-03-20,"March 20, 2021",Anticipated,2021-03-20,NA,Interventional,NOpreventCOVID,,NO Prevention of COVID-19 for Healthcare Providers,Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers,Not yet recruiting,NA,Phase 2,470,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-13T09:01:32Z,2020-04-13T09:01:32Z,4978332,NCT04312243,Coronavirus Infections,coronavirus infections,Drug,Inhaled nitric oxide gas,"Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-20,NA,NA,2020-02-20,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-21,Actual,"February 22, 2020",Anticipated,2020-02-22,February 2020,2020-02-29,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Fingolimod in COVID-19,Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19),Recruiting,NA,Phase 2,30,Anticipated,First Affiliated Hospital of Fujian Medical University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-01T09:23:33Z,2020-04-01T09:23:33Z,4278425,NCT04280588,Coronavirus Infections,coronavirus infections,Drug,Fingolimod 0.5 mg,"Each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days",1,Recruiting,Wan-Jin Chen,Fuzhou,,,China,1
"ClinicalTrials.gov processed this data on April 16, 2020",2020-04-06,NA,NA,2020-04-06,2020-04-06,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-07,Actual,"December 23, 2019",Actual,2019-12-23,March 2020,2020-03-31,"March 3, 2020",Actual,2020-03-03,"January 20, 2020",Actual,2020-01-20,NA,Observational,NA,,Clinical and Radiomic Model of COVID-19,A Clinical and Radiological Model to Predict the Prognosis for COVID-19 Patients,Completed,NA,NA,300,Actual,Maastricht University,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No share plan,2020-04-17T09:12:02Z,2020-04-17T09:12:02Z,5023014,NCT04337502,Coronavirus Infections,coronavirus infections,Diagnostic Test,Machine learning model,"Machine learning, such as logistic regression, random forest, and deep learning",1,,The central hospital of Wuhan,Wuhan,Hubei,,China,1
"ClinicalTrials.gov processed this data on April 16, 2020",2020-04-01,NA,NA,2020-04-06,2020-04-06,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-07,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,REMOTE-COVID,,Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus),REmote MOniToring usE in Suspected Cases of COVID-19 (Coronavirus): REMOTE-COVID Trial,Not yet recruiting,NA,NA,200,Anticipated,Imperial College London,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-17T09:12:02Z,2020-04-17T09:12:02Z,5023015,NCT04337489,Coronavirus Infections,coronavirus infections,Device,SensiumVitals wearable sensor,"A waterproof, light, wearable sensor measuring vital signs (heart rate, respiratory rate, temperature) continuously.",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-25,NA,NA,2020-04-06,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-07,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,"March 30, 2022",Anticipated,2022-03-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,BRACE,,BCG Vaccination to Protect Healthcare Workers Against COVID-19,BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial,Recruiting,NA,Phase 3,4170,Anticipated,Murdoch Childrens Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,"Beginning 6 months following analysis and article publications, for long-term use","Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement",NA,Yes,"Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:
Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)",2020-04-17T09:14:10Z,2020-04-17T09:14:10Z,5023422,NCT04327206,Coronavirus Infections,coronavirus infections,Drug,BCG Vaccine,"Freeze-dried powder: Live attenuated strain of Mycobacterium bovis (BCG), Danish strain 1331.
Each 0.1 ml vaccine contains between 200000 to 800000 colony forming units. Adult dose is 0.1 ml given by intradermal injection",1,Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,Epworth Victoria Parade|Royal Children's Hospital|Epworth Richmond|Epworth Eastern|Monash Health- Monash Medical Centre|Fiona Stanley Hospital|Perth Children's Hospital|Sir Charles Gairdner Hospital,Melbourne|Melbourne|Melbourne|Melbourne|Melbourne|Murdoch|Perth|Perth,Victoria|Victoria|Victoria|Victoria|Victoria|Western Australia|Western Australia|Western Australia,3002|3052|3121|3128|3168|6150|6009|6009,Australia|Australia|Australia|Australia|Australia|Australia|Australia|Australia,8
"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-24,NA,NA,2020-04-05,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"April 5, 2020",Actual,2020-04-05,April 2020,2020-04-30,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,TOCIVID,,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,"Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial",Recruiting,NA,Phase 2,200,Anticipated,Frederiksberg University Hospital,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-04-17T09:14:28Z,2020-04-17T09:14:28Z,5023502,NCT04322773,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug|Other,RoActemra iv|RoActemra sc|Kevzara sc|Standard medical care,single dose treatment with tocilizumab 400 mg intravenously|single dose treatment with tocilizumab 2 x 162 mg subcutaneously|single dose treatment with sarilumab 1 x 200 mg subcutaneously|management as usual,4,Recruiting|Recruiting,Bispebjerg-Frederiksberg Hospital|HillerÃ¸d Hospital,Copenhagen|HillerÃ¸d,|,2000|,Denmark|Denmark,2
"ClinicalTrials.gov processed this data on April 16, 2020",2020-03-10,NA,NA,2020-04-04,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-04-04,2020-04-07,Actual,"March 21, 2020",Actual,2020-03-21,April 2020,2020-04-30,"March 21, 2022",Anticipated,2022-03-21,"March 21, 2021",Anticipated,2021-03-21,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.,Recruiting,NA,Phase 2,200,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-17T09:15:14Z,2020-04-17T09:15:14Z,5023719,NCT04306393,Coronavirus Infections,coronavirus infections,Drug,Nitric Oxide Gas,"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.
Weaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.",1,Recruiting|Recruiting|Recruiting,University of Alabama|Louisiana State University Health Shreveport|Massachusetts General Hospital,Birmingham|Shreveport|Boston,Alabama|Louisiana|Massachusetts,35294|71103|02114,United States|United States|United States,3
"ClinicalTrials.gov processed this data on April 16, 2020",2020-02-24,NA,NA,2020-04-05,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"March 5, 2020",Actual,2020-03-05,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,NA,,Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19),"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination With Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence",Recruiting,NA,Phase 2,90,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-17T09:15:55Z,2020-04-17T09:15:55Z,5023856,NCT04288102,Coronavirus Infections,coronavirus infections,Biological|Biological,MSCs|Saline containing 1% Human serum albuminï¼ˆsolution of MSCï¼‰,"3 times of MSCs(4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.|3 times of placeboï¼ˆintravenously at Day 0, Day 3, Day 6ï¼‰",2,Recruiting|Recruiting,Maternal and Child Hospital of Hubei Province|Wuhan Huoshenshan Hospital,Wuhan|Wuhan,Hubei|Hubei,430000|430000,China|China,2
"ClinicalTrials.gov processed this data on April 10, 2020",2020-04-01,NA,NA,2020-04-02,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-03,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"July 6, 2020",Anticipated,2020-07-06,"June 6, 2020",Anticipated,2020-06-06,NA,Interventional,NA,,Piclidenoson for Treatment of COVID-19,Piclidenoson for Treatment of COVID-19 - A Randomized Open Label Pilot Trial,Not yet recruiting,NA,Phase 2,40,Anticipated,Can-Fite BioPharma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"January 2021, indefinitely",To be determined,NA,Yes,To be determined,2020-04-13T08:59:23Z,2020-04-13T08:59:23Z,4977864,NCT04333472,Coronavirus Infections,coronavirus infections,Drug,Piclidenoson,Piclidenoson 2 mg orally every 12 hours for up to 21 days,1,,Rabin Medical Center,Petah tikva,,,Israel,1
"ClinicalTrials.gov processed this data on April 15, 2020",2020-04-02,NA,NA,2020-04-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,,Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care,Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment,Enrolling by invitation,NA,Phase 4,1250,Anticipated,Providence Health & Services,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-04-16T09:15:03Z,2020-04-16T09:15:03Z,5010151,NCT04334967,Coronavirus Infections,coronavirus infections,Drug|Dietary Supplement,Hydroxychloroquine|Vitamin C,"Treatment arm medication will be administered on an outpatient basis. Due to the emergent health crisis, study drug will be delivered to patients by institution staff or contract courier using a non-contact protocol.|Control arm supplement will be administered on an outpatient basis. Due to the emergent health crisis, study supplies will be delivered to patients by institution staff or contract courier using a non-contact protocol.",2,,Portland Providence Medical Center,Portland,Oregon,97213,United States,1
"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-23,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-24,Actual,"March 25, 2020",Anticipated,2020-03-25,March 2020,2020-03-31,"July 20, 2020",Anticipated,2020-07-20,"May 15, 2020",Anticipated,2020-05-15,NA,Observational,COVID-19,,"Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","Investigation of Physical Activity, Quality of Life and Stress Levels of Individuals Who Live in Their Homes Isolated Because of Coronavirus (COVID-19) Disease",Not yet recruiting,NA,NA,200,Anticipated,Istanbul University-Cerrahpasa,,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-03T09:19:55Z,2020-04-03T09:19:55Z,4856373,NCT04319211,Coronavirus Infections,coronavirus infections,Other,"Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","The study will include those who isolate themselves at home for fear of contracting Coronavirus disease or suspected of having it. The last three sections of the International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.",1,,Istanbul University Cerrahpasa,Istanbul,,,Turkey,1
"ClinicalTrials.gov processed this data on April 02, 2020",2020-03-20,NA,NA,2020-03-23,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-23,2020-03-24,Actual,March 2020,Anticipated,2020-03-31,March 2020,2020-03-31,April 2022,Anticipated,2022-04-30,March 2022,Anticipated,2022-03-31,NA,Observational,COVIDSOT,,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Not yet recruiting,NA,NA,50,Anticipated,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"
      -  Biochemical analysis

        -  Hemogram

        -  Microbiological testing will be made: blood culture, pleural liquid culture, gram stain
           and culture of sputum, detection of pneumococcus and Legionella pneumophila antigen in
           urine, in cases of pneumonia.

        -  Nasopharyngeal swabs
    ",One year after the initiation of the study,Spanish Network for Research in Infectious Disease (REIPI) and Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC),NA,Yes,Planning for the study will be shared with potential sites pertaining to Spanish Network for Research in Infectious Disease (REIPI) and Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC) for participation. IPD is not foreseen out of this groups due to the specific characteristics of patients and sites to be candidates for study participation.,2020-04-03T09:19:56Z,2020-04-03T09:19:56Z,4856377,NCT04319172,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-26,NA,NA,2020-03-26,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-31,Actual,"March 27, 2020",Anticipated,2020-03-27,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,6 Months,Observational [Patient Registry],COntAGIouS,,In-depth Immunological Investigation of COVID-19.,In-depth Characterisation of the Dynamic Host Immune Response to Coronavirus SARS-CoV-2,Not yet recruiting,NA,NA,100,Anticipated,Universitaire Ziekenhuizen Leuven,,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood, plasma, PBMC, BAL, lung tissue
    ",NA,NA,NA,Undecided,NA,2020-04-10T09:15:45Z,2020-04-10T09:15:45Z,4939982,NCT04327570,Coronavirus Infections,coronavirus infections,Other,Patient sampling,"Blood draw, NP/rectal swab, bronchoscopy if clinically indicated, lung tissue if applicable",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-17,NA,NA,2020-03-18,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-18,2020-03-20,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"January 1, 2023",Anticipated,2023-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Observational,CovidTox,,Adverse Events Related to Treatments Used Against Coronavirus Disease 2019,Adverse Events Related to Treatments Used Against Coronavirus Disease 2019,Recruiting,NA,NA,1000,Anticipated,Groupe Hospitalier Pitie-Salpetriere,,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,No individual data is available per se. They need to be retrieved from the World Health Organization.,2020-04-01T09:19:14Z,2020-04-01T09:19:14Z,4274060,NCT04314817,Coronavirus Infections,coronavirus infections,Drug,Any drug used to treat Covid-19,"lopinavir/ritonavir, remdesivir, interferon beta-1a, chloroquine and/or azithromycin. This list may be amended at a further date.",1,Recruiting,AP-HP Assistance Publique Hopitaux de Paris,Paris,,,France,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-10,NA,NA,2020-03-12,2020-03-12,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-03-12,2020-03-13,Actual,"March 11, 2020",Actual,2020-03-11,March 2020,2020-03-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2,150,Anticipated,Asan Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:20:10Z,2020-04-01T09:20:10Z,4275026,NCT04307693,Coronavirus Infections,coronavirus infections,Drug|Drug,Lopinavir/ritonavir|Hydroxychloroquine sulfate,Lopinavir / Ritonavir tablet|Hydroxychloroquine sulfate tablet,2,Recruiting,"Asan Medical Center, University of Ulsan College of Medicine",Seoul,,138-736,"Korea, Republic of",1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-15,NA,NA,2020-02-20,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"January 20, 2020",Actual,2020-01-20,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,NA,,Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection,Investigation on Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection in Isolation Unit,Recruiting,NA,NA,100,Anticipated,"Third Affiliated Hospital, Sun Yat-Sen University",,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-01T09:23:39Z,2020-04-01T09:23:39Z,4278533,NCT04279782,Coronavirus Infections,coronavirus infections,Other,Comprehensive treatment,"Comprehensive treatment includes antiviral therapy, antibiotics therapy, symptomatic treatment, supportive therapy.",1,Recruiting,The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,510630,China,1
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-16,NA,NA,2020-02-21,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 15, 2020",Anticipated,2020-02-15,February 2020,2020-02-29,"July 31, 2020",Anticipated,2020-07-31,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Not yet recruiting,NA,Phase 1,30,Anticipated,Ruijin Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2020-04-01T09:24:02Z,2020-04-01T09:24:02Z,4278867,NCT04276987,Coronavirus Infections,coronavirus infections,Biological,MSCs-derived exosomes,"5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).",1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 17, 2020",2020-03-09,NA,NA,2020-04-07,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"March 21, 2020",Actual,2020-03-21,April 2020,2020-04-30,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial,Recruiting,NA,Phase 2,240,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-19T09:04:36Z,2020-04-19T09:04:36Z,5047828,NCT04305457,Coronavirus Infections,coronavirus infections,Drug,Nitric Oxide,"Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient.",1,Recruiting,Massachusetts General Hospital,Boston,Massachusetts,02114-2621,United States,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-26,NA,NA,2020-04-13,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,CoDEX,,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,"COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)",Recruiting,NA,Phase 3,290,Anticipated,Hospital Sirio-Libanes,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-25T09:18:57Z,2020-04-25T09:18:57Z,5111254,NCT04327401,Coronavirus Infections,coronavirus infections,Drug,Dexamethasone,Dexamethasone administration for 10 consecutive days after randomization.,1,Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting,Hospital Ana Nery|Instituto de Cardiologia do Distrito Federal|FundaÃ§Ã£o Social Rural de Colatina|Hospital Vera Cruz AS|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda|Universidade Estadual de Londrina|Eurolatino Natal Pesquisas MÃ©dicas Ltda|Irmandade da Santa Casa de Misericordia de Porto Alegre|Maestri E Kormann Consultoria Medico-Cientifica|Sociedade Literaria e Caritativa Santo Agostinho|FundaÃ§Ã£o Pio XII|Santa Casa de Misericordia de Votuporanga|Associacao Beneficente Siria|Hospital das ClÃ­nicas da Faculdade de Medicina de RibeirÃ£o Preto da USP - HCFMRP|Hospital Israelita Albert Einstein|Prevent Senior Private Operadora de Saude Ltda|Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia/SP|Santa Casa de MisericÃ³rdia|Secretaria de SaÃºde do Estado de SÃ£o Paulo|Sociedade Beneficente de Senhoras Hospital SÃ­rio-LibanÃªs|Universidade Federal de SÃ£o Paulo,Salvador|BrasÃ­lia|Colatina|Belo Horizonte|PoÃ§os De Caldas|Londrina|Natal|Porto Alegre|Blumenau|CriciÃºma|Barretos|Votuporanga|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo,Bahia|Distrito Federal|EsoÃ­rito Santo|Minas Gerais|Minas Gerais|ParanÃ¡|Rio Grande Do Norte|Rio Grande Do Sul|Santa Catarina|Santa Catarina|SÃ£o Paulo|SÃ£o Paulo|||||||||,||||||||||||||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,21
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-25,NA,NA,2020-04-14,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 27, 2021",Anticipated,2021-03-27,NA,Interventional,CORIMUNO-SARI,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",NA,Phase 2/Phase 3,239,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-25T09:19:05Z,2020-04-25T09:19:05Z,5111291,NCT04324073,Coronavirus Infections,coronavirus infections,Drug,Sarilumab,(an IV dose of 400 mg of sarilumab in a 1 hour-infusion at D1,1,|||,Kremlin Bicetre hospital APHP|Cochin Aphp|HEGP|NECKER Hospital,Le Kremlin-BicÃªtre|Paris|Paris|Paris,Ile De France|Ile De France|Ile De France|,|||75005,France|France|France|France,4
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-19,NA,NA,2020-04-13,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"March 23, 2020",Actual,2020-03-23,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,CloroCOVID19,,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Recruiting,NA,Phase 2,440,Anticipated,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2020-04-25T09:19:08Z,2020-04-25T09:19:08Z,5111315,NCT04323527,Coronavirus Infections,coronavirus infections,Drug,Chloroquine diphosphate,150mg chloroquine diphosphate tablets.,1,Recruiting,Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz,Manaus,Amazonas,69093-415,Brazil,1
"ClinicalTrials.gov processed this data on April 24, 2020",2020-03-24,NA,NA,2020-04-14,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"July 20, 2020",Anticipated,2020-07-20,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,ColCOVID-19,,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA,Not yet recruiting,NA,Phase 2,310,Anticipated,Azienda Ospedaliero-Universitaria di Parma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data will be avaliable from July 2020 and documentation will be shared for 10 years,The sponsor recognizes the importance of communicating study data and will disclose and publish the results in a suitable form regardless of outcome. The sponsor will publish the results of this study in scientific journals,NA,Yes,NA,2020-04-25T09:19:11Z,2020-04-25T09:19:11Z,5111325,NCT04322565,Coronavirus Infections,coronavirus infections,Drug,Colchicine,Cochicine 1mg/day,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 24, 2020",2020-02-11,NA,NA,2020-04-13,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 10, 2020",Actual,2020-02-10,April 2020,2020-04-30,"March 31, 2020",Actual,2020-03-31,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Completed,NA,Phase 2,127,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-25T09:20:36Z,2020-04-25T09:20:36Z,5111678,NCT04276688,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug,Lopinavir/ritonavir|Ribavirin|Interferon Beta-1B,400mg/100mg twice daily for 14 days|400mg twice daily for 14 days|0.25mg subcutaneous injection alternate day for 3 days,3,,"University of Hong Kong, Queen Mary Hospital",Hong Kong,,,Hong Kong,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-04-08,NA,NA,2020-04-10,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-13,Actual,"March 25, 2020",Actual,2020-03-25,April 2020,2020-04-30,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,NA,,Acquiring Convalescent Specimens for COVID-19 Antibodies,Acquiring Convalescent Specimens to Isolate and Identify Potent Monoclonal Antibodies Against COVID-19,Recruiting,NA,NA,12,Anticipated,Columbia University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Whole blood from which peripheral blood mononuclear cells (PBMCs) and plasma will be
      processed.
    ",NA,NA,NA,NA,NA,2020-04-23T09:13:43Z,2020-04-23T09:13:43Z,5086781,NCT04342195,Coronavirus Infections,coronavirus infections,Procedure,Blood draw,Participants will have approximately 45 ml of whole blood drawn (3 Tablespoons) drawn at the study visit.,1,Recruiting,Columbia University Irving Medical Center/NYP,New York,New York,10032,United States,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-03-23,NA,NA,2020-04-09,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 24, 2020",Actual,2020-03-24,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"June 30, 2020",Anticipated,2020-06-30,NA,Observational,B-DT-COV2,,Biomarkers for Identification of COVID-19 Infection,Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection,Recruiting,NA,NA,110,Anticipated,University of Catanzaro,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-23T09:15:27Z,2020-04-23T09:15:27Z,5087130,NCT04322513,Coronavirus Infections,coronavirus infections,Diagnostic Test,Biomarkers expression,Evaluation in biomarkers expression between 2 groups,1,Recruiting,Luca Gallelli,Catanzaro,,88100,Italy,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-03-23,NA,NA,2020-04-10,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-13,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,ProPAC-COVID,,Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19,"Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19",Recruiting,NA,Phase 2,226,Anticipated,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-23T09:15:28Z,2020-04-23T09:15:28Z,5087135,NCT04322396,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug|Drug,Azithromycin|Hydroxychloroquine|Placebo oral tablet|Placebo oral tablet,Azithromycin|Hydroxychloroquine|Placebo Azithromycin|Placebo Hydroxychloroquine,4,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,Aalborg Sygehus|Bispebjerg Hospital|Herlev-Gentofte Hospital|Hvidovre Hospital|NordsjÃ¦llands Hospital|Odense Universitetshospital|Roskilde Sygehus|Slagelse Sygehus,Aalborg|Copenhagen|Copenhagen|Copenhagen|HillerÃ¸d|Odense|Roskilde|Slagelse,|||||||,|||||||,Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark|Denmark,8
"ClinicalTrials.gov processed this data on April 22, 2020",2020-03-24,NA,NA,2020-04-09,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,Coalition-I,,Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus (COVID-19),"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azytromicyn for COVID-19 Infection on Hospitalized, Noncritical Patients",Recruiting,NA,Phase 3,630,Anticipated,Hospital do Coracao,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-23T09:15:29Z,2020-04-23T09:15:29Z,5087144,NCT04322123,Coronavirus Infections,coronavirus infections,Drug|Drug,Hydroxychloroquine Oral Product|Hydroxychloroquine + azithromycin,Hydroxychloroquine 400 mg BID|Hydroxychloroquine 400 mg BID + azithromycin 500 mg once a day,2,Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Recruiting|Recruiting|Recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting|Not yet recruiting,Hospital Geral ClÃ©riston Andrade|Hospital Ana Nery - HAN/SESAB|HHospital SAMUR|Hospital Geral de VitÃ³ria da Conquista|Hospital de BrasÃ­lia|Instituto de Cardiologia do Distrito Federal|Hospital Maternidade SÃ£o JosÃ© - UNESC - FundaÃ§Ã£o Social Rural de Colatina|Hospital Vila da Serra|Santa Casa de MisericÃ³rdia de SÃ£o JoÃ£o Del Rei|AssociaÃ§Ã£o EvangÃ©lica Beneficente de Londrina - Hospital EvangÃ©lico de Londrina|Instituto Estadual do CÃ©rebro Paulo Niemeyer|Hospital Geral de Caxias do Sul|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre|Hospital SÃ£o Francisco - Irmandade Santa Casa de Porto Alegre|Hospital SÃ£o JosÃ©|Hospital BaÃ­a Sul - BaÃ­a Sul Medical Center|Hospital Nereu Ramos|Centro Hospitalar Unimed|Hospital de Amor - Unidade Barretos (FundaÃ§Ã£o PIO XII)|Casa de SaÃºde Santa Marcelina|Hospital Albert Einstein|Hospital BeneficÃªncia Portuguesa - Real e BenemÃ©rita AssociaÃ§Ã£o Portuguesa de BeneficÃªncia|Hospital BP Mirante - Real e BenemÃ©rita|Hospital das ClÃ­nicas da FMUSP|Hospital do Servidor PÃºblico Estadual - HSPE - IAMSPE|Hospital SÃ£o Paulo - UNIFESP|Hospital SÃ­rio-LibanÃªs|Hospital SEPACO,Feira De Santana|Salvador|VitÃ³ria Da Conquista|VitÃ³ria Da Conquista|Brasilia|BrasÃ­lia|Colatina|Nova Lima|SÃ£o JoÃ£o Del Rei|Londrina|Rio De Janeiro|Caxias do Sul|Porto Alegre|Porto Alegre|Criciuma|FlorianÃ³polis|FlorianÃ³polis|Joinville|Barretos|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo|SÃ£o Paulo,BA|BA|BA|BA|DF|DF|ES|MG|MG|PR|RJ|RS|RS|RS|SC|SC|Sc|SC|SP|SP|SP|SP|SP|SP|SP|SP|SP|S,|||||||||||||||||||||||||||,Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil|Brazil,28
"ClinicalTrials.gov processed this data on April 01, 2020",2020-02-14,NA,NA,2020-03-19,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-19,2020-03-23,Actual,"February 16, 2020",Actual,2020-02-16,March 2020,2020-03-31,"April 30, 2020",Anticipated,2020-04-30,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,NA,,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Enrolling by invitation,NA,N/A,60,Anticipated,Second Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-02T09:23:21Z,2020-04-02T09:23:21Z,4842921,NCT04273763,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug,Bromhexine Hydrochloride Tablets|Arbidol Hydrochloride Granules|Recombinant Human Interferon Î±2b Spray,Bromhexine Hydrochloride Tablets|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.|Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.,3,,The Second AffIliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,325000,China,1
"ClinicalTrials.gov processed this data on April 03, 2020",2020-03-17,NA,NA,2020-03-25,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-26,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,6 Months,Observational [Patient Registry],COVID19-HCW,,COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,Recruiting,NA,NA,400,Anticipated,"University College, London",,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      Blood samples Nasal and oropharygeal swabs
    ",NA,NA,NA,Yes,Publication of results in open access journals; sharing of results in scientific databases.,2020-04-05T09:05:57Z,2020-04-05T09:05:57Z,4883383,NCT04318314,Coronavirus Infections,coronavirus infections,Diagnostic Test,COPAN swabbing and blood sample collection,COPAN swabbing of nostrils and/or oropharynx and blood sample collection,1,"Recruiting|Active, not recruiting",Barts Heart Center|Royal Free London NHS Foundation Trust,London|London,|,|,United Kingdom|United Kingdom,2
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-29,NA,NA,2020-04-01,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-03,Actual,"April 1, 2020",Anticipated,2020-04-01,March 2020,2020-03-31,"May 31, 2021",Anticipated,2021-05-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,STROMA-CoV2,,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,Not yet recruiting,NA,Phase 1/Phase 2,60,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-04-13T08:59:27Z,2020-04-13T08:59:27Z,4977881,NCT04333368,Coronavirus Infections,coronavirus infections,Biological|Other,Umbilical cord Wharton's jelly-derived human|NaCl 0.9%,"Umbilical cord Wharton's jelly-derived human MSC (at the dose of 1 Million / kg) will be administered via a peripheral or central venous line over 30-45 minutes, using tubing with a 200-Î¼m filter. Cells, in a 150 mL volume, will be delivered at D1 - D3 - D5.|NaCl 0.9% (150 mL) given via an intravenous route at D1 - D3 - D5",2,|,HÃ´pital PitiÃ©-SalpÃªtriÃ¨re - APHP|HÃ´pital EuropÃ©en Georges Pompidou - APHP,Paris|Paris,|,75013|75015,France|France,2
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-25,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 27, 2020",Anticipated,2020-03-27,March 2020,2020-03-31,"June 1, 2020",Anticipated,2020-06-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Treating COVID-19 With a Bidirectional Oxygenation Valve,The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection,Recruiting,NA,N/A,15,Anticipated,TMC HealthCare,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-04-11T09:13:55Z,2020-04-11T09:13:55Z,4953500,NCT04326452,Coronavirus Infections,coronavirus infections,Device,bidirectional oxygenation mouthpiece,Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.,1,Recruiting|Recruiting|Recruiting,TMC HealthCare|Stanford University|Emory Saint Joseph's Hospital,Tucson|Stanford|Atlanta,Arizona|California|Georgia,85712|94305|30342,United States|United States|United States,3
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-15,NA,NA,2020-03-02,2020-03-02,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-02,2020-03-03,Actual,"March 1, 2020",Anticipated,2020-03-01,March 2020,2020-03-31,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,NA,,Efficacy and Safety of IFN-Î±2Î² in the Treatment of Novel Coronavirus Patients,"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon Î±1Î² in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan",Not yet recruiting,NA,Early Phase 1,328,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-01T09:21:54Z,2020-04-01T09:21:54Z,4276658,NCT04293887,Coronavirus Infections,coronavirus infections,Drug,Recombinant human interferon Î±1Î²,Saline needle 2ml + recombinant human interferon Î±1Î²10ug bid nebulization inhalation,1,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 31, 2020",2020-02-25,NA,NA,2020-02-25,2020-02-25,2020-02-27,Actual,NA,NA,NA,NA,NA,NA,2020-02-25,2020-02-27,Actual,"February 23, 2020",Anticipated,2020-02-23,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,,The Clinical Study of Carrimycin on Treatment Patients With COVID-19,"The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study",Not yet recruiting,NA,Phase 4,520,Anticipated,Beijing YouAn Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:22:50Z,2020-04-01T09:22:50Z,4277613,NCT04286503,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,Carrimycin|lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|basic treatment,3,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on April 17, 2020",2020-04-06,NA,NA,2020-04-08,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"March 27, 2020",Actual,2020-03-27,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 6, 2020",Anticipated,2020-10-06,NA,Interventional,NA,,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,Recruiting,NA,Phase 4,200,Anticipated,Sharp HealthCare,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-04-19T09:01:34Z,2020-04-19T09:01:34Z,5047207,NCT04340557,Coronavirus Infections,coronavirus infections,Drug,Losartan,Standard of care plus the starting dose of losartan 12.5mg (investigator has option to increase dose on days 2-10 based on tolerance of SBP) of losartan taken twice daily for up to 10 days.,1,Recruiting|Recruiting|Recruiting|Recruiting,Sharp Grossmont Hospital|Sharp Chula Vista Medical Center|Sharp Coronado Hospital|Sharp Memorial Hospital,La Mesa|San Diego|San Diego|San Diego,California|California|California|California,91942|91911|92118|92123,United States|United States|United States|United States,4
"ClinicalTrials.gov processed this data on April 09, 2020",2020-03-26,NA,NA,2020-03-27,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"March 13, 2020",Actual,2020-03-13,March 2020,2020-03-31,"February 28, 2023",Anticipated,2023-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,CORSER,,Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples,Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples,Recruiting,NA,NA,1000,Anticipated,Institut Pasteur,,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"
      serum, plasma
    ",NA,NA,NA,Undecided,NA,2020-04-10T09:16:16Z,2020-04-10T09:16:16Z,4940124,NCT04325646,Coronavirus Infections,coronavirus infections,Other,Human Biological samples,Blood samples for serological tests,1,Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting|Recruiting,CHU Amiens-Picardie|CHU FranÃ§ois Mitterand|CHU Limoges|HÃ´pital de la Croix Rousse|HÃ´pitaux de Brabois|CHR OrlÃ©ans|Institut Pasteur|CHU Poitiers|HÃ´pital Pontchaillou|CHU Saint-Etienne|CH de Tourcoing|HÃ´pital Bretonneau,Amiens|Dijon|Limoges|Lyon|Nancy|OrlÃ©ans|Paris|Poitiers|Rennes|Saint-Ã‰tienne|Tourcoing|Tours,|||||||||||,||||||75015|||||,France|France|France|France|France|France|France|France|France|France|France|France,12
"ClinicalTrials.gov processed this data on April 17, 2020",2020-02-16,NA,NA,2020-04-07,2020-02-16,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,"February 19, 2020",Actual,2020-02-19,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,"April 4, 2020",Actual,2020-04-04,NA,Observational,NA,,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool (COV_NUTRIC),"Active, not recruiting",NA,NA,117,Actual,Peking University Third Hospital,,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-18T09:14:07Z,2020-04-18T09:14:07Z,5036434,NCT04274322,Coronavirus Infections,coronavirus infections,Other,Nutrition support,"Calories and proteins are given to patients by using ways as parenteral nutriton, enteral nutrition, oral nutrition supplement",1,,Peking University Third Hospital,Beijing,,,China,1
"ClinicalTrials.gov processed this data on April 15, 2020",2020-03-27,NA,NA,2020-04-02,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"March 31, 2020",Anticipated,2020-03-31,March 2020,2020-03-31,"June 15, 2020",Anticipated,2020-06-15,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,ATCO,,"Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial",Not yet recruiting,NA,Phase 2/Phase 3,60,Anticipated,Erasme University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-04-16T09:15:53Z,2020-04-16T09:15:53Z,5010294,NCT04332666,Coronavirus Infections,coronavirus infections,Drug|Drug,Angiotensin 1-7|Placebos,endogenous peptide dilution: angiotensin-(1-7) 0.5 mg / L NaCl 0.9%|infusion of NaCl 0.9% without diluted peptide in it,2,NA,NA,NA,NA,NA,NA,NA
"ClinicalTrials.gov processed this data on March 31, 2020",2020-03-16,NA,NA,2020-03-16,2020-03-16,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-19,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"May 1, 2020",Anticipated,2020-05-01,3 Weeks,Observational [Patient Registry],NA,,The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia,The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia,Recruiting,NA,NA,80,Anticipated,Xiangya Hospital of Central South University,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-04-01T09:19:19Z,2020-04-01T09:19:19Z,4274139,NCT04314271,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting,"Xiangya Hospital, Central South University",Changsha,Hunan,410000,China,1
"ClinicalTrials.gov processed this data on April 22, 2020",2020-03-30,NA,NA,2020-04-09,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,"March 1, 2021",Anticipated,2021-03-01,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CORONACION,,Coronavirus (COVID-19) ACEi/ARB Investigation,The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial,Recruiting,NA,Phase 4,2414,Anticipated,"National University of Ireland, Galway, Ireland",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,12-24 months,To be determined,NA,Yes,NA,2020-04-23T09:14:57Z,2020-04-23T09:14:57Z,5087007,NCT04330300,Coronavirus Infections,coronavirus infections,Drug|Drug|Drug|Drug,Thiazide or Thiazide-like diuretics|Calcium Channel Blockers|ACE inhibitor|Angiotensin receptor blocker,Anti-hypertensive (Active Arm)|Anti-hypertensive (Active Arm)|Anti-hypertensive (Control Arm)|Anti-hypertensive (Control Arm),4,Recruiting,University Hospital Galway,Galway,,H91 YR71,Ireland,1
"ClinicalTrials.gov processed this data on April 10, 2020",2020-03-25,NA,NA,2020-03-31,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 27, 2021",Anticipated,2021-03-27,NA,Observational,CORIMUNO-19,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Recruiting,NA,NA,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-04-11T09:14:11Z,2020-04-11T09:14:11Z,4953572,NCT04324047,Coronavirus Infections,coronavirus infections,NA,NA,NA,NA,Recruiting|Recruiting|Recruiting,Kremlin Bictre APHP|Cochin Aphp|Hegp Aphp,Le Kremlin-BicÃªtre|Paris|Paris,Ile De France|Ile De France|Ile De France,||,France|France|France,3
